**Title:** Effectiveness of nirmatrelvir-ritonavir against hospital admission or death: a cohort study in a large US healthcare system

**Authors:** Joseph A. Lewnard, PhD<sup>1,2,3,\*</sup>; John M. McLaughlin, PhD<sup>4</sup>; Debbie Malden, DPhil<sup>5</sup>; Vennis Hong, MPH<sup>5</sup>; Laura Puzniak, PhD, MPH<sup>4</sup>; Bradley K. Ackerson, MD<sup>5</sup>; Bruno J. Lewin, MD<sup>5</sup>; Jeniffer S. Kim, PhD<sup>5</sup>; Sally F. Shaw, DrPH<sup>5</sup>; Harpreet Takhar, MPH<sup>5</sup>; Luis Jodar, PhD<sup>4</sup>; Sara Y. Tartof, PhD, MPH<sup>5,6,\*</sup>

#### Affiliations:

- 1. Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
- 2. Division of Infectious Diseases & Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
- Center for Computational Biology, College of Engineering, University of California, Berkeley, Berkeley, California 94720, United States
- 4. Pfizer Inc, New York, New York.
- Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, United States
- Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California 91101, United States
- \* Addresses for correspondence:

Joseph A. Lewnard 2121 Berkeley Way Berkeley, California 94720 jLewnard@berkeley.edu 510-664-4050 Sara Y. Tartof 100 South Los Robles Pasadena, California 91101 <u>Sara.Y.Tartof@kp.org</u> 626-564-3001

#### ABSTRACT

**Background:** In the United States, oral nirmatrelvir-ritonavir (Paxlovid<sup>TM</sup>) is authorized for use among patients aged  $\geq$ 12 years with mild-to-moderate SARS-CoV-2 infection who are at risk for progression to severe COVID-19, including hospitalization. However, effectiveness under current real-world prescribing practices in outpatient settings is unclear.

**Methods:** We undertook a matched observational cohort study of non-hospitalized cases with SARS-CoV-2 infection to compare outcomes among those who received or did not receive nirmatrelvir-ritonavir within the Kaiser Permanente Southern California healthcare system. Cases were matched on testing date, age, sex, clinical status (including care received, presence or absence of acute COVID-19 symptoms at testing, and time from symptom onset to testing), history of vaccination, Charlson comorbidity index, prior-year healthcare utilization, and body mass index. Primary analyses evaluated effectiveness of nirmatrelvir-ritonavir in preventing hospital admission or death within 30 days after a positive test. Secondary analyses evaluated effectiveness against intensive care unit admission, mechanical ventilation, or death within 60 days after a positive test. We measured treatment effectiveness as (1–adjusted hazards ratio [aHR])×100%, estimating the aHR via Cox proportional hazards models.

**Results:** Analyses included 7,274 nirmatrelvir-ritonavir recipients and 126,152 non-recipients with positive results from SARS-CoV-2 tests undertaken in outpatient settings between 8 April and 7 October, 2022. Overall, 114,208 (85.6%) and 81,739 (61.3%) of 133,426 participants had received  $\geq 2$  and  $\geq 3$  COVID-19 vaccine doses, respectively. A total of 111,489 (83.6% of 133,426) cases were symptomatic at the point of testing, with 5,472 (75.2% of 7,274) treatment recipients and 84,657 (67.1% of 126,152) non-recipients testing within 0–5 days after symptom onset. Effectiveness in preventing hospital admission or death within 30 days after a positive test was 79.6% (95% confidence interval: 33.9% to 93.8%) for cases dispensed nirmatrelvir-ritonavir within 0–5 days after symptom onset; within the subgroup of cases tested 0–5 days after symptom onset and dispensed treatment on the day of their test, effectiveness was 89.6% (50.2% to 97.8%). Effectiveness declined to 43.8% (–33.3% to 81.7%) for treatment course dispensed ≥6 days after symptom onset or to cases who were not experiencing acute clinical symptoms. Overall, for cases dispensed treatment at any time within their clinical course, effectiveness was 53.6% (6.6% to 77.0%). Effectiveness in preventing the secondary endpoint of intensive care unit admission, mechanical ventilation, or death within 60 days after a positive test was 89.2% (–25.0% to 99.3%) for cases dispensed treatment 0–5 days after symptom onset and 84.1% (18.8% to 96.9%) for cases dispensed treatment at any time. Subgroup analyses identified similar effectiveness estimates among cases who had received ≥2 or ≥3 COVID-19 vaccine doses.

**Implications:** In a setting with high levels of COVID-19 vaccine and booster uptake, receipt of nirmatrelvir-ritonavir 0–5 days after symptom onset was associated with substantial reductions in risk of hospital admission or death within 30 days after a positive outpatient SARS-CoV-2 test.

Funding: US Centers for Disease Control and Prevention, US National Institutes of Health

#### INTRODUCTION

In conjunction with vaccination as a primary prevention strategy, therapeutic drugs to prevent severe outcomes of SARS-CoV-2 infection are of key importance to current efforts aimed at mitigating the burden of COVID-19. In early trials, neutralizing monoclonal antibody therapies<sup>1–3</sup> and remdesivir,<sup>4</sup> an antiviral agent repurposed for treatment of COVID-19 cases, showed success in preventing hospital admissions when administered early in patients' clinical course. However, the need to deliver these treatments by intravenous infusion has limited their utility for broad implementation in ambulatory care settings. Additionally, many monoclonal antibody therapies have been rendered ineffective by continuing mutations in the Spike protein of SARS-CoV-2.<sup>5</sup> In the randomized phase II/III EPIC-HR trial among high-risk, unvaccinated, and non-hospitalized adults,<sup>6</sup> oral nirmatrelvir-ritonavir (Paxlovid<sup>™</sup>, Pfizer, Inc.) reduced the risk of COVID-19 related hospital admission by 89% over 28 days following treatment dispense. Based on this evidence, the US Food and Drug Administration issued Emergency Use Authorization for nirmatrelvir-ritonavir for adults and children aged ≥12 years weighing ≥40 kilograms who are at high risk for progression to severe COVID-19.

Amid the broad implementation of nirmatrelvir-ritonavir as a treatment option for COVID-19 cases diagnosed in ambulatory settings,<sup>7</sup> evidence is needed on effectiveness in preventing severe disease under real-world conditions of use. In recent observational studies, nirmatrelvir-ritonavir was estimated to confer 21-79% reductions in risk of hospital admission or other severe endpoints, with the strongest evidence of clinical benefit among high-risk subgroups including older adult cases, obese cases, and cases not known to have immunity to SARS-CoV-2 from prior infection or vaccination.<sup>8-14</sup> Factors explaining this wide range of effectiveness estimates remain uncertain. Whereas timing of administration may be of crucial importance to the effectiveness of antiviral therapies, prior effectiveness studies have lacked symptoms data, making it difficult to compare results across studies potentially enrolling cases with heterogeneous clinical status. Expansions in nirmatrelvir-ritonavir access and availability have led to widening uptake among a broader patient population including non-elderly and vaccinated cases, as well as those without high-risk chronic comorbid conditions, further contributing to potential variation across studies.<sup>15,16</sup> Last, rollout of nirmatrelvir-ritonavir has occurred during periods dominated by circulation of the BA.2, BA.4, and BA.5 SARS-CoV-2 Omicron lineages, when most individuals in the United States and other countries have shown antibody evidence of prior SARS-CoV-2 infection.<sup>17</sup> These circumstances present a notable contrast to the EPIC-HR trial, which (1) randomized participants to treatment or placebo within the first 5 days after symptom onset; (2) enrolled only unvaccinated high-risk (e.g. older, chronically ill, or obese) adults without a history of prior infection; and (3) was conducted while the Delta (B.1.617.2) variant, which has been associated with greater disease severity,<sup>18,19</sup> remained the predominant circulating SARS-CoV-2 lineage.

While data from the United States have shown that COVID-19 related emergency department (ED) presentations and hospital admissions are infrequent among cases receiving nirmatrelvir-ritonavir in ambulatory care settings,<sup>18,20</sup> systematic assessments of effectiveness remain lacking. We therefore aimed to measure the effectiveness of nirmatrelvir-ritonavir in preventing severe outcomes of SARS-CoV-2 infection among cases ascertained via outpatient testing within a large, integrated US healthcare system.

#### METHODS

**Setting and eligibility criteria.** Our study was conducted within Kaiser Permanente Southern California (KPSC), a comprehensive healthcare system providing integrated care across virtual, outpatient, emergency department (ED), and inpatient settings to 4.7 million members (~19% of the population of southern California). Members of KPSC are enrolled through employer-provided, pre-paid, and federally-sponsored insurance plans and represent the diverse socioeconomic characteristics and racial/ethnic backgrounds of the geographic areas served.<sup>21,22</sup> Electronic health records (EHRs) capture all within-network care delivery including diagnoses, pharmacy dispenses, laboratory tests and results, and vaccinations received. Care received out of network is captured through insurance claim reimbursements. COVID-19 vaccinations received outside KPSC were captured through linkage with the California Immunization Registry, (to which providers were required to report all COVID-19 vaccine administrations within 24 hours<sup>23</sup>) as well as other health systems using the Epic EHR system.

Although Emergency Use Authorization for nirmatrelvir-ritonavir was granted in December, 2021, real-world uptake remained low through the first months of 2022 due to limited supplies, and treatment was initially prioritized to KPSC patients who were immunocompromised or on immunosuppressive medications, aged ≥65 years and incompletely vaccinated, or aged ≥65 years with risk factors for severe disease. By April, 2022, nirmatrelvir-ritonavir was available to KPSC patients receiving a positive SARS-CoV-2 test result in any outpatient setting or reporting a positive at-home antigen test, with no requirement for an in-person appointment. Patients taking statins or hormonal contraceptives containing ethinyl estradiol were instructed to withhold taking these medications while taking nirmatrelvir-ritonavir, while those taking medication for HIV infection were instructed to continue taking HIV antiretroviral medications and arrange follow-up with care providers to monitor for side effects. Patients taking other concomitant medications with potential interactions were referred for clinical evaluation to determine appropriate therapeutic options, including withholding of other medications, dose adjustment, or increased monitoring to assess drug interactions.

Cases were eligible for inclusion in the current study if they: (1) received a positive SARS-CoV-2 polymerase chain reaction (PCR) test result, defined as their index test, between 8 April and 7 October, 2022 (a period when  $\geq$ 5% of outpatient-diagnosed cases at KPSC received nirmatrelvir-ritonavir each week); (2) had no prior positive test result within the preceding 90 days; were  $\geq$ 12 years old at the time of their index test; (3) were not hospitalized at the time of their index test or within the preceding 7 days; and (4) had  $\geq$ 1 year of continuous enrollment in KPSC health plans before their index test (allowing for a 45-day gap during previous membership due to potential delays in renewal). We included follow-up for clinical endpoints in this study through 30 or 60 days after cases' index test (as detailed below), through disenrollment, or through 20 October, 2022, whichever occurred earliest.

**Exposures.** The primary exposures were receipt of nirmatrelvir-ritonavir 0–5 days after symptom onset, and receipt of nirmatrelvir-ritonavir at any time after testing positive for SARS-CoV-2 (regardless of the presence or timing of symptoms). We considered participants to be exposed to nirmatrelvir-ritonavir beginning on the date of treatment dispense, as recorded in KPSC pharmacy records or adjudicated out-of-network insurance claims. Cases who received nirmatrelvir-ritonavir  $\geq$ 1 day after their index test were considered unexposed during the time between their index test and date of treatment dispense.

Data on symptoms associated with SARS-CoV-2 infection were abstracted from structured questionnaires administered with each SARS-CoV-2 test order, and from unstructured text fields within EHRs, as described previously.<sup>24</sup> The date of SARS-CoV-2 symptom onset was defined as the earliest date that cases reported acute fever, cough, headache, fatigue, dyspnea, chills, sore throat, myalgia, anosmia, diarrhea, vomiting/nausea, or abdominal pain within 14 days before or after their index test date. If new-onset symptoms were not recorded within this period, we categorized cases as not experiencing acute COVID-19 symptoms in association with their infection. To support exploratory analyses addressing effectiveness of nirmatrelvir-ritonavir at differing clinical stages in cases' clinical course, we defined additional subgroups including cases treated 0–3 days after symptom onset (the primary exposure assessed in the EPIC-HR trial<sup>6</sup>); cases treated ≥6 days after symptom onset or in the absence of acute COVID-19 symptoms; and cases treated at any time after symptom onset. As an additional exploratory analysis aiming to emulate the design of the EPIC-HR trial, in which cases were randomized to treatment or placebo at the point of testing, we distinguished courses dispensed on the day of testing, censoring observations from cases who received treatment at later points in time.

Additional variables recorded at the time of participants' index test included: age, sex, race/ethnicity (non-Hispanic White, Black, Asian, or Pacific Islander; Hispanic [belonging to any race]; or other/unknown/multiple race), body mass index (BMI), current or former cigarette smoking, socioeconomic status (measured by census-tract neighborhood deprivation index<sup>25</sup> quintiles), COVID-19 vaccine doses received, prior documented SARS-CoV-2 infection, comorbid conditions (from which we computed Charlson comorbidity index values for each case as a summary measure of risk<sup>26–28</sup>), healthcare utilization in the prior year (comprising interactions across outpatient, emergency department [ED], and inpatient settings), and receipt of other vaccines (including 2021-22 season influenza vaccination, pneumococcal polysaccharide vaccine, and pneumococcal conjugate vaccine; **Table 1**).

**Endpoints.** The primary endpoint of this study was hospital admission or death due to any cause within 30 days after participants' index positive SARS-CoV-2 test. This endpoint was selected to maximize comparability to the endpoint of the EPIC-HR trial,<sup>6</sup> which monitored participants for COVID-19 related hospital admission or death due to any cause after a positive test. Throughout the study period, KPSC implemented a home-based monitoring program for COVID-19 cases aiming to preserve hospital capacity by standardizing admission criteria, as described previously.<sup>29</sup> Briefly, cases judged to be at high risk of severe outcomes based on their risk factors and clinical status at the point of testing were given medical-grade pulse oximeters and thermometers, and monitored for clinical deterioration on the basis of daily readings, reported through either a mobile application or daily telephone calls from providers. Standardized criteria were used for subsequent ED referral and inpatient admission, including SpO<sub>2</sub> readings, respiratory rate, and patient-reported shortness of breath or other clinical signs or symptoms. Hospital admission was thus considered to represent an internally-consistent disease severity threshold within our sample monitored from the point of outpatient testing.

As a secondary endpoint indicating progression to more severe disease, we also evaluated intensive care unit (ICU) admission, mechanical ventilation, or death within 60 days after participants' index test date. We selected a 60-day interval for evaluation of this secondary endpoint to accommodate potential lags in the occurrence of severe clinical outcomes.<sup>21</sup>

**Design and statistical analysis.** We compared clinical outcomes associated with nirmatrelvir-ritonavir receipt in a matched cohort framework, monitoring participants from the point of their index test to the occurrence of each study endpoint or censoring (due end of follow-up, study end, or disenrollment, whichever occurred earlier). We updated participants' treatment assignments at the date of treatment dispense if this occurred  $\geq 1$  day after the index test. For each study endpoint, we defined treatment effectiveness as  $(1 - \text{adjusted hazards ratio [aHR]}) \times 100\%$ , for the aHR comparing outcomes among cases who had received or had not received nirmatrelvir-ritonavir. Effectiveness estimates based on the aHR throughout cases' full follow-up duration should be interpreted as weighted averages of the instantaneous aHRs comparing cases who had received or had not received treatment at each point in time.<sup>30,31</sup> We estimated the aHR and accompanying 95% confidence interval (CI) via Cox proportional hazards models, using the Andersen-Gill extension<sup>32</sup> to update time-varying exposures. We estimated cluster-robust standard errors to account for multiple observations from cases whose treatment status changed during follow-up. We verified the proportional hazards assumption by testing for non-zero slopes of Schoenfeld residuals from fitted models.<sup>33</sup>

To mitigate confounding driven by factors associated with cases' likelihood of both receiving nirmatrelyir-ritonavir and experiencing severe clinical outcomes, we constructed a directed acyclic graph identifying a minimal set of covariates for statistical adjustment (Figure S1). We defined regression strata (matches) among cases on the basis of their week of SARS-CoV-2 testing; age (within bands of 12-19, 20-29, 30-39, ..., 80-89, and ≥90 years); sex; clinical status; healthcare utilization in the year prior to the index test (0-4, 5-14, 15-29, or ≥30 outpatient visits and ≥1 ED presentation or inpatient admission); COVID-19 vaccine doses received; presence of comorbidities (Charlson comorbidity index values of 0, 1-2, 3–5, or  $\geq$ 6) and body mass index category (underweight, normal weight, overweight, obese, or morbidly obese, as defined in Table 1). We measured clinical status according to two criteria: (1) receipt of any clinical care in association with testing (across ED, urgent care, outpatient, or telehealth settings), and (2) days from symptom onset, or absence of acute symptoms, at the start of the observation interval. As prescribing guidelines have assigned differing priority to cases with one or more risk factors (e.g., age, obesity, comorbidity, or lack of vaccination),<sup>34</sup> and interactions are present in the effects of these risk factors on cases' likelihood of severe disease.<sup>35,36</sup> this approach was selected to allow differing baseline hazards across all combinations of the listed covariates. We further controlled for race/ethnicity, current or former cigarette smoking, documentation of prior SARS-CoV-2 infection, neighborhood deprivation index guintile, and receipt of other vaccines (as an additional measure of healthcare-seeking behavior) as covariates in regression models, as effect modification was considered less likely among these variables. We repeated analyses in subgroups who received ≥2 or ≥3 COVID-19 vaccine doses.

Because smoking status, BMI, and census-tract neighborhood deprivation index measures may be missing within KSPC records,<sup>19</sup> we conducted multiple imputation to sample from the joint distribution of these variables with respect to all other observed characteristics of cases.<sup>37</sup> We repeated analyses across each of 5 independent pseudo-datasets completed via imputation of missing observations. Reported results pool parameter estimates across analyses undertaken with each of the 5 pseudo-datasets according to Rubin's rules.<sup>38</sup>

All analyses were performed using R software (version 4.2.1; R Foundation for Statistical Computing, Vienna, Austria). The study was approved by the KPSC Institutional Review Board, which granted a waiver of informed consent.

**Role of the sponsor.** This study was sponsored by the US Centers for Disease Control and Prevention and the National Institutes of Health. The funders of the study had no role in study design, data collection, analysis, interpretation, preparation of the report, or the decision to submit for publication.

#### RESULTS

In total, 197,484 KPSC members without a prior positive test result within 90 days received positive SARS-CoV-2 molecular test results during the study period, among whom 166,980 were aged  $\geq$ 12 years with  $\geq$ 1 year of continuous enrollment before their test date and thus eligible for inclusion (Table S1). Within this population, 12,574 (7.5% of 166,980) cases received nirmatrelvir-ritonavir at any point in their clinical course, among whom 10,038 (79.8% of 12,574) were tested within 0–5 days after symptom onset, 1,755 (14.0%) were tested ≥6 days after symptom onset, and 781 (6.2%) did not have acute SARS-CoV-2 symptoms recorded at the point of testing (Figure 1). Among all treated cases, 11,653 (92.7% of 12,574) did not have clinical care interactions with providers in ED, urgent care, outpatient, or telehealth settings in association with their index test. Among 154,406 cases who did not receive nirmatrelvir-ritonavir, 101,537 (65.8%) were tested within 0–5 days of symptom onset, 26,903 (17.4%) were tested ≥6 days after symptom onset, 25,966 (16.8%) did not have acute symptoms recorded at the point of testing, and 146,609 (95.0%) did not have interactions with outpatient care providers in association with testing (Table S1). Recipients of nirmatrelvir-ritonavir were generally older than non-recipients (60.3% [7,582] of recipients and 28.8% [44,500] of non-recipients were ≥60 years old), were more likely to have chronic comorbid conditions (57.6% [7,237] of recipients and 28.1% [43,314] of non-recipients; Table S2), were more likely to be obese or morbidly obese (44.6% [5.604] of recipients and 32.7% [50.544] of non-recipients), had higher levels of healthcare utilization within the prior year (40.7% [5,115] of recipients and 24.2% [37,407] of nonrecipients had ≥1 ED presentation or inpatient admission), and were more likely to have received COVID-19 vaccines (90.8% [11,411] of recipients and 83.0% [128,090] of non-recipients had received  $\geq 2$  doses, while 7.4% [932] of recipients and 14.5% [22,338] of non-recipients had received 0 doses). Differences between recipients and non-recipients in race/ethnicity, cigarette smoking, and community socioeconomic characteristics were less clearly pronounced. Among cases aged 12-39 years or 40-64 years, presence of comorbidities and high BMI were associated with greater increases in the likelihood of receiving nirmatrelvir-ritonavir than among cases aged ≥65 years (Table S3).

The proportion of cases receiving nirmatrelvir-ritonavir increased with time throughout the study period. Whereas the weeks from 31 December, 2021 to 7 April, 2022 saw dramatic increases in nirmatrelvir-ritonavir dispenses first among cases aged  $\geq$ 65 years, those with comorbid conditions, and those with BMI values indicating obesity or morbid obesity, differences in the relative likelihood of nirmatrelvir-ritonavir dispense among these groups were became pronounced for cases diagnosed between 8 April to 7 October, 2022 (**Figure 2**).

Among all eligible cases, 7,274 (57.8% of 12,574) nirmatrelvir-ritonavir recipients and 126,152 (81.7% of 154,406) nonrecipients were retained in analyses with ≥1 eligible match based on their week of SARS-CoV-2 testing, age, sex, clinical status, prior-year healthcare utilization, COVID-19 vaccine doses received, Charlson comorbidity index, and BMI (**Table 1**; **Table S4**). In comparison to the full eligible population, cases for whom matches were identified were less likely to have received outpatient care in association with testing (1.5% [1,952] versus 5.2% [8,718]), were slightly younger (26.5% [35,354] versus 31.2% [52,082] aged ≥60 years), were less likely to have comorbid conditions (22.6% [30,170] versus

69.7% [50,551]), and were less likely to have had  $\geq$ 1 ED presentation or inpatient admission in the prior year (18.9% [25,272] versus 25.5% [42,522]). In total, the frequency of hospital admission, ICU admission, mechanical ventilation, and death during follow-up was 0.5% (687), 0.1% (173), 42 (<0.1%), and 134 (0.1%), respectively, within the population retained in analyses, as compared to 0.9% (1,440), 0.3% (429), 0.1% (133), and 423 (0.3%), respectively, within the full eligible population. Differences between recipients and non-recipients of nirmatrelvir-ritonavir within the analytic sample resembled those within the full eligible population (**Table 1**, **Table S1**, **Table S4**).

The primary endpoint of hospital admission or death due to any cause within 30 days from the positive index test occurred among 51 (0.7% of 7,274) nimatrelvir-ritonavir recipients and 695 (0.5% of 126,152) non-recipients (**Table S5**). Disenrollment or censoring before 30 days, or before occurrence of the primary endpoint, occurred for 212 (2.9% of 7,274) treated participants and 2,790 (2.1% of 126,152) participants who did not receive treatment. After adjustment for the aforementioned differences in risk status among treated and untreated cases, receipt of nirmatrelvir-ritonavir 0–5 days after symptom onset was associated with 79.6% (33.9% to 93.8%) effectiveness against progression to the primary endpoint of hospital admission or death due to any cause within 30 days after cases' index test (**Table 2**). Courses administered at any time, regardless of the presence or timing of symptoms, were associated with 53.6% (6.6% to 77.0%) effectiveness against progression to the same endpoint. Among cases who received nirmatrelvir-ritonavir, cases who progressed to hospital admission or death within 30 days of their index test were older (82.4% [42/51] versus 53.8% [3,887/7,223] treated cases experiencing and not experiencing the outcome, respectively); more likely to have been tested  $\geq 6$  days after symptom onset (41.2% [21] versus 17.6% [1,269] of treated cases experiencing or not experiencing the outcome; **Table S6**).

For the secondary endpoint of ICU admission, mechanical ventilation, or death within 60 days after cases' index test date, receipt of nirmatrelvir-ritonavir was associated with 89.2% (–25.0% to 99.3%) effectiveness when administered within 0–5 days of symptom onset (**Table 2**). For dispenses occurring at any time in the clinical course, effectiveness against the same endpoint was 84.1% (18.8% to 96.9%). Attributes distinguishing cases who experienced this secondary endpoint from those who did not resembled attributes predicting hospital admission or death within 30 days after cases' index test (**Table S7**).

Exploratory analyses identified varying estimates of treatment effectiveness according to the timing of dispense in relation to symptom onset. Nirmatrelvir-ritonavir was associated with 89.6% (50.2% to 97.8%) effectiveness against progression to the primary endpoint of hospital admission or death due to any cause within 30 days after a positive test for cases who received treatment on the day of their index test and 0–5 days from symptom onset, consistent with the design of the EPIC-HR trial (**Table S8**). For all cases dispensed treatment on the day of their index test, effectiveness against the same endpoint was 77.7% (31.3% to 92.7%). Treatment dispenses occurring 0–3 days after symptom onset and at any time after symptom onset were associated with 81.1% (34.1% to 94.6%) and 59.5% (12.8% to 81.2%) effectiveness against hospital admission or death within 30 days after the index test, respectively. Effectiveness of treatment dispenses occurring  $\geq$ 6 days after symptom onset or in the absence of acute symptoms was 43.8% (–33.3% to 81.7%; **Table S9**). Cases tested and treated at later stages of their clinical course were generally older than those tested or treated within 0–

5 days, more likely to receive outpatient care in association with testing, and more likely to have chronic comorbid conditions (**Table S10**, **Table S11**, and **Table S12**).

In subgroup analyses of cases who had received  $\geq 2$  and  $\geq 3$  COVID-19 vaccine doses, effectiveness of nirmatrelvirritonavir against the primary endpoint of hospital admission or death within 30 days was 83.1% (30.4% to 95.9%) and 92.2% (52.0% to 98.7%), respectively, when treatment dispense occurred 0–5 days from symptom onset (**Table 3**). Effectiveness against the same endpoint for treatment dispenses occurring at any time was 55.3% (6.6% to 78.7%) for cases who had received  $\geq 2$  COVID-19 vaccine doses, and 66.5% (24.0% to 85.3%) for cases who had received  $\geq 3$ COVID-19 vaccine doses.

#### DISCUSSION

In this cohort study conducted among a highly vaccinated population in a large US healthcare system, nirmatrelvirritonavir was effective in preventing hospitalization or death within 30 days following a positive outpatient test for SARS-CoV-2 infection. For treatment courses administered at any point during the clinical course, including in the absence of symptoms, effectiveness against the primary endpoint of hospital admission or death due to any cause was 53.6% (6.6% to 77.0%). Early treatment was associated with the greatest clinical benefit: dispenses occurring within 0-5 and 0-3 days from symptom onset were associated with 79.6% (33.9% to 93.8%) and 81.1% (34.1% to 94.6%) effectiveness against this endpoint, respectively. Among cases tested 0-5 days following symptom onset, receipt of nirmatrelvir-ritonavir on the day of testing was associated with 89.6% (50.2% to 97.8%) effectiveness against the primary endpoint. This finding closely emulates results of the EPIC-HR trial, in which cases who were randomized to treatment or placebo on the day of their test (and 0-5 days after symptom onset) experienced an 87.8% reduction in risk of COVID-19 associated hospital admission or death due to any cause.<sup>6</sup> In our study population, cases treated ≥6 days after symptom onset constituted only 22.2% of nirmatrelvir-ritonavir recipients, but accounted for 45.7% of recipients who were hospitalized, 70.0% of recipients who required intensive care or mechanical ventilation, and 60.0% of recipients who died within 60 days of their index test. Taken together, our findings suggest that early receipt of nirmatrelvir-ritonavir within 0-5 days after symptom onset likely best reduces risk of hospital admission or death for cases testing positive for SARS-CoV-2 in outpatient settings, underscoring the continued need for prompt testing and treatment among cases at high risk for progression to severe COVID-19.

Postlicensure studies of nirmatrelvir-ritonavir effectiveness in Israel, Hong Kong, and the United States have yielded discordant results, estimating 21–79% effectiveness against severe disease or hospital admission endpoints in outpatient samples.<sup>8–14</sup> Differences in the populations enrolled, as well as the circumstances of nirmatrelvir-ritonavir access and availability within each setting, merit consideration when reconciling these findings. Studies undertaken during the initial rollout of nirmatrelvir-ritonavir generally enrolled populations at high risk of disease progression; for instance, in two studies in Israel, the mean age of treated cases was 67–69 years, and the prevalence of obesity, diabetes, hypertension, and cardiovascular disease among treated cases each exceeded 30%.<sup>8,10</sup> One of these studies estimated greater effectiveness of nirmatrelvir-ritonavir among adults aged  $\geq$ 65 years than adults aged 40–64 years, and among adults who had received  $\geq$ 2 doses or experienced prior natural infection in comparison to those without previous immunity.<sup>8</sup> However, such patterns are inconsistent across reports. One US study estimated greater effectiveness among adults aged <65

years than those aged 65–79 or ≥80 years, while another US study<sup>14</sup> and a separate study in Hong Kong<sup>12</sup> did not identify differences in effectiveness across subgroups defined by age, immunity, or presence of comorbidities. In further contrast to findings in Israel, studies in Hong Kong<sup>11,12</sup> which have enrolled the most elderly samples (majority of treated cases aged >70 years) with the lowest vaccine coverage (33–42% considered fully vaccinated against COVID-19) have generated the lowest estimates of effectiveness of nirmatrelvir-ritonavir, spanning 21–33%. Differences across settings or over time in hospital admission criteria for COVID-19 cases may also contribute to variation in effectiveness estimates.

Because the perceived risk for a cases to progress to severe disease likely factors into clinical decision-making around nirmatrelvir-ritonavir prescribing and cases' adherence to treatment, controlling for potential differences in clinical status among cases who receive or do not receive treatment is important for causal inference in pharmacoepidemiologic studies. Whereas we identify time from symptom onset as a potential modifier of treatment effectiveness, symptoms data were lacking in prior observational studies from all<sup>8-12,14</sup> or most<sup>13</sup> cases analyzed. Our estimate of 53.6% effectiveness against the primary endpoint for cases treated at any time in their clinical course aligns with estimates of 45-51% effectiveness against hospitalization in other US observational studies which did not collect symptoms data or restrict according to symptom onset timing.<sup>9,14</sup> Other unique features of KPSC data may also have helped to control for differences in clinical status and healthcare-seeking behavior in our study. These included the opportunity to match cases according to whether they received clinical care in association with testing (a potential proxy for disease severity); comprehensive information on healthcare-seeking behavior from prior-year interactions across outpatient, ED, and inpatient settings; and documentation of receipt of other vaccines, including 2021-22 seasonal influenza vaccination. Whereas cases with higher rates of prior-year healthcare interactions, higher BMI, and greater burden of comorbid conditions were more likely to receive nirmatrelvir-ritonavir in our sample, the strength of these associations varied considerably across age groups (Table S3) and over time (Figure 2). Matching cases within regression strata provided an opportunity to account for potential interactions among variables associated with cases' likelihood of receiving treatment, as observed within our sample, as well as potential interactions among these variables influencing cases' risk for adverse clinical outcomes.<sup>35,36</sup> Covariate adjustment<sup>8,10,14</sup> and inverse probability weighting<sup>9,11</sup> frameworks applied in other studies may have afforded less flexibility as a strategy to mitigate confounding.

Our study has at least eight limitations. First, capture of several variables is incomplete within KPSC data. While multiple imputation provided a principled approach to address missing data on smoking or BMI, potential misclassification of cases' immunity from undiagnosed prior infections or those never reported to KPSC remains a concern. Second, as our study is observational in nature, unmeasured confounding may hinder causal inference. Regardless, KPSC records provided more comprehensive measures of clinical status and healthcare-seeking behavior than those available in previous studies,<sup>8–14</sup> yielding a novel opportunity to address factors potentially influencing receipt of nirmatrelvir-ritonavir and disease severity. Third, we cannot verify whether cases who received nirmatrelvir-ritonavir adhered to treatment as recommended. Our findings should thus be interpreted as measuring intention-to-treat effects under real-world conditions of use. Fourth, our approach to variable selection via a directed acyclic graph, and use of matching to accommodate potential interactions among confounding variables, prioritized validity over precision of estimates. Despite this, our analysis retains sufficient power to reject the null hypothesis when estimating effects of the primary exposures on the primary outcome. Fifth, due to relatively lower risk of severe disease within our study highly vaccinated population, primary and secondary endpoints were rarely observed. Concerns about sparse data bias<sup>39</sup> are nonetheless mitigated by

the fact that point estimates across all endpoints, exposures, and subgroups within our study spanned only 43.8% to 92.2%, with this variability largely explained by time between symptom onset and treatment. Our estimates of treatment effectiveness within three or five days of symptom onset closely matched the findings of the EPIC-HR trial.<sup>6</sup> Sixth, our analysis did not exclude cases who received other antivirals. Molnupiravir was the only other approved antiviral therapy for treatment of mild- to moderate COVID-19 in the outpatient setting during this study period, but was rarely prescribed as its use was reserved for cases with nirmatrelvir-ritonavir treatment contraindications. Seventh, our endpoint of hospital admission or death due to any cause following a positive outpatient SARS-CoV-2 test may have captured admissions unrelated to COVID-19. Although a substantial proportion of SARS-CoV-2 infections among hospitalized patients may be detected due to entry screening, cases' absolute risk of COVID-19 related hospital admission during SARS-CoV-2 infection greatly exceeds their risk of hospitalization due to other causes within the same timeframe.<sup>40</sup> The proportion of hospital admissions unrelated to COVID-19 during follow-up after outpatient testing is thus expected to be markedly lower than the proportion of hospital admissions in which SARS-CoV-2 infection is identified incidentally rather than causally.<sup>41</sup> If present, misclassification of incidental hospital admissions would be expected to bias our results to the null.<sup>42</sup> Last, aHR estimates should be interpreted in light of potential underlying depletion-of-susceptibles bias. Rapid progression to hospital admission among cases at the greatest risk may contribute to changes over time in the distribution of covariates among treated and untreated cases, confounding the comparison of instantaneous hazards.<sup>30</sup>

In summary, when compared to matched non-recipients, recipients of nirmatrelvir-ritonavir were substantially less likely to experience hospitalization or death following a positive outpatient SARS-CoV-2 test in southern California during the BA.2 and BA.4/BA.5 waves. Early treatment within 0–5 days from symptom onset was associated with greater effectiveness.

#### REFERENCES

- 1. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. *NEJM* 2021; 384: 229–37.
- 2. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab. *NEJM* 2021; 385: 1941–50.
- 3. Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with COVID-19. *NEJM* 2021; 385: e81.
- 4. Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe COVID-19 in outpatients. *NEJM* 2022; 386: 305–15.
- 5. Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. *Nature* 2022; 604: 553–6.
- 6. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. *NEJM* 2022; 386: 1397–408.
- Gold JAW. Dispensing of oral antiviral drugs for treatment of COVID-19 by zip code level social vulnerability United States, December 23, 2021–May 21, 2022. Morb Mortal Wkly Rep 2022; 71. doi:10.15585/mmwr.mm7125e1.
- 8. Arbel R, Wolff Sagy Y, Hoshen M, et al. Nirmatrelvir use and severe COVID-19 outcomes during the Omicron Surge. *NEJM* 2022; NEJMoa2204919.

- 9. Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system. *medRxiv* 2022; doi:10.1101/2022.06.14.22276393.
- 10. Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in reducing severe COVID-19 and mortality in high-risk patients. *Clin Infect Dis* 2022; ciac443.
- Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory COVID-19 patients during the BA.2.2 wave in Hong Kong: an observational study. Lancet 2022; 400: 1213–22.
- 12. Yip TCF, Lui GCY, Lai MSM, et al. Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients. *Clin Infect Dis* 2022; ciac687.
- Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis 2022; doi:10.1016/S1473-3099(22)00507-2.
- 14. Shah MM, Joyce B, Plumb ID, et al. Paxlovid associated with decreased hospitalization rate among adults with COVID-19—United States, April-September, 2022. *MMWR* 2022; 71: 1531–7.
- 15. Vasan A, Foote M, Long T. Ensuring widespread and equitable access to treatments for COVID-19. JAMA 2022; 328: 705–6.
- 16. Bajema KL, Wang XQ, Hynes DM, et al. Early adoption of anti-SARS-CoV-2 pharmacotherapies among US veterans with mild to moderate COVID-19, January and February 2022. JAMA Netw Open 2022; 5: e2241434.
- 17. Clarke KEN, Jones JM, Deng Y, et al. Seroprevalence of infection-induced SARS-CoV-2 antibodies United States, September 2021–February 2022. *Morb Mortal Wkly Rep* 2022; 71. doi:10.15585/mmwr.mm7117e3.
- 18. Lewnard JA, Hong V, Kim JS, et al. Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome. *medRxiv* 2022; doi:10.1101/2022.07.31.22278258.
- Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California. *Nat Med* 2022; 28: 1933–43.
- Malden DE, Hong V, Lewin BJ, et al. Hospitalization and emergency department encounters for COVID-19 after Paxlovid treatment — California, December 2021–May 2022. *Morb Mortal Wkly Rep* 2022; 71. doi:10.15585/mmwr.mm7125e2.
- 21. Lewnard JA, Liu VX, Jackson ML, et al. Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study. *BMJ* 2020; 369: m1923.
- 22. Koebnick C, Langer-Gould AM, Gould MK, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. *Perm J* 2012; 16: 37–41.
- 23. Andrejko KL, Myers JF, Fukui N, et al. Real-world uptake of COVID-19 vaccination among individuals expressing vaccine hesitancy: a registry-linkage study. *medRxiv* 2022; doi:10.1101/2022.08.02.22278300.
- 24. Malden DE, Tartof SY, Ackerson BK, et al. Natural language processing for improved COVID-19 characterization: evidence from more than 350,000 patients in a large integrated health care system. *JMIR Public Health Surveill* 2022; doi:10.2196/41529.
- 25. Messer LC, Laraia BA, Kaufman JS, et al. The development of a standardized neighborhood deprivation index. *J Urban Health* 2006; 83: 1041–62.
- 26. Glassheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A. Charlson comorbidity index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits 2019; 12: 188–97.

- 27. Sundarajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004; 57: 1288–94.
- 28. Kuswardhani RAT, Henrina J, Pranata R, Lim MA, Lawrensia S, Suastika K. Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: a systematic review and meta-analysis. Diabetes Metab Syndr 2020; 14: 2103–9.
- 29. Huynh DN, Millan A, Quijada E, John D, Khan S, Funahashi T. Description and early results of the Kaiser Permanente Southern California COVID-19 home monitoring program. Permanente J 2021; 25: 1–7.
- 30. Hernán MA. The hazards of hazard ratios. Epidemiology 2010; 21: 13-5.
- 31. Stensrud JM, Hernán MA. Why test for proportional hazards? JAMA 2020; 323: 1401–2.
- 32. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat 1982; **10**: 1100–20.
- 33. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982; 69: 239-41.
- US National Institutes of Health. Information on COVID-19 treatment, prevention, and research: COVID-19 Treatment Guidelines. Available from https://www.covid19treatmentguidelines.nih.gov (Accessed 2 December, 2022).
- 35. Tartof SY, Qian L, Hong V, et al. Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. Ann Intern Med 2020; 173: 773–81.
- Fernández Villalobos NV, Ott JJ, Klett-Tammen CJ, et al. Effect modification of the association between comorbidities and severe course of COVID-19 disease by age of study participants: a systematic review and meta-analysis. Syst Rev 2021; 10: 194.
- 37. Honaker J, King G, Blackwell M. Amelia II: a program for missing data. *J Stat Softw* 2011; doi:10.18637/jss.v045.i07.
- 38. Rubin DB. Multiple imputation after 18+ years: J Am Stat Assoc 1996; 91, 473-89.
- 39. Greenland S, Mansournia MA, Altman DG. Sparse data bias: a problem hiding in plain sight. *BMJ* 2016; 352: i1981.
- 40. Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of Omicron and Delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet 2022; 399: 1618–24.
- 41. Lewnard JA, Patel MM, Jewell NP, et al. Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines. Epidemiology 2021; 32: 508–17.
- 42. Stowe J, Andrews N, Kirsebom F, Ramsay M, Lopez Bernal J. Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalization: a test-negative case-control study. Nat Comm 2022; 13: 5736.

#### ACKNOWLEDGMENTS

This study was funded by the US Centers for Disease Control & Prevention (grant 75D3-121C11520 to SYT) and the National Institute for Allergy and Infectious Diseases of the US National Institutes of Health (grant R01-Al4812701A1 to JAL).

#### DATA SHARING STATEMENT

Anonymized data that support the findings of this study may be made available from the investigative team in the following conditions: (1) agreement to collaborate with the study team on all publications, (2) provision of external funding for administrative and investigator time necessary for this collaboration, (3) demonstration that the external investigative team is qualified and has documented evidence of training for human subjects protections, and (4) agreement to abide by the terms outlined in data use agreements between institutions.

#### DISCLOSURES

JAL discloses receipt of grants and honoraria from Pfizer, Inc. separately from this study. SYT discloses receipt of grants from Pfizer, Inc. separately from this study. LP, LJ, and JMM are employees of Pfizer, Inc.

Table 1: Characteristics of the analytic sample.

Characteristic		Expos	ure, <i>n</i> (%)
		Paxlovid received	Paxlovid not received
Age		N-7,274	71-120,132
5	12-19 years	11 (0.2)	11,054 (8.8)
	20-29 years	170 (2.3)	13,047 (10.3)
	30-39 years	505 (6.9)	20,761 (16.5)
	40-49 years	1,103 (15.2)	26,122 (20.7)
	50-59 years	1,556 (21.4)	23,742 (18.8)
	60-69 years	1,674 (23.0)	18,117 (14.4)
	70-79 vears	1.503 (20.7)	9.213 (7.3)
	80-89 years	602 (8.3)	3.325 (2.6)
	≥90 vears	150 (2.1)	770 (0.6)
Sex			
	Male	3,080 (42.3)	56,357 (44.7)
Time from symptoms onset to testing <sup>1</sup>			
	0-5 days	5,472 (75.2)	84,657 (67.1)
	6-14 days	1,290 (17.7)	20,070 (15.9)
	No acute symptoms indicated at point of testing	512 (7.0)	21,425 (17.0)
Outpatient care received $\leq 1$ day before testing <sup>2</sup>			
	Any outpatient care	209 (2.9)	1,743 (1.4)
Charlson comorbidity index			
	0	3,740 (51.4)	99,516 (78.9)
	1-2	2,728 (37.5)	22,055 (17.5)
	3-5	634 (8.7)	3,434 (2.7)
	≥6	172 (2.4)	1,147 (0.9)
Prior-year healthcare interactions		. ,	
•	0 outpatient visits	28 (0.4)	4.412 (3.5)
	1-4 outpatient visits	776 (10.7)	34.057 (27.0)
	5-9 outpatient visits	1,700(23.4)	35,836 (28,4)
	10-14 outpatient visits	1,415 (19.5)	20.027 (15.9)
	15-19 outpatient visits	1.043 (14.3)	11.089 (8.8)
	20-29 outpatient visits	1 164 (16.0)	11 495 (9 1)
	30-39 outpatient visits	486 (6 7)	4 445 (3 5)
	>10 outpatient visits	400 (0.7) 662 (0.1)	4,443 (3.3)
	Any ED procentation	2 270 (21 2)	4,791(3.0)
	Any inpatient admission	2,279 (31.3)	5 663 (4 5)
Prior SAPS-CoV-2 infection <sup>3</sup>	Any inpatient admission	412 (5.7)	5,005 (4.5)
	Any documented infection	176 (2.4)	5 540 (4 4)
Prior COVID-19 vaccination		170 (2.4)	3,340 (4.4)
	0 doses received	301 (51)	16 750 (13 3)
	1 dose received	<u> 10 (0 7)</u>	2 016 (1 6)
		49 (0.7)	2,010 (1.0)
	2 doses received	900 (10.0)	31,504 (25.0)
	3 doses received	4,433 (60.9)	66,738 (52.9)
Dece?	4 doses received	1,433 (19.7)	9,135 (7.2)
Race	White were live entry	4 004 (00 4)	20.004 (24.2)
	White, non-Hispanic	1,921 (26.4)	26,884 (21.3)
	Black, non-Hispanic	688 (9.5)	9,981 (7.9)
	Hispanic	3,061 (42.1)	60,249 (47.8)
	Asian	1,225 (16.8)	18,889 (15.0)
	Pacific Islander	74 (1.0)	1,247 (1.0)
	Other/unknown/mixed race	305 (4.2)	8,902 (7.1)
Body mass index⁴			
	Underweight (<18.5)	38 (0.5)	5,663 (4.5)
	Normal weight (18.5-24.9)	1,240 (17.0)	26,550 (21.0)
	Overweight (25.0-29.9)	2,190 (30.1)	33,131 (26.3)
	Obese (30-39.9)	2,703 (37.2)	33,418 (26.5)
	Morbidly obese (≥40.0)	550 (7.6)	6,064 (4.8)
Cigarette smoking <sup>3,4</sup>	· · · ·	. ,	. ,
-	Current smoker	254 (3.5)	4,105 (3.3)
	Former smoker	1,474 (20.3)	16,491 (13.1)
	Never smoked	4,993 (68.6)	83,486 (66.2)
Neighborhood deprivation index <sup>3,4</sup>		· /	· · /
	First guintile (least deprived)	1,235 (17.0)	17,836 (14.1)
	Second quintile	1,667 (22.9)	27,319 (21.7)
	Third quintile	1.825 (25.1)	31,852 (25.2)
	Fourth quintile	1,593 (21 9)	29,568 (23.4)
	Fifth quintile (most deprived)	948 (13 0)	19 483 (15 4)
Receipt of other respiratory vaccines <sup>3</sup>		J+0 (13.0)	10,700 (10.4)
Receipt of other respiratory vaccines	2021-22 seasonal influenza vessino	5 211 (72 1)	67 052 (52 0)
	Preumococcal conjugate vaccing	3,244 (12.1) 2 (171 (20 E)	01,302 (00.3) 22 257 (10 1)
	n neumococcal conjugate vaccine	2,011 (20.3)	20,207 (10.4)
Clinical outcomen	Fineumococcar polysacchanue vaccine	J,912 (JJ.8)	29,000 (23.7)
Cimical outcomes	Any boanital admission within 20 days		611 (O E)
	Any nospital admission within 30 days	40 (0.0)	041 (0.5)

Any intensive care unit admission within 60 days	9 (0.1)	164 (0.1)
Mechanical ventilation within 60 days	1 (<0.1)	41 (<0.1)
Death within 60 days	10 (0.1)	124 (0.1)

Data on exposure prevalence among treatment recipients and non-recipients include all eligible cases who were assigned matches. Comparisons to full eligible case population (*N*=12,574 recipients of nirmatrelvir-ritonavir and *N*=154,406 non-recipients) are presented in **Table S1**.

<sup>1</sup>Median time from symptoms onset to testing, among cases with symptoms at the point of testing, was 2 days for those who received and those who did not receive nirmatrelvir-ritonavir (interquartile range 1 to 4 days for both populations; **Figure 1**).

<sup>2</sup>Outpatient care received on or 1 day before the index test across emergency department, urgent care, physician office, and telehealth settings. <sup>3</sup>Variables not included in matching assignments; these variables were controlled for in regression models via covariate adjustment.

<sup>4</sup>Variables imputed due to missingness (17.0% [*n*=22,623] of smoking observations, 16.4% [*n*=21,879] of body mass index observations, and 0.1% [*n*=100] of neighborhood deprivation index observations among included participants). Percentages indicated in the table are computed among individuals with non-missing observations.

#### Table 2: Effectiveness of nirmatrelvir-ritonavir in preventing progression to severe disease endpoints.

Endpoint	Timing of dispense in relation to symptoms onset <sup>1</sup>	Discorda	Discordant pairs <sup>2</sup>		ordant pairs <sup>2</sup> Effectivenes		eness	
		Outcome observed for recipient, non- recipient censored	Outcome observed for non- recipient, recipient censored	Estimate, % (95% confidence interval)	<i>p</i> -value (two- sided)			
All-cause hospital admission or death within 30 days from positive SARS-CoV-2 test								
	0-5 days after symptoms onset	8	11	79.6 (33.9, 93.8)	<0.01			
	At any time, regardless of symptoms	26	23	53.6 (6.6, 77.0)	0.03			
All-cause intensive care unit admission, mechanical ventilation, or death within 60 days from positive SARS-CoV-2 test								
	0-5 days after symptoms onset	2	7	89.2 (-25.0, 99.3)	0.07			
	At any time, regardless of symptoms	10	11	84.1 (18.8, 96.9)	0.03			

Treatment effectiveness is measured as  $(1 - adjusted hazard ratio) \times 100\%$ , comparing outcomes among individuals who received treatment to those who did not. Time at risk is measured from the date of the index positive test, updating individuals' exposure status at the point of treatment. Estimates are fitted via Cox proportional hazards models across each of 5 pseudo-datasets generated by multiple imputation of missing values. Regression strata include age age (±10 years); sex; time from symptoms onset or absence of symptoms; receipt of outpatient care in association with testing; Charlson comorbidity index (0, 1-2, 3-5, and ≥6); prior-year healthcare interactions (including 0-4, 5-14, 15-24, 25-34, and ≥35 outpatient visits, and any emergency department presentation or inpatient admission); prior COVID-19 vaccination, defined by number of doses received ≥14 days prior testing; and body mass index (underweight [<18.5], normal weight [18.5-24.9], overweight [25.0-29.9], obese [30.0-39.9], or morbidly obese [≥40.0]). Further variables listed in **Table 1** are controlled for via covariate adjustment.

<sup>1</sup>We present effectiveness estimates for alternative subgroups, defined by time from symptoms onset to testing and presence or absence of symptoms, in **Table S8** and **Table S9**.

<sup>2</sup>Reasons for censoring and lengths of follow-up are enumerated in **Table S5**.

# Table 3: Effectiveness of Paxlovid in preventing progression to hospital admission or death within 30 days from positive SARS-CoV-2 test, according to prior COVID-19 vaccination or documented history of SARS-CoV-2 infection.

Population	Timing of dispense in relation to symptoms onset	Discord	ant pairs	Effectiveness		
		Outcome observed for recipient, non- recipient censored	Outcome observed for non- recipient, recipient censored	Estimate, % (95% confidence interval)	<i>p</i> -value (two- sided)	
Participants who received 0 COVID-19 vaccine doses						
	0-5 days after symptoms onset	1	0			
	At any time, regardless of symptoms	1	0			
Participants who received 1 COVID-19 vaccine dose						
	0-5 days after symptoms onset	0	0			
	At any time, regardless of symptoms	1	0			
Participants who received ≥2 COVID-19 vaccine doses						
	0-5 days after symptoms onset	7	11	83.1 (30.4, 95.9)	<0.01	
	At any time, regardless of symptoms	24	23	55.3 (6.6, 78.7)	0.03	
Participants who received ≥3 COVID-19 vaccine doses						
	0-5 days after symptoms onset	6	11	92.2 (52.0, 98.7)	<0.01	
	At any time, regardless of symptoms	21	22	66.5 (24.0, 85.3)	<0.01	

Treatment effectiveness is measured as  $(1 - adjusted hazard ratio) \times 100\%$ , comparing outcomes among individuals who received treatment to those who did not. Time at risk is measured from the date of the index positive test, updating individuals' exposure status at the point of treatment. Estimates are fitted via Cox proportional hazards models across each of 5 pseudo-datasets generated by multiple imputation of missing values. Regression strata include age age (±10 years); sex; time from symptoms onset or absence of symptoms; receipt of outpatient care in association with testing; Charlson comorbidity index (0, 1-2, 3-5, and ≥6); prior-year healthcare interactions (including 0-4, 5-14, 15-24, 25-34, and ≥35 outpatient visits, and any emergency department presentation or inpatient admission); prior COVID-19 vaccination, defined by number of doses received ≥14 days prior testing; and body mass index (underweight [<18.5], normal weight [18.5-24.9], overweight [25.0-29.9], obese [30.0-39.9], or morbidly obese [≥40.0]). Further variables listed in **Table 1** are controlled for via covariate adjustment. We use the symbol "--" to indicate cells for which estimates could not be obtained due to positivity violations.



**Figure 1: Timing of SARS-CoV-2 testing and nirmatrelvir-ritonavir dispense.** We present distributions of: (**A**) times from symptom onset to cases' index positive test for SARS-CoV-2 (defined as day 0), for all cases; (**B**) times from testing to nirmatrelvir-ritonavir dispense (defined as day 0), for cases who received treatment; and (**C**) times from symptom onset to nirmatrelvir-ritonavir dispense (defined as day 0), for cases who received treatment.



**Figure 2: Receipt of nirmatrelvir-ritonavir among cases over time and according to risk factors.** Indexing cases by week of their index positive test, panels in the top row illustrate (**A**) total new-onset positive SARS-CoV-2 cases identified via polymerase chain reaction testing in outpatient settings; (**B**) the number of outpatient-identified cases receiving nirmatrelvir-ritonavir; and (**C**) the proportion of outpatient-identified cases receiving oral nirmatrelvir-ritonavir. Panels in the middle and bottom rows disaggregate the proportion of outpatient-identified cases receiving oral nirmatrelvir-ritonavir according to (**D**) age group; (**E**) Charlson comorbidity index values (for which we enumerate specific underlying comorbid conditions within the sample in **Table S2**); (**F**) number of vaccine doses received; (**G**) body mass index; (**H**) receipt of outpatient/physician office, or telehealth setting; and (**I**) presence and timing of potential COVID-19 symptoms at the point of testing. Grey shaded areas delineate testing dates for which cases were included in the study period. Lines in panels **D-I** present 3-week moving averages incorporating data from 7 days before and after each study week.

#### **Supporting information**

Effectiveness of nirmatrelvir-ritonavir against hospital admission or death: a cohort study in a large US healthcare system

Joseph A. Lewnard, PhD<sup>1,2,3</sup>; John M. McLaughlin, PhD<sup>4</sup>; Debbie Malden, DPhil<sup>5</sup>; Vennis Hong, MPH<sup>5</sup>; Laura Puzniak, PhD, MPH<sup>4</sup>; Bradley K. Ackerson, MD<sup>5</sup>; Bruno J. Lewin, MD<sup>5</sup>; Jeniffer S. Kim, PhD<sup>5</sup>; Sally F. Shaw, DrPH<sup>5</sup>; Harpreet Takhar, MPH<sup>5</sup>; Luis Jodar, PhD<sup>4</sup>; Sara Y. Tartof, PhD, MPH<sup>5,6</sup>

- 1. Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
- 2. Division of Infectious Diseases & Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
- 3. Center for Computational Biology, College of Engineering, University of California, Berkeley, Berkeley, California 94720, United States
- 4. Pfizer Inc, New York, New York.
- 5. Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, United States
- 6. Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California 91101, United States

#### Contents of this supplement

Table S1	Characteristics of cases receiving and those not receiving nirmatrelvir-ritonavir within the analytic sample and among all eligible cases.	22
Table S2	Comorbid conditions within the analytic sample and among all eligible cases.	24
Table S3	Receipt of nirmatrelvir-ritonavir at ages 12-39 years, 40-64 years, and ≥65 years among cases within the analytic sample and among all eligible cases.	25
Table S4	Characteristics of cases included in the analytic sample and those excluded due to a lack of eligible matches.	27
Table S5	Censoring, outcomes, and lengths of follow-up in survival analyses.	29
Table S6	Characteristics of patients experiencing or not experiencing hospital admission or death within 30 days of testing.	30
Table S7	Characteristics of patients experiencing or not experiencing intensive care unit admission, mechanical ventilation, or death within 60 days of testing.	32
Table S8	Effectiveness of nirmatrelvir-ritonavir in preventing progression to severe disease endpoints when dispensed on patients' testing date.	34
Table S9	Effectiveness of nirmatrelvir-ritonavir in preventing progression to severe disease endpoints within subgroups treated at differing stages in the clinical course.	35
Table S10	Characteristics of individuals tested 0–5 days or 6–14 days after symptoms onset, or in the absence of acute symptoms.	36
Table S11	Characteristics of individuals dispensed nirmatrelvir-ritonavir 0–5 days or 6–14 days after symptoms onset, or in the absence of acute symptoms.	38
Table S12	Characteristics of individuals dispensed nirmatrelvir-ritonavir on or after the day of their index test.	40
Figure S1	Causal directed acyclic graph.	42

### Table S1: Characteristics of cases receiving and those not receiving nirmatrelvir-ritonavir within the analytic sample and among all eligible cases.

Characteristic			Frequency am	ong cases n (%)	
		Nirmatrelvir-rit	onavir received	Nirmatrelvir	-ritonavir not
				roor	ived
		۸		/ece	
		Analytic	All eligible	Analytic	All eligible
		sample	<u>cases</u>	sample	<u>cases</u>
		N=7,274	N=12,574	N=126,152	N=154,406
Age					
-	12-19 years	11 (0.2)	21 (0.2)	11054 (8.8)	13289 (8.6)
	20-29 years	170 (2 3)	294 (23)	13047 (10.3)	15469 (10 0)
	30 30 years	505 (6.0)	784 (6.2)	20761 (16.5)	23882 (15.5)
		1402 (45.2)	104 (0.2)	20701(10.3)	23002(13.3)
	40-49 years	1103 (15.2)	1594 (12.7)	26122 (20.7)	29550 (19.1)
	50-59 years	1556 (21.4)	2299 (18.3)	23742 (18.8)	27715 (17.9)
	60-69 years	1674 (23.0)	2771 (22.0)	18117 (14.4)	22685 (14.7)
	70-79 vears	1503 (20.7)	2909 (23.1)	9213 (7.3)	13536 (8.8)
	80-89 years	602 (8 3)	1463 (11.6)	3325 (2.6)	6320 (4 1)
		150 (2.1)	430 (3.5)	770 (0.6)	1050 (1.2)
Cov	≥90 years	150 (2.1)	400 (0.0)	110 (0.0)	1959 (1.5)
Sex		0000 (40.0)			00404 (44.0)
	Male	3080 (42.3)	5371 (42.7)	56357 (44.7)	69191 (44.8)
Time from symptoms onset to					
testing					
0	0-5 days	5472 (75 2)	10038 (79.8)	84657 (67 1)	101537 (65.8)
	6-14 days	1200 (17.7)	1755 (14.0)	20070 (15.9)	26003 (17 4)
	No coute symptoms indicated at point of	1230 (11.1)	1700 (14.0)	20070 (10.0)	20000 (17.4)
		<b>540 (7 0)</b>	704 (0.0)		05000 (40.0)
	testing	512 (7.0)	781 (6.2)	21425 (17.0)	25966 (16.8)
Outpatient care received ≤1 day					
before testing					
-	Any outpatient care	209 (2.9)	921 (7.3)	1743 (1.4)	7797 (5.0)
Charlson comorbidity index		200 (210)	021 (110)		
	0	37/0 (51 4)	5337 (10 1)	00516 /70 01	111002 (71 0)
	0	3740 (31.4)	5557 (42.4)	99510 (70.9)	111092 (71.9)
	1-2	2728 (37.5)	4965 (39.5)	22055 (17.5)	32047 (20.8)
	3-5	634 (8.7)	1713 (13.6)	3434 (2.7)	7828 (5.1)
	≥6	172 (2.4)	559 (4.4)	1147 (0.9)	3439 (2.2)
Prior-vear healthcare interactions					
,	0 outpatient visits	28 (0.4)	46 (0.4)	4412 (3.5)	4570 (3.0)
	1-4 outpatient visits	776 (10 7)	1105 (8.8)	34057 (27.0)	37234 (24.1)
	E 0 outpatient visits	170 (10.7)	2267(10.0)	25026 (20.4)	40147 (24.1)
		1700 (23.4)	2307 (10.0)	33030 (20.4)	40147 (20.0)
	10-14 outpatient visits	1415 (19.5)	2253 (17.9)	20027 (15.9)	23938 (15.5)
	15-19 outpatient visits	1043 (14.3)	1844 (14.7)	11089 (8.8)	14984 (9.7)
	20-29 outpatient visits	1164 (16.0)	2264 (18.0)	11495 (9.1)	16372 (10.6)
	30-39 outpatient visits	486 (6.7)	1186 (9.4)	4445 (3.5)	7917 (5.1)
	>40 outpatient visits	662 (9 1)	1509 (12 0)	4791 (3.8)	9244 (6 0)
	Any ED presentation	2270 (21.2)	1000 (12.0) 1000 (20 E)	20047 (15.0)	22001 (21 4)
		2219 (31.3)	4030 (30.3)	20047 (15.9)	33001 (21.4)
	Any inpatient admission	412 (5.7)	928 (7.4)	5663 (4.5)	10120 (6.6)
Prior SARS-CoV-2 infection					
	Any documented infection	176 (2.4)	347 (2.8)	5540 (4.4)	7076 (4.6)
Prior COVID-19 vaccination					
	0 doses received	394 (5.4)	932 (7.4)	16759 (13.3)	22338 (14.5)
	1 dose received	49 (0 7)	231 (1.8)	2016 (1.6)	3978 (2.6)
	2 doses received	065 (13 3)	1883 (15.0)	31504 (25.0)	38506 (24.9)
	2 doses received	4422 (60.0)	6502 (52.4)	66729 (52.0)	75950 (40.1)
		4433 (00.9)	0095 (02.4)	00736 (32.9)	10009 (49.1)
_	4 doses received	1433 (19.7)	2935 (23.3)	9135 (7.2)	13725 (8.9)
Race					
	White, non-Hispanic	1921 (26.4)	3658 (29.1)	26884 (21.3)	35131 (22.8)
	Black, non-Hispanic	688 (9.5)	1243 (9.9)	9981 (7.9)	13044 (8.4)
	Hispanic	3061 (42 1)	5135 (40.8)	60249 (47.8)	72609 (47.0)
	Asian	1225 (16.8)	1070 (15.7)	18880 (15.0)	22136 (14 3)
	Asian Decific Islander	74 (10.0)	110 (10.7)	10003 (10.0)	22130 (14.3)
		74 (1.0)	116 (0.9)	1247 (1.0)	1450 (0.9)
	Other/unknown/mixed race	305 (4.2)	450 (3.6)	8902 (7.1)	10036 (6.5)
Body mass index					
	Underweight (<18.5)	38 (0.5)	122 (1.0)	5663 (4.5)	7448 (4.8)
	Normal weight (18.5-24.9)	1240 (17.0)	2451 (19.5)	26550 (21.0)	33520 (21.7)
	Overweight (25,0-29,9)	2190 (30.1)	3735 (29.7)	33131 (26.3)	40671 (26.3)
	Obese $(30-39.9)$	2703 (37.2)	4364 (34 7)	33418 (26.5)	41092 (26.6)
	Marhidly abase $(>40.0)$	550 (J C)	12/0 (0 0)	6064 (4 0)	0150 (20.0)
Cincrette emplois -		000 (7.0)	1240 (9.9)	0004 (4.8)	9452 (0.1)
Gigarette smoking		1000 (00 0)	0.470 (07 1)	00400 (00 0)	100010 (00 5)
	Current smoker	4993 (68.6)	8478 (67.4)	83486 (66.2)	102813 (66.6)
	Former smoker	254 (3.5)	452 (3.6)	4105 (3.3)	5442 (3.5)
	Never smoked	1474 (20.3)	2876 (22.9)	16491 (13.1)	22423 (14.5)
Neighborhood deprivation index		· · · /	· · · /		- /
	First quintile (least deprived)	1235 (17.0)	2147 (17 1)	17836 (14-1)	21866 (14 2)
	Second quintile	1667 (22.0)		27210 (24 7)	23558 (34 7)
		1007 (22.9)	2003 (22.9)	21319(21.1)	33330 (21.7)
		1825 (25.1)	3154 (25.1)	31852 (25.2)	38806 (25.1)
	Fourth quintile	1593 (21.9)	2719 (21.6)	29568 (23.4)	36088 (23.4)
	Fifth quintile (most deprived)	948 (13.0)	1662 (13.2)	19483 (15.4)	23972 (15.5)
		. ,	· /	. ,	` <i>′</i> ~~

Receipt of other respiratory					
vaccines					
	2021-22 seasonal influenza vaccine	5244 (72.1)	9074 (72.2)	67952 (53.9)	84727 (54.9)
	Pneumococcal conjugate vaccine	2071 (28.5)	4516 (35.9)	23257 (18.4)	34068 (22.1)
	Pneumococcal polysaccharide vaccine	3912 (53.8)	7629 (60.7)	29853 (23.7)	43593 (28.2)
Clinical outcomes					
	Any hospital admission within 30 days Any intensive care unit admission within	46 (0.6)	132 (1.0)	641 (0.5)	1308 (0.8)
	60 days	9 (0.1)	24 (0.2)	164 (0.1)	405 (0.3)
	Mechanical ventilation within 60 days	1 (0.0)	5 (0.0)	41 (0.0)	128 (0.1)
	Death within 60 days	10 (0.1)	27 (0.2)	124 (0.1)	396 (0.3)

Data on exposure prevalence among treatment recipients and non-recipients within the analytic sample include all eligible cases who were assigned matches. Percentages indicated in the table are computed among individuals with non-missing observations; missing data are present in participants' smoking status, body mass index, and neighborhood deprivation index, as summarized in **Table 1**.

Condition	<b>HH</b>	Frequency among cases, <i>n</i> (%)				
		Nirmatrelvir-rit	tonavir received	Nirmatrelvir-ritor	navir not received	
		Analytic sample	All eligible cases	Analytic sample	All eligible cases	
		N=7,274	<i>N</i> =12,574	<i>N</i> =126,152	N=154,406	
Diabetes mellitus						
	Uncomplicated	1141 (15.7)	8415 (6.7)	2082 (16.6)	11632 (7.5)	
	Complicated	651 (8.9)	4056 (3.2)	1566 (12.5)	7960 (5.2)	
Cardiovascular/cerebrovascular conditions						
	Hyperlipidemia	2939 (40.4)	24576 (19.5)	5737 (45.6)	35460 (23.0)	
	Myocardial infarction	114 (1.6)	856 (0.7)	289 (2.3)	1772 (1.1)	
	Congestive heart failure	174 (2.4)	1217 (1.0)	440 (3.5)	2920 (1.9)	
	Peripheral vascular disease	1007 (13.8)	5437 (4.3)	2308 (18.4)	10495 (6.8)	
	Cerebrovascular disease	166 (2.3)	1107 (0.9)	411 (3.3)	2283 (1.5)	
Liver disease						
	Mild	386 (5.3)	3172 (2.5)	797 (6.3)	5237 (3.4)	
	Moderate or severe	14 (0.2)	99 (0.1)	30 (0.2)	304 (0.2)	
Respiratory conditions						
	Asthma	886 (12.2)	7599 (6.0)	1840 (14.6)	12794 (8.3)	
	Chronic obstructive pulmonary disease	1056 (14.5)	8585 (6.8)	2317 (18.4)	14915 (9.7)	
Immunocompromising/immunosuppressive conditions						
	Rheumatic/connective tissue disorders	178 (2.4)	836 (0.7)	363 (2.9)	1513 (1.0)	
	Cancer—Metastatic carcinoma	61 (0.8)	235 (0.2)	205 (1.6)	883 (0.6)	
	Cancer—Other	247 (3.4)	1601 (1.3)	598 (4.8)	3066 (2.0)	
	HIV/AIDS	4 (0.1)	18 (0.0)	31 (0.2)	129 (0.1)	
	Solid organ transplantation	1 (0.0)	163 (0.1)	4 (0.0)	442 (0.3)	
	Other	329 (4.5)	3330 (2.6)	661 (5.3)	5359 (3.5)	
Other diseases or disorders						
	Renal disease	354 (4.9)	2884 (2.3)	943 (7.5)	6515 (4.2)	
	Obstructive sleep apnea	657 (9.0)	4952 (3.9)	1335 (10.6)	7456 (4.8)	
	Peptic ulcer disease	15 (0.2)	155 (0.1)	47 (0.4)	349 (0.2)	
	Paraplegia or hemiplegia	21 (0.3)	150 (0.1)́	63 (0.5)	397 (0.3)	
	Hypothyroid	529 (7.3)	4482 (3.6)	1092 (8.7)	6616 (4.3)	
	Dementia	81 (1.1)	421 (0.3)	216 (1.7)	1032 (0.7)	
	Depression	948 (13.0)	10835 (8.6)	1870 (14.9)	15522 (10.1)	

#### Table S2: Comorbid conditions within the analytic sample and among all eligible cases.

Data on exposure prevalence among treatment recipients and non-recipients within the analytic sample include all eligible cases who were assigned matches.

Characteristic		Freque	ency of Paxlovi	d receipt amo	ng cases withir	n each stratum,	n (%)
		<u>Ages 12-39v</u>	Ages 40-64v	<u>Aqes ≥65v</u>	Ages 12-39v	Ages 40-64v	<u>Aqes ≥65y</u>
Sex							
	Female	428 (1.6)	2137 (6.0)	1629 (13.0)	675 (2.2)	3194 (7.6)	3334 (16.8)
	Male	258 (1.3)	1396 (5.0)	1426 (12.0)	424 (1.8)	2084 (6.4)	2863 (15.4)
Time from symptoms onset to testing			0770 (0.0)	0404 (45 0)	000 (0.4)	4004 (0.0)	4054 (04 5)
	U-5 days	538 (1.7)	2770 (6.2)	2164 (15.3)	893 (2.4)	4294 (8.3)	4851 (21.5)
	0-14 days	30 (0.4)	223(2.7)	019(11.1)	160 (2.1)	700 (0.9) 278 (2.6)	009 (9.9) 457 (6.6)
Outpatient care received <1 day before testing	No acute symptoms indicated at point of testing	30 (0.4)	210 (2.2)	272 (5.7)	40 (0.5)	270 (2.0)	437 (0.0)
Supatient date received = r day before testing	No outpatient care	656 (1.5)	3450 (5.5)	2959 (12.3)	1016 (2.0)	4917 (6.9)	5720 (16.0)
	Any outpatient care	30 (5.1)	83 (8.9)	96 (22.2)	83 (3.5)	361 (10.2)	477 (17.0)
Charlson comorbidity index							
•	0	539 (1.3)	2223 (4.4)	978 (9.3)	726 (1.6)	2906 (5.2)	1705 (12.3)
	1-2	138 (3.8)	1221 (10.1)	1369 (15.0)	347 (5.1)	2004 (12.2)	2614 (18.9)
	3-5	7 (58.3)	70 (14.0)	557 (15.7)	19 (10.1)	269 (14.4)	1425 (19.1)
	≥6	2 (100.0)	19 (26.8)	151 (12.1)	7 (14.0)	99 (15.5)	453 (13.7)
Prior-year healthcare interactions			= .				
	0 outpatient visits	11 (0.5)	14 (0.7)	3 (1.6)	14 (0.6)	23 (1.1)	9 (3.8)
	1-4 outpatient visits	130 (0.8)	503 (3.1)	143 (6.3)	1/3 (1.0)	621 (3.5)	311 (9.7)
	5-9 outpatient visits	173 (1.3)	944 (5.1)	583 (10.3)	226 (1.5)	1180 (5.8)	961 (13.0)
	10-14 outpatient visits	140 (2.4) 69 (2.5)	097 (0.3) 454 (7.9)	576 (12.1) 521 (14.5)	202 (2.9)	902 (7.9) 714 (0.7)	1069 (15.6)
	20.20 outpatient visits	00 (2.3) 87 (3.1)	434 (7.0)	521(14.3)	154 (3.5)	7 14 (9.7) 825 (10.0)	990 (17.0) 1270 (18.2)
	30-39 outpatient visits	35 (3.2)	186 (8.0)	265 (14.3)	77 (4.0)	401 (11 2)	708 (10.2)
	≥40 outpatient visits	42 (3.2)	249 (12.4)	371 (17.5)	114 (4.7)	542 (14.0)	853 (19.2)
	No ED presentation	433 (1.1)	2581 (4.8)	1981 (10.8)	631 (1.5)	3496 (5.8)	3609 (14.0)
	≥1 ED presentation	253 (3.7)	952 (10.3)	1074 (17.6)	468 (4.4)	1782 (12.3)	2588 (20.3)
	No inpatient admission	644 (1.5)	3385 (5.5)	2833 (12.7)	1008 (2.0)	4977 (7.0)	5661 (16.8)
	Any inpatient admission	42 (2.2)	148 (7.3)	222 (10.6)	91 (3.1)	301 (8.8)	536 (11.4)
Prior SARS-CoV-2 infection							
	No documented infection	666 (1.5)	3415 (5.6)	3017 (12.6)	1054 (2.1)	5069 (7.1)	6104 (16.2)
	Any documented infection	20 (0.8)	118 (4.3)	38 (8.9)	45 (1.4)	209 (6.0)	93 (12.2)
Prior COVID-19 vaccination	0 deses received	105 (1.0)	100 (2.2)	00 (0 1)	160 (1 4)	117 (5 1)	346 (12 7)
	1 dose received	5 (0 7)	29 (2.5)	90 (9.1) 15 (11 8)	25 (1.7)	417 (J.1) 110 (5 7)	87 (12.7)
	2 doses received	153 (1.0)	570 (4.0)	242 (9.6)	274(1.7)	926 (5.4)	683 (13.6)
	3 doses received	417 (2 2)	2432 (6.3)	1584 (11.8)	601 (2.8)	3170 (7 4)	2822 (15.3)
	4 doses received	6 (8.8)	303 (9.8)	1124 (15.2)	30 (8.8)	646 (13.8)	2259 (19.4)
Race/ethnicity		- ()					
	White, non-Hispanic	122 (1.6)	738 (5.7)	1061 (13.0)	201 (2.2)	1156 (7.4)	2301 (16.5)
	Black, non-Hispanic	60 (1.9)	309 (6.3)	319 (12.4)	101 (2.5)	507 (8.3)	635 (15.3)
	Hispanic	381 (1.6)	1667 (5.5)	1013 (11.4)	610 (2.1)	2493 (7.0)	2032 (15.2)
	Asian	72 (1.2)	596 (5.7)	557 (14.8)	112 (1.7)	822 (7.0)	1036 (18.6)
	Pacific Islander	4 (1.2)	40 (5.2)	30 (14.0)	8 (2.1)	57 (6.7)	53 (16.2)
	Other/unknown/mixed race	47 (1.1)	183 (4.3)	75 (9.2)	67 (1.5)	243 (5.1)	140 (12.4)
Body mass index		<b>-</b> / - / ·		04/00 0		00 (0 0)	07 (/ - 0)
	Underweight (<18.5)	7 (0.1)	7 (5.0)	24 (29.6)	15 (0.2)	20 (6.6)	87 (15.0)
	Normal weight (18.5-24.9)	102 (0.8)	389 (4.0)	/49 (12.7)	1// (1.2)	655 (5.5)	1619 (16.5)
	Overweight (25.0-29.9)	125 (1.5)	910 (5.1)	1155 (12.6)	218 (2.2)	1317 (6.3)	2200(10.3)
	ODESE (30-33.3)	200 (3.1)	1520 (7.4)	911 (12.9)	300 (J.O)	2170 (9.0)	1000 (10.4)

### Table S3: Receipt of nirmatrelvir-ritonavir at ages 12-39 years, 40-64 years, and ≥65 years among cases within the analytic sample and among all eligible cases.

	Morbidly obese (≥40.0)	109 (5.5)	361 (8.8)	80 (15.2)	209 (7.1)	736 (11.9)	295 (18.6)
Cigarette smoking							
	Current smoker	529 (1.6)	2488 (6.1)	1976 (13.2)	854 (2.2)	3727 (7.7)	3897 (16.8)
	Former smoker	20 (2.2)	145 (5.8)	89 (9.5)	43 (3.5)	235 (7.3)	174 (11.8)
	Never smoked	50 (2.5)	568 (6.2)	856 (12.5)	86 (3.5)	911 (8.0)	1879 (16.3)
Neighborhood deprivation index							
	First quintile (least deprived)	76 (1.4)	560 (6.1)	599 (13.7)	119 (1.9)	817 (7.6)	1211 (17.6)
	Second quintile	139 (1.5)	770 (5.5)	758 (12.9)	208 (2.0)	1151 (7.0)	1524 (16.4)
	Third quintile	177 (1.6)	910 (5.6)	738 (12.2)	296 (2.2)	1347 (7.0)	1511 (16.0)
	Fourth quintile	162 (1.4)	805 (5.5)	626 (12.3)	267 (2.0)	1213 (7.0)	1239 (15.6)
	Fifth quintile (most deprived)	132 (1.6)	486 (5.2)	330 (10.8)	209 (2.2)	747 (6.7)	706 (14.6)
Receipt of other respiratory vaccines							
	2021-22 seasonal influenza vaccine not received	320 (1.3)	1159 (4.0)	551 (9.4)	499 (1.7)	1759 (5.2)	1242 (12.9)
	2021-22 seasonal influenza vaccine received	366 (1.8)	2374 (6.9)	2504 (13.5)	600 (2.5)	3519 (8.6)	4955 (17.2)
	Pneumococcal conjugate vaccine not received	645 (1.9)	3355 (5.4)	1203 (10.0)	1010 (2.6)	4927 (6.8)	2121 (12.9)
	Pneumococcal conjugate vaccine received	41 (0.4)	178 (13.9)	1852 (14.9)	89 (0.6)	351 (15.5)	4076 (18.5)
	Pneumococcal polysaccharide vaccine not received	566 (1.3)	2232 (4.5)	564 (7.9)	858 (1.7)	3089 (5.5)	998 (10.5)
	Pneumococcal polysaccharide vaccine received	120 (4.3)	1301 (9.5)	2491 (14.4)	241 (6.2)	2189 (11.9)	5199 (17.9)

Data on exposure prevalence among treatment recipients and non-recipients within the analytic sample include all eligible cases who were assigned matches. Percentages indicated in the table are computed among individuals with non-missing observations; missing data are present in participants' smoking status, body mass index, and neighborhood deprivation index, as summarized in **Table 1**.

### Table S4: Characteristics of cases included in the analytic sample and those excluded due to a lack of eligible matches.

Anatypic         Excided analysis         Classistic analysis         Classistic analysis         Classistic analysis         Classistic analysis           Age         12-10 years         1207 (9.9)         2246 (6.7)         1337 (9.9)         2246 (6.7)         1337 (9.9)           20-20 years         1227 (9.9)         2246 (1.67)         1337 (9.9)         2246 (1.67)         1337 (9.9)           20-30 years         22725 (20.4)         339 (1.17)         7144 (127, 1.2)         1144 (127, 1.2)           20-30 years         22725 (20.4)         339 (1.17)         7138 (4.7)         2348 (4.1)           20-30 years         2020 (1.2)         1728 (1.4)         2288 (1.4)         238 (1.1)           20-30 years         201 (1.2)         1424 (127, 1.2)         1444 (127, 1.2)         1444 (127, 1.2)           Sex         Male         64 days         61 (1.2)         2136 (1.1)         7466 (1.4)         2288 (1.4)           Charlson comorbidity index         10-4 days         2138 (1.6)         7237 (1.6)         3871 (12, 2.2)         8716 (12, 2.2)           Prior year healthcare interactions         12-3 day         1313 (10, 2.2)         8716 (12, 2.2)         8716 (12, 2.2)         8716 (12, 2.2)           Charlson comorbidity index         10-3 day interaction (1.1)         2246 (1.7)	Characteristic		Freque	ency among case	s n (%)
Age         NH33.62A         NH33.62A         NH33.62A           Age         12.19 years         11005 (8.3)         2245 (6.7)         13310 (8.0)           30.39 years         12.290 (1.9.3)         3400 (1.1.1)         24408 (1.4.3)         2440 (1.4.1)           30.40 years         22.252 (2.4.3)         319 (1.1.7.)         24408 (1.4.3)         3114 (1.4.1.2)           50.49 years         22.258 (1.9.0)         47.6 (1.4.1.3)         3014 (1.1.5)         77.78 (1.1.3)           Sex         Male         50447 (44.5)         15125 (45.1)         74562 (47.7)           Sex         Male         50437 (44.5)         15125 (45.1)         74562 (47.7)           Outpatient care received s1 day before         -         12130 (1.6.0)         27248 (2.1.8)         11157 (68.3)           Outpatient care received s1 day before         -         -         12230 (1.0.0)         27247 (16.0)           Chartson comorbidity index         0         -         12230 (1.0.0)         27247 (16.0)           Argo outpatient visits         12432 (8.0)         11157 (68.2)         716 (4.2.2)         716 (5.2)           Outpatient visits         12432 (8.0)         2723 (8.0)         2747 (16.0)         2747 (16.0)           Outpatient visits         27438 (1.7)	Characteristic		Analytic	Evoluded	
Age         h=133,42c         h=33,64         h=165,680           20-29 years         11056 (6.3)         2246 (7.0)         1575 (8.4)           30-39 years         22752 (15.4)         3359 (17.0)         1575 (8.4)           30-39 years         22752 (15.4)         3359 (17.1)         2359 (16.9)           30-39 years         22752 (15.4)         3359 (17.1)         2359 (16.9)           30-39 years         22752 (15.4)         3359 (17.1)         1576 (14.8)           30-39 years         3077 (2.8)         3866 (17.3)         777 9 years         302 (17.1)         11676 (4.6)         2868 (17.2)           30-39 years         3077 (16.9)         3056 (17.2)         786 (17.2)         786 (17.2)         786 (17.2)           20-4 gars         21390 (10.0)         7298 (21.8)         2869 (17.2)         786 (17.2)         786 (17.2)         786 (17.2)         787 (18.3)         286 (17.2)           Cutpatient care received ≤1 day befor         103226 (77.4)         1317 (18.3)         2874 (15.3)         11157 (16.8,3)         11157 (16.8,3)         11157 (16.8,3)         11157 (16.8,3)         11157 (16.8,3)         11157 (16.8,3)         11157 (16.8,3)         11157 (16.8,3)         11157 (17.1)         11157 (17.1)         11158 (17.2)         11157 (17.1)         11158 (17.2)			sample	sample	
Age         12-19 years 22-45 (6.7)         13310 (6.0) 13317 (0.9)         22-45 (6.7)         13310 (6.0) 13317 (0.9)           26-29 years 40-49 y			N-133 426	<u>Sample</u> N=33.544	
Jub         1105 (6.3)         2245 (7.5)         1330 (6.0)           30.39 years         2126 years         2126 (15.9)         3400 (11.7)         3114 (14.7)           30.39 years         2126 (15.9)         3400 (11.7)         3114 (14.7)         3114 (14.7)           30.39 years         2208 (16.0)         4716 (14.1)         3001 (11.7)         3114 (14.7)           30.7 years         3902 (12.7)         1318 (6.0)         920 (10.7)         1478 (14.1)         3001 (11.7)           Sex         Male         59437 (14.5)         15125 (45.1)         74562 (14.7)         7388 (14.7)           No acute symptoms indicated at point of testing         6.4 days         21390 (16.0)         2146 (03.9)         21157 (16.8)         8056 (17.2)           No acute symptoms indicated at point of testing         1302 (16.7)         1317 (13.8)         11157 (16.8)         3717 (12.9)         3856 (17.2)           Prior year healthcare interactions         0         1302 (16.1)         1317 (18.8)         1116429 (18.7)         3339 (20.7)         3356 (20.2)         8716 (20.2)         8716 (20.2)         8716 (20.2)         8716 (20.2)         8716 (20.2)         8716 (20.2)         8716 (20.2)         8716 (20.2)         8716 (20.2)         8716 (20.2)         8716 (20.2)         8716 (20.2)         8716 (20.2)<	Ago		11-135,420	77-33,344	71-100,900
25:29 jeams         1201 (199)         2540 (101)         2466 (16.8)           36.39 yeams         2725 (20.4)         3910 (101)         2466 (16.8)           36.99 yeams         2725 (20.4)         3910 (101)         2466 (16.8)           36.99 yeams         2725 (20.4)         3910 (101)         2466 (16.8)           36.99 yeams         3927 (2.9)         3956 (11.5)         7736 (47)           36.99 yeams         3927 (2.9)         3956 (11.5)         7736 (47)           36.99 yeams         3927 (2.9)         3956 (11.5)         7756 (7.7)           Non control         6.90 yeams         21390 (16.0)         7244 (63.9)         2556 (15.2)           Outpatient care received s1 day before         1002 (17.1)         2466 (14.8)         2477 (16.2)         2718 (27.8)           Outpatient care received s1 day before         1002 (17.1)         2746 (14.1)         3207 (28.2)         8717 (28.3)         1157 (64.8)           Outpatient visits         443 (3.3)         176 (3.8)         1157 (64.8)         9217 (22.2)         884 (27.1)         921 (27.1)         921 (28.2)         891 (27.1)         921 (27.1)         921 (27.1)         921 (27.1)         921 (27.1)         921 (27.1)         921 (27.1)         921 (27.1)         921 (27.1)         921 (27.1)         921 (	Aye	12 10 10 10 10	11065 (0.2)	2245 (6 7)	12210 (0.0)
20-35 years         120-35 years         120-35 years         120-35 years         120-35 years           20-35 years         2225 (20)         3919 (11,7)         3001 (18,0)           20-35 years         2235 (20)         3919 (11,7)         1644 (18,0)           60-69 years         200 (0,7)         1157 (14,1)         3001 (18,0)         177 (14,4)         566 (16,8)         254 (14,1)         3001 (18,0)         177 (14,4)         566 (16,8)         254 (14,1)         3001 (18,0)         1157 (14,4)         3001 (18,0)         1157 (14,4)         3001 (18,0)         1157 (14,4)         3001 (18,0)         1157 (14,4)         3001 (18,0)         3001 (18,0)         3001 (18,0)         3001 (18,0)         3001 (18,0)         3001 (18,0)         3001 (18,0)         3001 (18,0)         3001 (18,0)         3001 (18,0)         3001 (18,0)         3001 (18,0)         3001 (12,0)         3001 (13,0)         3001 (12,0)         30		12-19 years		2243 (0.7)	13310 (0.0)
30-39 Years         2100 110,10         2400 114,01         2400 114,01           40-39 Years         2520 (12,0)         395 (14,0)         3014 (16,0)           60-69 years         19716 (14,1)         566 (16,0)         2253 (17,1)           60-69 years         327 (2,9)         385 (11,5)         7738 (42,1)           Sax         Male         59437 (44,5)         15125 (45,1)         7456 (44,7)           Time from symptoms onsat to testing         0-5 days         2130 (16,0)         7238 (12,1)         2273 (16,0)         7238 (12,1)         2274 (16,0)           Oubgelient care received 51 day before         -5 days         2130 (16,1)         2130 (16,1)         2273 (16,1)         11157 (68,3)         116429 (83,7)           First         -5 days         2133 (16,1)         1233 (16,1)         122 (15,1)         676 (20,2)         7718 (5,2)           Charlson comorbidity index         0         103256 (77,4)         12173 (38,3)         116429 (83,7)         122 (22,2)         326         122 (16,1)         2279 (80,4)         3702 (22,7)           9 ad         -112 (11,1)         -11373 (18,3)         116429 (83,7)         1162 (15,1)         766 (12,2)         7718 (15,2)         6171 (16,0)         122 (12,2)         123 (16,1)         3733 (13,1)         1717 (16,1) <td></td> <td>20-29 years</td> <td>13217 (9.9)</td> <td>2546 (7.6)</td> <td>15763 (9.4)</td>		20-29 years	13217 (9.9)	2546 (7.6)	15763 (9.4)
Ad-49 years         2722 (20.4)         3911(17)         3114 (16.7)           Bd-59 years         19771 (16.8)         577 (17.1)         2100 (17.1)         3114 (16.7)           Bd-59 years         19771 (16.8)         577 (17.1)         2100 (17.1)         3114 (16.7)           Sex         290 years         3997 (2.9)         5856 (11.5)         7783 (2.4)         2398 (1.4)           Time from symptoms onset to testing         Hale         5437 (4.5)         5123 (5.6) (17.2)         21446 (03.2)         7788 (2.4)         2865 (17.2)           Outpatient care received 1 day before         Italian         21337 (16.4)         4810 (14.3)         2877 (16.3)         2876 (7.4)         11377 (05.6)         4810 (14.3)         2877 (16.3)         5971 (15.3)         5971 (15.3)         5971 (15.3)         5971 (15.3)         5971 (15.3)         5971 (15.3)         5971 (15.3)         5971 (15.3)         5971 (15.3)         5971 (15.3)         5971 (15.3)         5971 (15.3)         5971 (15.3)         5971 (15.3)         5971 (15.2)         597 (17.6)         5981 (15.7)         5971 (15.3)         5971 (15.3)         5971 (15.3)         5971 (15.3)         5971 (15.3)         5971 (15.3)         5971 (15.3)         5971 (15.1)         5971 (15.1)         5971 (15.7)         5778 (15.7)         5771 (15.2)         5971 (17.3) <td></td> <td>30-39 years</td> <td>21266 (15.9)</td> <td>3400 (10.1)</td> <td>24666 (14.8)</td>		30-39 years	21266 (15.9)	3400 (10.1)	24666 (14.8)
Socie         Socie <th< td=""><td></td><td>40-49 years</td><td>27225 (20.4)</td><td>3919 (11.7)</td><td>31144 (18.7)</td></th<>		40-49 years	27225 (20.4)	3919 (11.7)	31144 (18.7)
Bit-Bit years         1979 1(1.4.8)         568 (16.2)         245 (16.2)           Sox         332 (7.2.9)         335 (11.5)         7738 (4.7)           Sox         Male         593 (7.2.9)         335 (11.5)         7738 (4.7)           Time from symptoms onset to testing         D-5 days         593 (21.6)         2130 (16.4)         2130 (16.4)         2130 (16.4)         2450 (18.2)           Outpatient care received 11 day before         D-5 days         2130 (16.4)         2413 (16.4)         2416 (16.2)         2476 (16.1)         2475 (16.2)           Outpatient care received 11 day before         11157 (16.8)         2455 (17.2)         2478 (18.6)         1222 (17.5)         246 (18.3)         11157 (16.8)           Chartson comorbidity index         0         11157 (16.8)         2455 (17.2)         2478 (18.6)         1222 (17.2)         2478 (18.6)         1222 (12.2)         2478 (18.6)         1222 (12.2)         2478 (18.6)         1222 (12.2)         2478 (18.6)         1222 (12.2)         248 (12.2)         2498 (14.1)         1464 (21.2)         2471 (15.5)         1317 (19.3)         146429 (18.7)         1318 (10.3)         178 (12.2)         2471 (15.5)         1319 (10.1)         2472 (18.1)         1326 (11.2)         2414 (12.1)         1474 (14.2)         2414 (12.5)         1411 (15.1)		50-59 years	25298 (19.0)	4716 (14.1)	30014 (18.0)
70-79 years         10/71 (6.0.)         57.21 (7.1.)         164.45 (6.8.)           Sex         300 years         3027 (2.9.)         3355 (1.1.5)         7783 (4.7.)           Time from symptoms onset to tosting         0-5 days         6-14 days         7238 (7.9.)         7238 (7.9.)         7238 (7.9.)           Outpatient care neceived 11 day before testing         0123 (67.0.)         2144 (63.0.)         7238 (7.9.)         2665 (7.2.)           Outpatient care neceived 11 day before testing         0         1022 (7.7.1.)         6706 (20.2.)         8718 (5.2.)           Charston comorbidity index         0         1022 (7.7.1.)         6706 (20.2.)         8718 (5.2.)           Prior-year healthcare interactions         0         1022 (7.7.1.)         1717 (6.3.)         9511 (5.7.)           90 outpatient visits         4440 (7.3.)         1776 (7.6.)         9533 (2.6.)         4738 (4.9.)         9533 (2.6.)           91 outpatient visits         4440 (7.3.)         176 (1.0.)         2679 (0.0.)         3536 (2.6.)         4738 (4.8.)         8333 (2.3.)           91 outpatient visits         4440 (7.3.)         1776 (1.5.)         4616 (2.8.)         3533 (2.6.)         4737 (1.8.)         9533 (2.6.)         4737 (1.8.)         9533 (2.6.)         4737 (1.8.)         9533 (2.6.)         9533 (2.6.) </td <td></td> <td>60-69 years</td> <td>19791 (14.8)</td> <td>5665 (16.9)</td> <td>25456 (15.2)</td>		60-69 years	19791 (14.8)	5665 (16.9)	25456 (15.2)
80-89 years         13927 (2.9)         3855 (11.5)         7.783 (4.7)           Sex         200 years         90 years         91 years         17456 (4.4)         2338 (1.6)         7256 (2.1)         74552 (2.4)         74552 (2.4)         7455 (2.5)         7538 (1.7)         1747 (16.0)         21380 (16.0)         7259 (2.1)         2656 (17.2)         75718 (5.7)         1747 (16.0)         2656 (17.2)         26718 (5.2)		70-79 vears	10716 (8.0)	5729 (17.1)	16445 (9.8)
Sax         Male         5920 (0.7)         1476 (4.4)         2398 (1.4)           Time from symptoms onset to testing         0-5 days         59129 (47.5)         15125 (45.1)         74582 (44.7)           Duptatient care received \$1 day before testing         0-5 days         91129 (67.5)         21387 (16.0)         21444 (63.9)         11157 (68.8)           Charlson comorbidity index         0         103256 (77.4)         13173 (38.3)         116429 (69.7)           Charlson comorbidity index         0         103256 (77.4)         13173 (38.3)         116429 (69.7)           2-2         24783 (18.6)         12228 (36.4)         37012 (22.2)         68.41         37012 (22.2)           Prior-year healthcare interactions         0         0 outpatient visits         24443 (18.6)         12228 (36.4)         37012 (22.2)           Prior-year healthcare interactions         0 outpatient visits         24442 (18.1)         4748 (14.2)         2619 (15.7)           200 cupatient visits         12432 (18.6)         1275 (18.6)         42514 (25.5)         4161 (2.8)           1-4 outpatient visits         12432 (18.1)         4749 (14.2)         2619 (15.7)         1383 (12.0)           2010 cupatient visits         12442 (16.1)         4749 (14.2)         2619 (15.7)         1476 (14.8)         11048 (6.6)		80-89 years	3927 (2.9)	3856 (11.5)	7783 (4 7)
Sex         Lob (1.47)         Lob (1.47)         Lob (1.47)         Lob (1.47)           Time from symptoms onset to testing         0.5 days 0.4 days		>00 vears	920 (0 7)	1478 (4 4)	2308 (1 /)
Male         59437 (44.5)         15125 (45.1)         74562 (47.7)           Time from symptoms onset to testing         0-5 days 0-5 days No acute symptoms indicated at point of testing         00129 (67.5) 21300 (16.0)         72446 (63.3) 7259 (21.8)         111575 (68.6) 2658 (17.2)           Outpatient care received ≤1 day before testing         Arry outpatient care         1952 (1.5)         6766 (20.2)         6718 (5.2)           Charison comorbidity index         0         1252 (20.1)         1243 (18.6)         2228 (16.4)         3971 (22.2)           1-2         24783 (18.6)         2228 (16.4)         3971 (22.2)         9644 (15.7)           2-5         1319 (10.)         2679 (16.0)         3988 (24.0)           2-6         1319 (10.)         2679 (16.0)         3988 (24.0)           2-6         1319 (10.)         2679 (16.0)         3988 (24.0)           2-6         1319 (10.)         2679 (16.0)         3839 (20.0)           2-6         2004patient visits         3463 (26.1)         3606 (11.0)         3839 (20.0)           2-6         2014patient visits         3463 (26.1)         3606 (14.0)         3839 (20.0)           2-6         2014patient visits         34440 (25.1)         3746 (14.8)         24514 (25.5)           2010 statent visits         3469 (14.0)	Sox		520 (0.7)	1470 (4.4)	2000 (1.4)
Image         Data (14-3)         Disp (14-3) <thdisp (14-3)<="" th=""> <thdisp (14-3)<="" th=""> <thdi< td=""><td>Sex</td><td>Mala</td><td>E0427 (44 E)</td><td>15105 (45 1)</td><td>74562 (44 7)</td></thdi<></thdisp></thdisp>	Sex	Mala	E0427 (44 E)	15105 (45 1)	74562 (44 7)
Inite num symptoms offset to testing         0.4 days No acute symptoms indicated at point of testing         0.123 (67.0) 21360 (16.0)         21446 (63.9) 21350 (16.4)         21457 (16.4) 26558 (17.2)           Outpatient care received ≤1 day before testing         Any outpatient care         1952 (1.5)         6766 (20.2)         8718 (5.2)           Charison comorbidity index         0         111275 (36.8)         11127 (30.3)         116429 (69.7)           Prior-year healthcare interactions         0         24733 (18.6)         1222 (36.4)         3701 (22.2)           Prior-year healthcare interactions         0         0utpatient visits         3433 (28.1)         3560 (10.4)         3533 (28.1)           Prior-year healthcare interactions         0         0utpatient visits         3433 (28.1)         3560 (10.4)         3333 (28.1)           20-29 outpatient visits         12132 (8.1)         4497 (14.2)         2111 (15.7)         11117 (18.1)         1868 (11.2)           20-29 outpatient visits         12132 (6.1)         4476 (1.4)         4297 (17.2)         11111 (17.8)         11111 (17.8)         11111 (17.8)         1111 (17.8)         11111 (17.8)         11111 (17.8)         11111 (17.8)         11111 (17.8)         11111 (17.8)         11111 (17.8)         11111 (17.8)         11111 (17.8)         11111 (17.8)         11111 (17.8)         11111 (17.8)<	Time from symptoms exact to testing	Male	59457 (44.5)	15125 (45.1)	74502 (44.7)
L2-6 days         90124 (b7.6)         7248 (b2.3)         11157 (b6.3)           No acute symptoms indicated at point of testing         21937 (16.4)         4810 (14.3)         26747 (16.0)           Outpatient care received ≤1 day before testing         Any outpatient care         1952 (1.5)         6766 (20.2)         8718 (5.2)           Chartson comorbidity index         0         103256 (77.4)         13173 (38.3)         116429 (60.7)           1-2         3463 (30.5)         5473 (15.3)         9544 (67.7)         37012 (22.2)           Prior-year healthcare interactions         0         0         1319 (1.0)         24783 (18.6)         3998 (2.4)           Prior-year healthcare interactions         0         0         1319 (1.0)         2478 (1.6)         4616 (2.2)           Prior-year healthcare interactions         0         0         1461 (2.8)         1461 (2.8)         1461 (2.8)           14 outpatient visits         1213 (2.6)         1468 (1.6)         1398 (1.0)         2393 (2.8)         1399 (1.0)         2632 (2.6)           10-14 outpatient visits         12269 (0.6)         1478 (1.6)         1462 (6.6)         1463 (2.6)         1478 (1.6)         1463 (1.2)         1653 (1.1)           10-14 outpatient visits         1216 (0.6)         1229 (0.6) (1.0)         1538 (1.6) <td>Time from symptoms onset to testing</td> <td></td> <td></td> <td>04440 (00.0)</td> <td></td>	Time from symptoms onset to testing			04440 (00.0)	
Bit Adds         21360 (16.0)         7298 (21.8)         24656 (17.2)           Outpatient care received ≤1 day before testing         Any outpatient care         1952 (1.5)         6766 (20.2)         8718 (5.2)           Charlson comorbidity index         0         103256 (77.4)         13173 (30.3)         116429 (69.7)           Prior-year healthcare interactions         0         24738 (18.6)         1222 (36.4)         3701 (22.2)           3-5         4066 (3.0)         2673 (16.3)         9564 (57.2)         353           2-4         0-01 (23.2)         353 (28.1)         3576 (28.1)         3596 (24.1)           Prior-year healthcare interactions         0         0-01 (24.1)         3453 (28.1)         476 (0.5)         4616 (2.8)           1-4         outpatient visits         34533 (28.1)         478 (14.8)         4251 (12.5)         144 (14.8)         4251 (12.5)           1-51 0 outpatient visits         12135 (2.1)         4468 (10.1)         1203 (28.1)         1473 (14.8)         4251 (12.5)           1-71 0 outpatient visits         12253 (2.5)         5471 (17.8)         3571 (12.8)         1571 (12.8)         3571 (12.8)         1571 (12.8)         3571 (12.8)         1571 (12.8)         3571 (12.8)         1571 (12.8)         3571 (12.8)         1571 (12.8)         3277 (13.9)<		0-5 days	90129 (67.5)	21446 (63.9)	111575 (66.8)
No acute symptoms indicated at point of lessing         21937 (16.4)         4810 (14.3)         22747 (16.0)           Outpatient care received \$1 day before lessing         Any outpatient care         1952 (1.5)         6766 (20.2)         8718 (5.2)           Charison comorbidity index         0         103256 (77.4)         1316 (25)         373 (16.6)         12223 (36.4)         37012 (22.2)           Prior-year healthcare interactions         0         24783 (18.6)         12229 (36.4)         37012 (22.2)           Prior-year healthcare interactions         0         0utpatient visits         4440 (3.3)         176 (0.5)         4616 (2.8)           Prior-year healthcare interactions         0         0utpatient visits         3433 (26.1)         3506 (14.4)         3393 (22.0)           S-5         outpatient visits         2442 (16.1)         4478 (14.8)         1448 (14.2)         2611 (14.2)         2611 (15.7)           S-5         outpatient visits         2453 (4.1)         5300 (14.2)         2636 (11.2)         30.39 (16.1)         303 (25.0)         30.39 (25.0)           Prior SARS-CoV-2 infection         Any documented infection         5716 (4.3)         1707 (1.8)         16568 (11.2)         30.39 (16.2)         2669 (11.6)         2232 (15.6)         3739 (22.2)         13.39 (22.2)         13.33 (11.6) <td< td=""><td></td><td>6-14 days</td><td>21360 (16.0)</td><td>7298 (21.8)</td><td>28658 (17.2)</td></td<>		6-14 days	21360 (16.0)	7298 (21.8)	28658 (17.2)
testing         21937 (16.4)         4810 (14.3)         26747 (16.0)           Outpatient care received ≤1 day before testing         Any outpatient care         1952 (1.5)         6766 (20.2)         8718 (5.2)           Charlson comorbidity index         0         103256 (77.4)         13173 (33.3)         116429 (69.7)           1-2         24783 (16.6)         6476 (20.2)         3998 (2.4)         37012 (22.2)           Prior-year healthcare interactions         0         0utpatient visits         34403 (3.5)         176 (0.5)         4676 (20.2)         3998 (2.4)           Prior-year healthcare interactions         0         0utpatient visits         34333 (26.1)         976 (10.5)         464 (25.5)           1-4 outpatient visits         12129 (5.1)         4698 (10.0)         16258 (11.2)         2619 (15.7)         1653 (20.1)         4688 (10.0)         16258 (11.0)         20.29 (11.6)         1635 (11.2)         10.3 (20.2)         10.3 (5.5)         3797 (17.8)         18658 (11.0)         1252 (1.0, 11.530 (15.6)         10753 (6.4)         4708 (14.8)         4254 (1.5)         10.7 (5.3 (6.4)         10753 (6.4)         10753 (6.4)         10753 (6.4)         10753 (6.4)         10753 (6.4)         10753 (6.4)         10753 (6.4)         10753 (6.4)         10753 (6.4)         10753 (6.4)         10753 (6.4)         10753		No acute symptoms indicated at point of			
Outpatient care received ±11 day before testing         Any outpatient care         1952 (1.5)         6766 (20.2)         8718 (5.2)           Charlson comorbidity index         0         103266 (77.4)         13173 (39.3)         116429 (66.7)           1-2         3-5         4068 (3.0)         5473 (16.3)         9541 (5.7)           Prior-year healthcare interactions         0         cutpatient visits         3483 (26.1)         3450 (10.4)         3451 (12.5)           Prior-year healthcare interactions         0         cutpatient visits         3483 (26.1)         3450 (10.4)         3453 (12.5)           Prior-year healthcare interactions         0         cutpatient visits         3483 (26.1)         3450 (10.4)         3453 (12.5)           Prior year healthcare interactions         0         cutpatient visits         3453 (26.1)         3450 (10.4)         3453 (12.5)           Prior CoV-2 indication visits         1242 (16.1)         4456 (14.0)         18836 (10.1)         10753 (6.4)         10753 (6.4)           Prior SARS-CoV-2 Infection         Any documented infection         5716 (4.3)         1707 (5.1)         7423 (4.4)           Prior COVID-19 vaccination         0 doses received         2266 (1.5)         2144 (6.4)         2202 (1.5)           0 doses received         22680 (21.6)         941		testing	21937 (16.4)	4810 (14.3)	26747 (16.0)
tesing Charlson comorbidity index 0 Charlson comorbidity index 0 Charlso	Outpatient care received ≤1 day before	Ũ			
Any outpatient care         1952 (1.5)         6.766 (20.2)         8718 (5.2)           Chartson comorbidity index         0         103286 (77.4)         13173 (49.3)         116429 (69.7)           3-5         24783 (18.6)         5473 (16.3)         5941 (5.7)         3998 (2.4)           Prior-year healthcare interactions         0         0utpatient visits         4440 (3.3)         176 (0.5)         4616 (2.8)           Prior-year healthcare interactions         0         0utpatient visits         3453 (28.1)         3908 (24.1)           Prior-year healthcare interactions         0         0utpatient visits         3453 (28.1)         3976 (14.8)         3938 (24.0)           3-5         3-5         0utpatient visits         3453 (3.7)         44717 (14.2)         2811 (15.7)           15-19 outpatient visits         12569 (19.5)         5577 (17.8)         18628 (10.1)         18628 (10.1)           20-29 outpatient visits         1259 (15.9)         5577 (17.8)         18628 (10.1)         1973 (6.4)           Prior SARS-CoV-2 infection         Any inpatient admission         6075 (4.6)         4973 (14.8)         22270 (13.9)           10 doses received         2066 (1.5)         2144 (6.4)         22270 (13.9)         11048 (6.6)           20 doses received         2066 (1.5)	testing				
Charlson comorbidity index         First expension tents           Prior-year healthcare interactions         0         0.02266 (77.4)         1319 (1.0)         2679 (8.0)         3998 (2.4)           Prior-year healthcare interactions         0         0.0utpatient visits         34433 (26.1)         3506 (10.4)         3339 (23.0)           5-9         0.0utpatient visits         34433 (26.1)         3506 (10.4)         3339 (23.0)           6-0         0.0utpatient visits         34433 (26.1)         3506 (10.4)         3339 (23.0)           2-9         0.0utpatient visits         21422 (16.1)         4496 (14.0)         16828 (10.1)           2-9         0.0utpatient visits         12459 (15.7)         4478 (14.8)         42514 (25.5)           2-9         0.0utpatient visits         1343 (10.1)         1073 (5.4)         1073 (5.4)           2-9         0.0utpatient visits         4393 (12.7)         4737 (14.8)         11048 (65.5)           3-0-9         0.0utpatient visits         4393 (12.7)         11048 (65.5)         37919 (22.7)           Prior COVID-19 vaccination         0         doses received         17151 (12.9)         6117 (18.2)         22270 (13.9)	5	Any outpatient care	1952 (1.5)	6766 (20.2)	8718 (5.2)
Onlinearie definition of the second	Charlson comorbidity index		1002 (1.0)	0,00 (20.2)	01.10 (0.2)
signal         0.02200 (1/A)         1319 (39.3)         1104/3 (196.7)           Prior-year healthcare interactions         0         2473 (18.6)         92473 (18.6)         9341 (6.7)           Prior-year healthcare interactions         0         0         uppatient visits         3483 (26.1)         3506 (26.1)         4616 (2.8)           1-4 outpatient visits         3483 (26.1)         3506 (26.1)         4778 (14.6)         4839 (23.0)           1-5 outpatient visits         3473 (26.7)         4778 (14.6)         4839 (23.0)         4441 (25.7)           1-5 outpatient visits         2142 (9.1)         4778 (14.6)         16328 (11.7)         1636 (11.0)         16328 (11.7)           20-00 outpatient visits         1250 (26.1)         4778 (14.6)         11078 (6.4)         11078 (6.4)           400 outpatient visits         1269 (16.1)         1399 (16.6)         37919 (22.7)         11048 (6.6)         11078 (6.4)           400 outpatient visits         1269 (16.7)         1590 (16.6)         37919 (22.7)         11048 (6.6)         11078 (6.4)           400 outpatient visits         1269 (16.1)         1272 (9.1)         1471 (8.2)         22320 (16.7)         1590 (26.6)         37919 (22.7)           Prior SARS-CoV-2 infection         Any documented infection         7171 (3.1)		0	103256 /77 1	13173 /20 21	116/20 (60 7)
1-2         2473 (16.5)         1229 (36.4)         3012 (22.2)           Prior-year healthcare interactions         0 outpatient visits         440 (3.3)         176 (0.5)         4616 (2.6)           0 outpatient visits         3433 (25.1)         3556 (110.4)         4833 (25.1)         3566 (110.4)         3833 (23.0)           5-9 outpatient visits         37536 (22.1)         4978 (14.8)         42514 (25.5)         42514 (25.5)           0.202 outpatient visits         12432 (16.1)         4479 (14.2)         2519 (15.7)         15.19 (0.1)         2629 (0.1)         1763 (0.5)         4616 (2.8)         1773 (15.3)         1232 (21.1)         4978 (14.2)         2519 (15.7)         15.19 (0.1)         2629 (0.1)         2659 (9.5)         5977 (17.6)         18636 (11.2)         30.39 (0.6)         10753 (6.4)         1073 (6.4)         1073 (6.4)         1073 (6.4)         1073 (6.4)         11048 (6.6)         1073 (6.4)         11048 (6.6)         1073 (6.4)         11048 (6.6)         1073 (6.4)         11048 (6.6)         11048 (6.6)         11048 (6.6)         1073 (6.4)         11048 (6.6)         1073 (6.4)         11048 (6.6)         1073 (6.4)         10048 (6.5)         716 (4.3)         11048 (6.6)         11048 (6.6)         11048 (6.6)         11048 (6.6)         11048 (6.6)         11048 (6.6)         11048 (6.6)		0	103230 (77.4)	13173 (39.3)	110429 (09.7)
3-5         4008 (30)         54/3 (10.3)         934/1 (5.7)         9349 (2.7)           Prior-year healthcare interactions         0         0         0         0         3498 (2.4)           0         0         0         0         0         3498 (2.4)         3506 (10.4)         33393 (23.0)           1-4         0         0         0         3453 (22.1)         3506 (10.4)         38339 (23.0)           1-4         0.01patient visits         21432 (21.1)         4749 (14.2)         26191 (15.7)         16388 (11.2)           15.19         0.01patient visits         21432 (9.1)         4666 (14.0)         16838 (11.2)         30.30 (15.6)         10753 (6.4)         101632 (10.1)         20.29 (10.1)         10.33 (15.5)         10.1 (15.6)         10753 (6.4)         10173 (6.4)         1019 (22.7)         Any ED presentation         22326 (15.7)         17.43 (14.8)         11048 (6.6)           Prior COVID-19 vaccination         0         0         0         2005 (15.1)         2144 (6.4)         4209 (22.7)         Any inpatient admission         6075 (4.6)         1707 (5.1)         7423 (4.4)           1         1040se received         2065 (15.5)         2144 (6.4)         4209 (2.2)         10488 (6.6)         17171 (15.2)         22270 (13.9) <td< td=""><td></td><td>1-2</td><td>24783 (18.6)</td><td>12229 (36.4)</td><td>37012 (22.2)</td></td<>		1-2	24783 (18.6)	12229 (36.4)	37012 (22.2)
Prior-year healthcare interactions         26         1319 (1.0)         2679 (6.0)         3996 (2.4)           Prior-year healthcare interactions         0 outpatient visits         34430 (26.1)         3556 (1.0.4)         3858 (22.0)           14 outpatient visits         37538 (28.1)         4978 (14.8)         42514 (25.5)           5-9 outpatient visits         12139 (9.1)         4749 (14.8)         42514 (25.5)           10-14 outpatient visits         12139 (9.1)         4749 (14.8)         1422 (16.1)           20-29 outpatient visits         4331 (3.7)         4172 (12.4)         9103 (5.5)           240 outpatient visits         4533 (4.1)         5300 (15.6)         10753 (6.4)           Any inpatient admission         6057 (4.6)         4973 (14.8)         11048 (6.6)           Prior SARS-CoV-2 infection         Any documented infection         5716 (4.3)         1707 (5.1)         7423 (4.4)           Prior COVID-19 vaccination         0 doses received         17153 (12.9)         6117 (18.2)         23270 (13.9)           1 dose received         17153 (12.9)         6117 (18.2)         23270 (13.9)           1 doses received         17153 (12.9)         6117 (18.2)         23270 (13.9)           1 doses received         1715 (12.3)         6122 (16.66)         6030 (16.0)		3-5	4068 (3.0)	5473 (16.3)	9541 (5.7)
Prior-year healthcare interactions         0 outpatient visits         4440 (3.3)         176 (0.5)         4616 (2.8)           1-4 outpatient visits         34633 (26.1)         3506 (10.4)         38339 (23.0)           5-9 outpatient visits         21753 (28.1)         4506 (1.4)         4858 (1.4)         4255 (1.4)           15-9 outpatient visits         2135 (25.1)         4478 (14.2)         26191 (15.7)         10-14 outpatient visits         1235 (21.4)         4508 (14.2)         26128 (10.1)           20-39 outpatient visits         1235 (21.4)         4508 (14.2)         16836 (11.2)         6173 (14.9)         1073 (6.4)           20-39 outpatient visits         4433 (3.7)         15533 (46.5)         37919 (22.7)         Any inpatient admission         6075 (4.6)         4973 (14.8)         11048 (6.6)           Prior COVID-19 vaccination         0         0 doses received         17153 (12.9)         6117 (18.2)         23270 (13.9)           11 dose received         17153 (12.9)         6117 (18.2)         23270 (13.9)         3038 (24.2)           2 doses received         10568 (6.2)         7949 (24.6)         40389 (24.2)         2436 (4.6)         40389 (24.9)         3618 (10.8)         4227 (13.9)           2 doses received         17153 (12.9)         6117 (18.2)         23270 (13.9)         4		≥6	1319 (1.0)	2679 (8.0)	3998 (2.4)
0 outpatient visits         4403 (3.)         176 (0.5)         4616 (2.8)           14 outpatient visits         37536 (2.8.1)         4978 (14.8)         42514 (25.5)           5-9 outpatient visits         21442 (16.1)         4749 (14.8)         42514 (25.5)           10-14 outpatient visits         1213 (2.1)         4666 (14.0)         16828 (10.1)           20-29 outpatient visits         12659 (3.5)         5977 (17.8)         18638 (11.2)           20-29 outpatient visits         4393 (3.7)         4172 (12.4)         9103 (5.5)           240 outpatient visits         4393 (1.7)         4172 (12.4)         9103 (5.5)           240 outpatient visits         4533 (1.1)         5503 (16.5)         3761 (6.2)           Prior SARS-CoV-2 infection         Any inpatient admission         6075 (4.6)         4973 (14.8)         11048 (6.6)           Prior COVID-19 vaccination         11 dose received         2066 (12.5)         2144 (6.4)         4209 (2.5)           2 doses received         2066 (1.5)         2144 (6.4)         4209 (2.5)         2048 (2.4)         1720 (23.6)         4038 (24.2)           2 doses received         2066 (1.6)         984 (29.8)         38789 (23.2)         1268 (1.6)         1421 (1.6)         4227 (1.6)           2 doses received         2066 (1.6) <td>Prior-year healthcare interactions</td> <td></td> <td></td> <td></td> <td></td>	Prior-year healthcare interactions				
1-4 outpatient visits         34833 (26.1)         3506 (10.4)         38339 (23.0)           5-9 outpatient visits         37536 (25.1)         4776 (14.8)         42514 (25.5)           10-14 outpatient visits         21422 (16.1)         4749 (14.2)         26191 (15.7)           15-19 outpatient visits         12132 (1.2)         30-39 outpatient visits         4361 (3.7)         4172 (2.4)         9103 (5.5)           20-29 outpatient visits         5453 (4.1)         5000 (15.8)         10753 (6.4)         97103 (5.5)         37919 (2.7)           Any inpatient admission         6075 (4.6)         4973 (14.8)         11048 (6.5)         37919 (2.7)           Prior SARS-CoV-2 infection         Any inpatient admission         6075 (16.4)         4742 (14.8)         11048 (6.5)           Prior COVID-19 vaccination         0 doses received         7153 (12.9)         6117 (18.2)         22270 (13.9)           1 dose received         17153 (12.9)         6117 (18.2)         23270 (13.9)         10438 (24.5)           2 doses received         10568 (7.9)         6092 (16.2)         16660 (10.0)           Race         White, non-Hispanic         28605 (21.6)         9494 (29.8)         3478 (23.2)           Race         Underweight (18.5)         7771 (4.3)         1869 (5.6)         7771 (4.66.1)		0 outpatient visits	4440 (3.3)	176 (0.5)	4616 (2.8)
5-9 outpatient visits         37536 (28.1)         4778 (14.8)         42514 (25.5)           10-14 outpatient visits         21442 (11.1)         4749 (14.2)         26191 (15.7)           15-19 outpatient visits         12659 (55.5)         5977 (17.8)         18638 (11.2)           20-29 outpatient visits         5931 (3.7)         4172 (12.4)         9103 (5.5)           30-39 outpatient visits         5931 (3.7)         4172 (12.4)         9103 (5.5)           Any ED presentation         22326 (16.7)         15593 (46.5)         37919 (22.7)           Any ED presentation         22326 (16.7)         15593 (46.5)         37919 (22.7)           Any ED presentation         22326 (16.7)         15593 (46.5)         37919 (22.7)           Any ED presentation         2055 (1.5)         2144 (6.4)         42090 (2.5)           1 dose received         2055 (1.5)         2144 (6.4)         4209 (2.5)           2 doses received         2055 (1.5)         2144 (6.4)         4209 (2.5)           3 doses received         2014 (15.3)         11281 (10.8)         82452 (49.4)           4 doses received         2015 (1.5)         21444 (6.4)         42093 (2.5)           3 doses received         71171 (15.3)         11281 (10.8)         82452 (49.4)           4 doses rece		1-4 outpatient visits	34833 (26.1)	3506 (10.4)	38339 (23.0)
10-14 outpatient visits         2142 (16.1)         4749 (14.2)         26191 (15.7)           15-19 outpatient visits         12659 (0.5)         5977 (17.8)         18836 (11.2)           30-39 outpatient visits         12659 (0.5)         5977 (17.8)         18836 (11.2)           30-39 outpatient visits         4931 (3.7)         4172 (12.4)         9103 (5.5)           30-39 outpatient visits         5453 (4.1)         3000 (15.6)         10753 (6.4)           Any inpatient admission         6075 (16.4)         4973 (14.8)         11048 (6.5)           Prior SARS-CoV-2 infection         Any iopatient admission         6075 (16.4)         4973 (14.8)         11048 (6.6)           Prior COVID-19 vaccination         0 doses received         17153 (12.9)         6117 (18.2)         23270 (13.9)           1 dose received         17153 (12.9)         6117 (18.2)         23270 (13.9)         13088 (24.5)           2 doses received         10568 (7.9)         6092 (18.2)         16660 (10.0)         1434 (43.0)         7774 (46.6)           Race         White, non-Hispanic         2805 (21.6)         9944 (29.8)         37878 (23.2)         14287 (18.6)           Back, non-Hispanic         1201 (1.5)         5701 (4.3)         1404 (4.0.0)         7774 (46.6)           Asian         20114		5-9 outpatient visits	37536 (28.1)	4978 (14.8)	42514 (25.5)
15-19 outpatient visits         12132 (2.1)         4608 (14.0)         16228 (10.1)           20-29 outpatient visits         4931 (3.7)         4172 (12.4)         18636 (11.2)           240 outpatient visits         4931 (3.7)         4172 (12.4)         1903 (5.5)           240 outpatient visits         4931 (3.7)         4172 (12.4)         1913 (5.5)           240 outpatient visits         4931 (3.7)         4172 (12.4)         1707 (5.6)         7753 (6.4)           Prior SARS-CoV-2 infection         22326 (16.7)         15593 (46.5)         37919 (22.7)         Any abcumented infection         5716 (4.3)         1707 (5.1)         7423 (4.4)           Prior COVID-19 vaccination         0 doses received         2065 (5.5)         2144 (6.4)         4209 (2.5)         1 doses received         10568 (7.9)         6092 (18.2)         16600 (10.0)           Race         White, non-Hispanic         28805 (21.6)         9984 (29.8)         38789 (23.2)           Black, non-Hispanic         63310 (47.4)         14434 (43.0)         1777 (46.6)           Asian         2014 (15.1)         3992 (11.9)         24106 (14.4)         44268 (26.6)           Oberyunknown/mixed race         9207 (6.9)         1279 (3.8)         10486 (6.3)           Oberyunknown/mixed race         9207 (6.9)         127		10-14 outpatient visits	21442 (16.1)	4749 (14.2)	26191 (15.7)
Bit Society Strategy         12122 (21.)         12122 (21.)         12123 (21.)         12133 (21.)         12133 (21.)         12133 (21.)         12133 (21.)         12133 (21.)         12133 (21.)         12133 (21.)         12133 (21.)         12133 (21.)         12133 (21.) </td <td></td> <td>15-19 outpatient visits</td> <td>12132 (9.1)</td> <td>4696 (14.0)</td> <td>16828 (10.1)</td>		15-19 outpatient visits	12132 (9.1)	4696 (14.0)	16828 (10.1)
20-29 Outpatient visits         493 (3.7)         417 (1.7.6)         1803 (3.5)           30-39 outpatient visits         493 (3.7)         417 (1.7.6)         1903 (5.5)           240 outpatient visits         493 (1.8.7)         4172 (12.4)         1903 (5.5)           Any ED presentation         22326 (16.7)         1553 (4.6.5)         37919 (22.7)           Any inpatient admission         22326 (16.7)         1559 (4.6.5)         37919 (22.7)           Any approximation         0 doses received         17153 (12.9)         6117 (18.2)         22270 (13.9)           1 doses received         2065 (5.5)         2144 (6.4)         4209 (2.5)         2 doses received         2066 (1.5)         2144 (6.4)         4209 (2.5)           2 doses received         32469 (24.3)         7920 (2.3.6)         40389 (24.2)         3 doses received         10566 (1.0.0)         1666 (1.0.0)           Race         White, non-Hispanic         28805 (21.6)         9984 (29.8)         36789 (23.2)           Black, non-Hispanic         63310 (47.4)         14343 (43.0)         77744 (4.6.6)           Asian         20114 (15.1)         3992 (11.9)         24106 (14.6)           Hispanic         63310 (47.4)         14347 (45.0)         7776 (4.5)           Normal weight (18.5-24.9)         2716		20.20 outpatient visits	12152 (9.1)	4030 (14.0) 5077 (17.9)	10020 (10.1)
Subscription         Subscription<		20-29 outpatient visits	12039 (9.3)	3977(17.0)	10030 (11.2)
Any ED presentation Any ED presentation Any inpatient admission         24252 (16.7) (15583 (46.5)         5309 (19.5.6) (15583 (46.5)         10753 (6.4) (15583 (46.5)           Prior SARS-CoV-2 infection         Any documented infection         5716 (4.3)         1707 (5.1)         7423 (4.4)           Prior COVID-19 vaccination         0 doses received         17153 (12.9)         6117 (18.2)         23270 (13.9)           1 dose received         2065 (1.5)         2144 (6.4)         4209 (2.5)           2 doses received         32469 (24.3)         7920 (23.6)         40389 (24.2)           3 doses received         10568 (7.6)         6092 (18.2)         16660 (10.0)           Race         White, non-Hispanic         28080 (21.6)         9984 (29.8)         38789 (23.2)           Black, non-Hispanic         10669 (8.0)         3618 (10.8)         14287 (8.6)           Hispanic         10669 (8.0)         3618 (10.8)         14287 (8.6)           Asian         20114 (15.1)         3992 (11.9)         24106 (14.4)           Pacific Islander         2027 (2.8)         8181 (24.4)         35971 (21.5)           Other/unknown/mixed race         9207 (0.8)         8181 (24.4)         35971 (21.5)           Overweight (<18.5)		30-39 outpatient visits	4931 (3.7)	4172 (12.4)	9103 (5.5)
Any ED presentation         2222 (E (6.7)         15583 (46.5)         37919 (22.7)           Prior SARS-CoV-2 infection         Any documented infection         6075 (4.6)         4973 (14.8)         11048 (6.6)           Prior COVID-19 vaccination         0 doses received         2015 (12.9)         6117 (18.2)         22270 (13.9)           1 dose received         2066 (1.5)         2144 (6.4)         4209 (2.5)         2 doses received         2046 (24.3)         7920 (23.6)         40389 (24.2)           2 doses received         7117 (15.3)         11281 (33.6)         82452 (49.4)         11281 (33.6)         82452 (49.4)           4 doses received         10568 (7.9)         6092 (18.2)         16660 (10.0)         14287 (8.6)           Race         White, non-Hispanic         28805 (21.6)         9984 (29.8)         38789 (23.2)           Black, non-Hispanic         10669 (8.0)         3618 (10.8)         14287 (8.6)           Asian         20114 (15.1)         3992 (11.9)         24106 (14.4)           Asian         20114 (15.1)         3992 (19.9)         10486 (6.3)           Body mass index         Underweight (<18.5)		≥40 outpatient visits	5453 (4.1)	5300 (15.8)	10753 (6.4)
Any inpatient admission         6075 (4.6)         4973 (14.8)         11048 (6.6)           Prior SARS-CoV-2 infection         Any documented infection         5716 (4.3)         1707 (5.1)         7423 (4.4)           Prior COVID-19 vaccination         0 doses received         2065 (1.5)         2144 (6.4)         4209 (2.5)         2144 (6.4)         4209 (2.5)         2065 (1.5)         2144 (6.4)         4209 (2.5)         2068 (2.5)         2068 (2.6)         0389 (24.2)         16600 (10.0)           Race         White, non-Hispanic         2805 (21.6)         9944 (29.8)         33789 (23.2)         16600 (10.0)           Black, non-Hispanic         10669 (8.0)         3618 (10.8)         14287 (8.6)         14453 (43.0)         777744 (46.6)           Asian         1014 (15.1)         3992 (19.9         24106 (14.4)         14434 (43.0)         77744 (46.6)           Body mass index         Underweight (<18.5)		Any ED presentation	22326 (16.7)	15593 (46.5)	37919 (22.7)
Prior SARS-CoV-2 infection         Any documented infection         5716 (4.3)         1707 (5.1)         7423 (4.4)           Prior COVID-19 vaccination         0 doses received         17153 (12.9)         6117 (18.2)         23270 (13.9)           1 dose received         2065 (1.5)         2144 (6.4)         4209 (2.5)         20389 (24.2)           2 doses received         32469 (24.3)         7920 (23.6)         40389 (24.2)           3 doses received         1171 (53.3)         11281 (36.6)         82452 (49.4)           4 doses received         10568 (7.9)         6092 (18.2)         16660 (10.0)           Race         White, non-Hispanic         28805 (21.6)         9984 (29.8)         38789 (23.2)           Black, non-Hispanic         10668 (0.0)         3618 (10.8)         14287 (8.6)           Hispanic         43301         77744 (46.6)         44030)         77744 (46.6)           Asian         20114 (15.1)         3992 (11.9)         24106 (14.4)         Pacific Islander         1321 (1.0)         247 (0.7)         1588 (0.9)           Body mass index         Underweight (<18.5)		Any inpatient admission	6075 (4.6)	4973 (14.8)	11048 (6.6)
Any documented infection         5716 (4.3)         1707 (5.1)         7423 (4.4)           Prior COVID-19 vaccination         0 doses received         17153 (12.9)         6117 (18.2)         23270 (13.9)           1 dose received         2065 (1.5)         2144 (6.4)         4209 (2.5)         20389 (24.2)           2 doses received         30469 (24.3)         7920 (23.6)         40389 (24.2)           3 doses received         71171 (53.3)         11281 (33.6)         82452 (49.4)           4 doses received         10669 (8.0)         3618 (10.8)         14287 (8.6)           Hispanic         28805 (21.6)         9984 (29.8)         38789 (23.2)           Back, non-Hispanic         63310 (47.4)         14434 (43.0)         77744 (46.6)           Asian         20114 (15.1)         3992 (11.9)         24106 (14.4)           Pacific Islander         1321 (1.0)         247 (0.7)         1568 (0.9)           Other/unknown/mixed race         9207 (6.9)         1279 (3.8)         10486 (6.3)           Cigarette smoking         Underweight (51.5-24.9)         27790 (20.8)         8181 (24.4)         35971 (21.5)           Overweight (25.0-29.9)         33521 (26.5)         9065 (27.1)         44406 (26.6)         2069 (5.4)           Cigarette smoking         Current smoker	Prior SARS-CoV-2 infection				
Prior COVID-19 vaccination         0         doses received         17153 (12.9)         6117 (18.2)         23270 (13.9)           1         doses received         32668 (24.3)         7920 (23.6)         40389 (24.2)         3 doses received         32468 (24.3)         7920 (23.6)         40389 (24.2)         3 doses received         32468 (24.3)         7920 (23.6)         40389 (24.2)         16660 (10.0)           Race         White, non-Hispanic         28805 (21.6)         9984 (29.8)         38789 (23.2)         16660 (10.0)           Black, non-Hispanic         10568 (7.9)         6092 (18.2)         16660 (10.0)         14287 (8.6)           Hispanic         63310 (47.4)         14434 (43.0)         77744 (46.6)         Asian         20114 (15.1)         3992 (11.9)         24106 (14.4)           Pacific Islander         1321 (1.0)         247 (0.7)         1568 (0.9)         0144 (43.0)         77744 (46.6)           Moral veight (<18.5)		Any documented infection	5716 (4.3)	1707 (5.1)	7423 (4.4)
0 doses received         17153 (12.9)         6117 (18.2)         23270 (13.9)           1 dose received         2065 (1.5)         2144 (6.4)         4209 (2.5)           2 doses received         32469 (24.3)         77920 (23.6)         40389 (24.2)           3 doses received         71171 (53.3)         11281 (33.6)         82452 (49.4)           4 doses received         10568 (7.9)         6092 (18.2)         16660 (10.0)           Race         White, non-Hispanic         28805 (21.6)         9984 (29.8)         38789 (23.2)           Black, non-Hispanic         63310 (47.4)         14434 (43.0)         77774 (46.6)           Asian         20114 (15.1)         3992 (11.9)         24106 (14.4)           Pacific Islander         1321 (1.0)         247 (0.7)         1568 (0.9)           Overweight (51.5)         5701 (4.3)         1869 (5.6)         7570 (4.5)           Normal weight (18.5-2)         5701 (4.3)         1869 (5.6)         7570 (4.5)           Overweight (25.0-29.9)         35321 (26.5)         9085 (27.1)         44406 (26.6)           Overweight (25.0-29.9)         35321 (26.5)         9085 (27.1)         44406 (26.6)           Overweight (25.0-29.9)         35321 (26.5)         9085 (27.1)         44406 (26.6)           Overweight (2	Prior COVID-19 vaccination				
1 dose received         2065 (1.5)         2144 (6.4)         4209 (2.5)           2 doses received         32469 (24.3)         7920 (23.6)         40389 (24.2)           3 doses received         10568 (7.9)         6092 (18.2)         16660 (10.0)           Race         White, non-Hispanic         28805 (21.6)         9984 (29.8)         38789 (23.2)           Black, non-Hispanic         10669 (8.0)         3618 (10.8)         14287 (8.6)           Hispanic         10304 (7.4)         14434 (43.0)         77744 (46.6)           Asian         20114 (15.1)         3992 (11.9)         24106 (14.4)           Pacific Islander         1321 (1.0)         247 (0.7)         1568 (0.9)           Other/unknown/mixed race         9207 (6.9)         1279 (3.8)         10486 (6.3)           Body mass index         Underweight (18.5)         5701 (4.3)         1869 (5.6)         7570 (4.5)           Normal weight (18.5-24.9)         27790 (20.8)         8181 (24.4)         35971 (21.5)         00ese (30-39.9)         35121 (27.1)         9335 (27.8)         44406 (26.6)           Overweight (25.0-29.9)         35121 (27.1)         935 (27.8)         45456 (27.2)         00ese (30-39.9)         35121 (27.1)         935 (27.8)         45456 (27.2)           Neighborhood deprivation index <td></td> <td>0 doses received</td> <td>17153 (12.9)</td> <td>6117 (18.2)</td> <td>23270 (13.9)</td>		0 doses received	17153 (12.9)	6117 (18.2)	23270 (13.9)
Acce         Descrived 3 doses received 4 doses received         Descrived 71171 (53.3)         T1281 (33.6) 11281 (33.6)         B2452 (49.4) 82452 (49.4)           Race         White, non-Hispanic         26805 (21.6)         9984 (29.8)         38789 (23.2)           Black, non-Hispanic         10666 (8.0)         3618 (10.8)         14227 (8.6)           Black, non-Hispanic         63310 (47.4)         14434 (43.0)         77744 (46.6)           Asian         20114 (15.1)         3992 (11.9)         24106 (14.4)           Pacific Islander         1321 (1.0)         247 (0.7)         1568 (0.9)           Other/unknown/mixed race         9207 (6.9)         1279 (3.8)         10486 (6.3)           Body mass index         Underweight (<18.5)		1 dose received	2065 (1.5)	2144 (6.4)	4209 (2.5)
Body mass index         Underweight (<18.5)         5710 (±1.5)         11281 (33.6)         82452 (49.4)           Race         White, non-Hispanic         28805 (21.6)         9984 (29.8)         38789 (23.2)           Black, non-Hispanic         10669 (8.0)         3618 (10.8)         14287 (8.6)           Asian         20114 (15.1)         3992 (11.9)         24106 (14.4)           Pacific Islander         1321 (1.0)         247 (0.7)         1568 (0.9)           Other/unknown/mixed race         9207 (6.9)         1279 (3.8)         10486 (6.3)           Body mass index         Underweight (<18.5)		2 doses received	32469 (24-3)	7920 (23.6)	40389 (24.2)
Body mass index         International (3.5)         International (3.5) <thinternational (3.5)<="" th="">         Internaternaternational (3.5)&lt;</thinternational>		2 doses received	71171 (52.3)	11281 (23.6)	92452 (40 4)
Race       White, non-Hispanic       28805 (21.6)       9984 (29.8)       38789 (23.2)         Black, non-Hispanic       10669 (8.0)       3618 (10.8)       14287 (8.6)         Hispanic       63310 (47.4)       14434 (43.0)       77744 (46.6)         Asian       20114 (15.1)       3992 (11.9)       24106 (14.4)         Pacific Islander       1321 (1.0)       247 (0.7)       1568 (0.9)         Other/unknown/mixed race       9207 (6.9)       1279 (3.8)       10486 (6.3)         Body mass index       Underweight (<18.5)			10569 (7.0)	6002 (19.2)	16660 (10.0)
Hace         White, non-Hispanic         28805 (21.6)         9984 (29.8)         38789 (23.2)           Black, non-Hispanic         10669 (8.0)         3618 (10.8)         14287 (8.6)           Hispanic         63310 (47.4)         14434 (43.0)         77744 (46.6)           Asian         20114 (15.1)         3992 (11.9)         24106 (14.4)           Pacific Islander         1321 (1.0)         247 (0.7)         1568 (0.9)           Other/unknown/mixed race         9207 (6.9)         1279 (3.8)         10486 (6.3)           Body mass index         Underweight (18.5)         5701 (4.3)         1869 (5.6)         7570 (4.5)           Normal weight (18.5-24.9)         27790 (20.8)         8181 (24.4)         35971 (21.5)           Overweight (25.0-29.9)         35321 (26.5)         9085 (27.1)         44406 (26.6)           Obese (30.39.9)         36121 (27.1)         9335 (27.8)         45456 (27.2)           Morbidly obese (≥40.0)         6614 (5.0)         4078 (12.2)         10692 (6.4)           Cigarette smoking         Intrest moker         88479 (66.3)         22812 (68.0)         111291 (66.6)           Former smoker         4359 (3.3)         1535 (4.6)         5894 (3.5)         1894 (3.5)         1141291 (66.6)           Fordart quintile         1907	Deer	4 doses received	10000 (7.9)	6092 (16.2)	10000 (10.0)
White, non-Hispanic         28805 (21.6)         9984 (29.8)         38789 (23.2)           Black, non-Hispanic         10669 (8.0)         3618 (10.8)         14227 (8.6)           Hispanic         63310 (47.4)         14434 (43.0)         77744 (46.6)           Asian         20114 (15.1)         3992 (11.9)         24106 (14.4)           Pacific Islander         1321 (1.0)         247 (0.7)         1568 (0.9)           Other/unknown/mixed race         9207 (6.9)         1279 (3.8)         10486 (6.3)           Body mass index         Underweight (<18.5)	Race				
Black, non-Hispanic         10669 (8.0)         3618 (10.8)         14287 (8.6)           Hispanic         63310 (47.4)         14434 (43.0)         7774 (46.6)           Asian         20114 (15.1)         3992 (11.9)         24106 (14.4)           Pacific Islander         1321 (1.0)         247 (0.7)         1568 (0.9)           Other/unknown/mixed race         9207 (6.9)         1279 (3.8)         10486 (6.3)           Body mass index         Underweight (<18.5)		White, non-Hispanic	28805 (21.6)	9984 (29.8)	38789 (23.2)
Hispanic       63310 (47.4)       14434 (43.0)       77744 (46.6)         Asian       20114 (15.1)       3992 (11.9)       24106 (14.4)         Pacific Islander       1321 (1.0)       247 (0.7)       1568 (0.9)         Other/unknown/mixed race       9207 (6.9)       1279 (3.8)       10486 (6.3)         Body mass index       underweight (<18.5)		Black, non-Hispanic	10669 (8.0)	3618 (10.8)	14287 (8.6)
Asian         20114 (15.1)         3992 (11.9)         24106 (14.4)           Pacific Islander         1321 (1.0)         247 (0.7)         1568 (0.9)           Body mass index         0ther/unknown/mixed race         9207 (6.9)         1279 (3.8)         10486 (6.3)           Body mass index         Underweight (<18.5)		Hispanic	63310 (47.4)	14434 (43.0)	77744 (46.6)
Pacific Islander Other/unknown/mixed race         1321 (1.0)         247 (0.7)         1568 (0.9)           Body mass index         0ther/unknown/mixed race         9207 (6.9)         1279 (3.8)         10486 (6.3)           Body mass index         Underweight (<18.5)		Asian	20114 (15.1)	3992 (11.9)	24106 (14.4)
Body mass index         Other/unknown/mixed race         9207 (6.9)         1279 (3.8)         10486 (6.3)           Body mass index         Underweight (<18.5)		Pacific Islander	1321 (1.0)	247 (0.7)	1568 (0.9)
Body mass index         Underweight (<18.5)         5701 (4.3)         1869 (5.6)         7570 (4.5)           Normal weight (18.5/24.9)         27790 (20.8)         8181 (24.4)         35971 (21.5)           Overweight (25.0-29.9)         35321 (26.5)         9085 (27.1)         44406 (26.6)           Obese (30-39.9)         36121 (27.1)         9335 (27.8)         45456 (27.2)           Morbidly obese (≥40.0)         6614 (5.0)         4078 (12.2)         10692 (6.4)           Cigarette smoking         Current smoker         88479 (66.3)         22812 (68.0)         111291 (66.6)           Former smoker         4359 (3.3)         1535 (4.6)         5894 (3.5)         Never smoked         17965 (13.5)         7334 (21.9)         25299 (15.2)           Neighborhood deprivation index         First quintile (least deprived)         19071 (14.3)         4942 (14.7)         24013 (14.4)           Second quintile         28986 (21.7)         7455 (22.2)         36441 (21.8)           Third quintile         33677 (25.2)         8283 (24.7)         41960 (25.1)           Fourth quintile         31161 (23.4)         7646 (22.8)         38807 (23.2)           Fifth quintile (most deprived)         20431 (15.3)         5203 (15.5)         25634 (15.4)           Receipt of other respiratory vaccines		Other/unknown/mixed race	9207 (6.9)	1279 (3.8 <sup>́</sup> )	10486 (6.3)
Underweight (<18.5)         5701 (4.3)         1869 (5.6)         7570 (4.5)           Normal weight (18.5-24.9)         27790 (20.8)         8181 (24.4)         35971 (21.5)           Overweight (25.0-29.9)         35321 (26.5)         9085 (27.1)         44406 (26.6)           Obese (30-39.9)         36121 (27.1)         9335 (27.8)         45456 (27.2)           Morbidly obese (≥40.0)         6614 (5.0)         4078 (12.2)         10692 (6.4)           Cigarette smoking         Eurrent smoker         88479 (66.3)         22812 (68.0)         111291 (66.6)           Former smoker         4359 (3.3)         1535 (4.6)         5894 (3.5)         Never smoked           Neighborhood deprivation index         First quintile (least deprived)         19071 (14.3)         4942 (14.7)         24013 (14.4)           Second quintile         28986 (21.7)         7455 (22.2)         36441 (21.8)         3807 (23.2)           Third quintile         33677 (25.2)         8283 (24.7)         41960 (25.1)         Fourth quintile (most deprived)         20431 (15.3)         5203 (15.5)         25634 (15.4)           Receipt of other respiratory vaccines         2021-22 seasonal influenza vaccine         73196 (54.9)         20605 (61.4)         93801 (56.2)           Pneumococcal conjugate vaccine         25328 (19.0)         13256 (39.	Body mass index				
Normal weight (18.5-24.9)       27790 (20.8)       8181 (24.4)       35971 (21.5)         Overweight (25.0-29.9)       35321 (26.5)       9085 (27.1)       44406 (26.6)         Obese (30-39.9)       36121 (27.1)       9335 (27.8)       45456 (27.2)         Morbidly obese (≥40.0)       6614 (5.0)       4078 (12.2)       10692 (6.4)         Cigarette smoking       Current smoker       88479 (66.3)       22812 (68.0)       111291 (66.6)         Former smoker       4359 (3.3)       1535 (4.6)       5894 (3.5)         Never smoked       17965 (13.5)       7334 (21.9)       25299 (15.2)         Neighborhood deprivation index       First quintile (least deprived)       19071 (14.3)       4942 (14.7)       24013 (14.4)         Second quintile       28986 (21.7)       7455 (22.2)       36441 (21.8)         Third quintile       33677 (25.2)       8283 (24.7)       41960 (25.1)         Fourth quintile (most deprived)       20431 (15.3)       5203 (15.5)       25634 (15.4)         Receipt of other respiratory vaccines       2021-22 seasonal influenza vaccine       73196 (54.9)       20605 (61.4)       93801 (56.2)         Pneumococcal conjugate vaccine       25328 (19.0)       13256 (39.5)       38584 (23.1)		Underweight (<18.5)	5701 (4 3)	1869 (5.6)	7570 (4 5)
Normal weight (25.0-29.9)       35321 (26.5)       9085 (27.1)       44406 (26.6)         Overweight (25.0-29.9)       35321 (26.5)       9085 (27.1)       44406 (26.6)         Obese (30-39.9)       36121 (27.1)       9335 (27.8)       45456 (27.2)         Morbidly obese (≥40.0)       6614 (5.0)       4078 (12.2)       10692 (6.4)         Cigarette smoking       22892 (68.0)       111291 (66.6)         Former smoker       4359 (3.3)       1535 (4.6)       5894 (3.5)         Neighborhood deprivation index       First quintile (least deprived)       19071 (14.3)       4942 (14.7)       24013 (14.4)         Second quintile       28986 (21.7)       7455 (22.2)       36441 (21.8)         Third quintile       33677 (25.2)       8283 (24.7)       41960 (25.1)         Fourth quintile (most deprived)       20431 (15.3)       2503 (15.5)       232.2)         Fifth quintile (most deprived)       20431 (15.3)       2503 (15.5)       25634 (15.4)         Receipt of other respiratory vaccines       2021-22 seasonal influenza vaccine       73196 (54.9)       20605 (61.4)       93801 (56.2)         Pneumococcal conjugate vaccine       25328 (19.0)       13256 (39.5)       38584 (23.1)		Normal weight (18.5,24.0)	27700 (20.8)	9191 (24 A)	35071 (21 5)
Cigarette smoking         Overweight (25.0-29.9)         35.321 (26.5)         9085 (27.1)         44406 (26.6)           Obese (30-39.9)         36121 (27.1)         9335 (27.8)         45456 (27.2)           Morbidly obese (≥40.0)         6614 (5.0)         4078 (12.2)         10692 (6.4)           Cigarette smoking         Eurrent smoker         88479 (66.3)         22812 (68.0)         111291 (66.6)           Neighborhood deprivation index         Former smoker         4359 (3.3)         1535 (4.6)         5894 (3.5)           Never smoked         17965 (13.5)         7334 (21.9)         25299 (15.2)           Neighborhood deprivation index         First quintile (least deprived)         19071 (14.3)         4942 (14.7)         24013 (14.4)           Second quintile         28986 (21.7)         7455 (22.2)         36441 (21.8)         3607 (25.2)         3823 (24.7)         41960 (25.1)           Fourth quintile         most deprived)         20431 (15.3)         5203 (15.5)         25634 (15.4)           Receipt of other respiratory vaccines         2021-22 seasonal influenza vaccine         73196 (54.9)         20605 (61.4)         93801 (56.2)           Pneumococcal conjugate vaccine         25328 (19.0)         13256 (39.5)         38584 (23.1)		Normal weight $(16.5-24.9)$	27790 (20.8)	0101 (24.4)	33971 (21.3)
Cigarette smoking       36121 (27.1)       9335 (27.8)       45456 (27.2)         Morbidly obese (≥40.0)       6614 (5.0)       4078 (12.2)       10692 (6.4)         Cigarette smoking       Current smoker       88479 (66.3)       22812 (68.0)       111291 (66.6)         Former smoker       4359 (3.3)       1535 (4.6)       5894 (3.5)         Neighborhood deprivation index       First quintile (least deprived)       19071 (14.3)       4942 (14.7)       24013 (14.4)         Second quintile       28986 (21.7)       7455 (22.2)       36441 (21.8)         Third quintile       33677 (25.2)       8283 (24.7)       41960 (25.1)         Fourth quintile       031161 (23.4)       7646 (22.8)       38807 (23.2)         Fifth quintile (most deprived)       20431 (15.3)       5203 (15.5)       25634 (15.4)         2021-22 seasonal influenza vaccine       73196 (54.9)       20605 (61.4)       93801 (56.2)         Pneumococcal conjugate vaccine       25328 (19.0)       13256 (39.5)       38584 (23.1)		Overweight (25.0-29.9)	35321 (26.5)	9085 (27.1)	44406 (26.6)
Morbidly obese (≥40.0)       6614 (5.0)       4078 (12.2)       10692 (6.4)         Cigarette smoking       Current smoker       88479 (66.3)       22812 (68.0)       111291 (66.6)         Former smoker       4359 (3.3)       1535 (4.6)       5894 (3.5)         Neighborhood deprivation index       First quintile (least deprived)       17965 (13.5)       7334 (21.9)       25299 (15.2)         Neighborhood deprivation index       First quintile (least deprived)       19071 (14.3)       4942 (14.7)       24013 (14.4)         Second quintile       28986 (21.7)       7455 (22.2)       36441 (21.8)         Third quintile       33677 (25.2)       8283 (24.7)       41960 (25.1)         Fourth quintile       31161 (23.4)       7646 (22.8)       38807 (23.2)         Fifth quintile (most deprived)       20431 (15.3)       5203 (15.5)       25634 (15.4)         2021-22 seasonal influenza vaccine       73196 (54.9)       20605 (61.4)       93801 (56.2)         Pneumococcal conjugate vaccine       25328 (19.0)       13256 (39.5)       38584 (23.1)		Obese (30-39.9)	36121 (27.1)	9335 (27.8)	45456 (27.2)
Cigarette smoking         Current smoker         88479 (66.3)         22812 (68.0)         111291 (66.6)           Former smoker         4359 (3.3)         1535 (4.6)         5894 (3.5)           Never smoked         17965 (13.5)         7334 (21.9)         25299 (15.2)           Neighborhood deprivation index         First quintile (least deprived)         19071 (14.3)         4942 (14.7)         24013 (14.4)           Second quintile         28986 (21.7)         7455 (22.2)         36441 (21.8)           Third quintile         33677 (25.2)         8283 (24.7)         41960 (25.1)           Fourth quintile (most deprived)         20431 (15.3)         5203 (15.5)         25034 (15.4)           Receipt of other respiratory vaccines         2021-22 seasonal influenza vaccine         73196 (54.9)         20605 (61.4)         93801 (56.2)           Pneumococcal conjugate vaccine         25328 (19.0)         13256 (39.5)         38584 (23.1)		Morbidly obese (≥40.0)	6614 (5.0)	4078 (12.2)	10692 (6.4)
Current smoker         88479 (66.3)         22812 (68.0)         111291 (66.6)           Former smoker         4359 (3.3)         1535 (4.6)         5894 (3.5)           Neighborhood deprivation index         First quintile (least deprived)         17965 (13.5)         7334 (21.9)         25299 (15.2)           Neighborhood deprivation index         First quintile (least deprived)         19071 (14.3)         4942 (14.7)         24013 (14.4)           Second quintile         28986 (21.7)         7455 (22.2)         36441 (21.8)           Third quintile         33677 (25.2)         8283 (24.7)         41960 (25.1)           Fourth quintile (most deprived)         20431 (15.3)         5203 (15.5)         25634 (15.4)           Receipt of other respiratory vaccines         Fifth quintile (most deprived)         20431 (15.3)         5203 (15.5)         25634 (15.4)           2021-22 seasonal influenza vaccine         73196 (54.9)         20605 (61.4)         93801 (56.2)           Pneumococcal conjugate vaccine         25328 (19.0)         13256 (39.5)         38584 (23.1)	Cigarette smoking				
Former smoker         4359 (3.3)         1535 (4.6)         5894 (3.5)           Neighborhood deprivation index         Never smoked         17965 (13.5)         7334 (21.9)         25299 (15.2)           First quintile (least deprived)         19071 (14.3)         4942 (14.7)         24013 (14.4)           Second quintile         28986 (21.7)         7455 (22.2)         36441 (21.8)           Third quintile         33677 (25.2)         8283 (24.7)         41960 (25.1)           Fourth quintile         most deprived)         20431 (15.3)         5203 (15.5)         25634 (15.4)           Receipt of other respiratory vaccines         Fifth quintile (most deprived)         20431 (15.3)         2201.52         25634 (15.4)           2021-22 seasonal influenza vaccine         73196 (54.9)         20605 (61.4)         93801 (56.2)           Pneumococcal conjugate vaccine         25328 (19.0)         13256 (39.5)         38584 (23.1)		Current smoker	88479 (66.3)	22812 (68.0)	111291 (66.6)
Neighborhood deprivation index         Never smoked         17965 (13.5)         7334 (21.9)         25299 (15.2)           First quintile (least deprived)         19071 (14.3)         4942 (14.7)         24013 (14.4)           Second quintile         28986 (21.7)         7455 (22.2)         36441 (21.8)           Third quintile         33677 (25.2)         8283 (24.7)         41960 (25.1)           Fourth quintile         31161 (23.4)         7646 (22.8)         38807 (23.2)           Fifth quintile (most deprived)         20431 (15.3)         5203 (15.5)         25634 (15.4)           2021-22 seasonal influenza vaccine         73196 (54.9)         20605 (61.4)         93801 (56.2)           Pneumococcal conjugate vaccine         25328 (19.0)         13256 (39.5)         38584 (23.1)		Former smoker	4359 (3.3)	1535 (4.6)	5894 (3.5)
Neighborhood deprivation index         First quintile (least deprived)         19071 (14.3)         4942 (14.7)         24013 (14.4)           Second quintile         28986 (21.7)         7455 (22.2)         36441 (21.8)           Third quintile         33677 (25.2)         8283 (24.7)         41960 (25.1)           Fourth quintile         31161 (23.4)         7646 (22.8)         38807 (23.2)           Fifth quintile (most deprived)         20431 (15.3)         5203 (15.5)         25634 (15.4)           2021-22 seasonal influenza vaccine         73196 (54.9)         20605 (61.4)         93801 (56.2)           Pneumococcal conjugate vaccine         25328 (19.0)         13256 (39.5)         38584 (23.1)		Never smoked	17965 (13.5)	7334 (21.9)	25299 (15.2)
First quintile (least deprived)         19071 (14.3)         4942 (14.7)         24013 (14.4)           Second quintile         28986 (21.7)         7455 (22.2)         36441 (21.8)           Third quintile         33677 (25.2)         8283 (24.7)         41960 (25.1)           Fourth quintile         31161 (23.4)         7646 (22.8)         38807 (23.2)           Fifth quintile (most deprived)         20431 (15.3)         5203 (15.5)         25634 (15.4)           2021-22 seasonal influenza vaccine         73196 (54.9)         20605 (61.4)         93801 (56.2)           Pneumococcal conjugate vaccine         25328 (19.0)         13256 (39.5)         38584 (23.1)	Neighborhood deprivation index			(	
Not quintile       1307 (11.3)       1307 (11.3)       1404 (11.4)         Second quintile       28986 (21.7)       7455 (22.2)       36441 (21.8)         Third quintile       33677 (25.2)       8283 (24.7)       41960 (25.1)         Fourth quintile       31161 (23.4)       7646 (22.8)       38807 (23.2)         Fifth quintile (most deprived)       20431 (15.3)       5203 (15.5)       25634 (15.4)         2021-22 seasonal influenza vaccine       73196 (54.9)       20605 (61.4)       93801 (56.2)         Pneumococcal conjugate vaccine       25328 (19.0)       13256 (39.5)       38584 (23.1)		First quintile (least deprived)	19071 (14-3)	4942 (14 7)	24013 (14 4)
Receipt of other respiratory vaccines         20201/2 (21.7)         7435 (22.2)         3044 (21.6)           20300 (21.7)         7436 (22.2)         3044 (21.6)         3044 (21.6)           Third quintile         33677 (25.2)         8283 (24.7)         41960 (25.1)           Fourth quintile         31161 (23.4)         7646 (22.8)         38807 (23.2)           Fifth quintile (most deprived)         20431 (15.3)         5203 (15.5)         25634 (15.4)           2021-22 seasonal influenza vaccine         73196 (54.9)         20605 (61.4)         93801 (56.2)           Pneumococcal conjugate vaccine         25328 (19.0)         13256 (39.5)         38584 (23.1)		Second quintile	28086 (21 7)	7455 (22 2)	36441 (21 8)
Receipt of other respiratory vaccines         Fifth quintile (most deprived)         53677 (25.2)         6263 (24.7)         41960 (25.1)           2021-22 seasonal influenza vaccine         31161 (23.4)         7646 (22.8)         38807 (23.2)           2021-22 seasonal influenza vaccine         73196 (54.9)         20605 (61.4)         93801 (56.2)           Pneumococcal conjugate vaccine         25328 (19.0)         13256 (39.5)         38584 (23.1)		Third quintilo	20000 (21.7)	2222 (21 Z)	11060 (25 1)
Fourth quintile         31161 (23.4)         7646 (22.8)         38807 (23.2)           Receipt of other respiratory vaccines         Fifth quintile (most deprived)         20431 (15.3)         5203 (15.5)         25634 (15.4)           2021-22 seasonal influenza vaccine         73196 (54.9)         20605 (61.4)         93801 (56.2)           Pneumococcal conjugate vaccine         25328 (19.0)         13256 (39.5)         38584 (23.1)			330// (23.2)	0203(24.7)	41900 (25.1)
Fifth quintile (most deprived)         20431 (15.3)         5203 (15.5)         25634 (15.4)           Receipt of other respiratory vaccines         2021-22 seasonal influenza vaccine         73196 (54.9)         20605 (61.4)         93801 (56.2)           Pneumococcal conjugate vaccine         25328 (19.0)         13256 (39.5)         38584 (23.1)		Fourth quintile	31161 (23.4)	7646 (22.8)	38807 (23.2)
Receipt of other respiratory vaccines         2021-22 seasonal influenza vaccine         73196 (54.9)         20605 (61.4)         93801 (56.2)           Pneumococcal conjugate vaccine         25328 (19.0)         13256 (39.5)         38584 (23.1)		Fifth quintile (most deprived)	20431 (15.3)	5203 (15.5)	25634 (15.4)
2021-22 seasonal influenza vaccine         73196 (54.9)         20605 (61.4)         93801 (56.2)           Pneumococcal conjugate vaccine         25328 (19.0)         13256 (39.5)         38584 (23.1)	Receipt of other respiratory vaccines				
Pneumococcal conjugate vaccine 25328 (19.0) 13256 (39.5) 38584 (23.1)		2021-22 seasonal influenza vaccine	73196 (54.9)	20605 (61.4)	93801 (56.2)
		Pneumococcal conjugate vaccine	25328 (19.0)	13256 (39.5)	38584 (23.1)

Clinical outcomoo	Pneumococcal polysaccharide vaccine	33765 (25.3)	17457 (52.0)	51222 (30.7)
Clinical outcomes	Any hospital admission within 30 days Any intensive care unit admission within 60	687 (0.5)	753 (2.2)	1440 (0.9)
	days	173 (0.1)	256 (0.8)	429 (0.3)
	Mechanical ventilation within 60 days	42 (0.0)	91 (0.3)	133 (0.1)
	Death within 60 days	134 (0.1)	289 (0.9)	423 (0.3)

Data on exposure prevalence among treatment recipients and non-recipients within the analytic sample include all eligible cases who were assigned matches. Percentages indicated in the table are computed among individuals with non-missing observations; missing data are present in participants' smoking status, body mass index, and neighborhood deprivation index, as summarized in **Table 1**.

#### Table S5: Censoring, outcomes, and lengths of follow-up in survival analyses.

Analytic endpoint	Exposure		Outco	omes among treatment recipi	ents	Median follow	v-up days (IQR)
		Endpoint	Change in	Disenrollment or censoring	Censored at intended	Endpoint	Endpoint not
		observed	treatment	before intended end of follow-up	end of follow-up	observed	observed
All-cause hospital admission or death within 30 days from positive SARS-CoV-2 test							
	Nirmatrelvir-ritonavir received	51 (0.7) 695 (0.5)	0 (0.0) 4 725 (3 6)	212 (2.9) 2 790 (2 1)	7,011 (96.4) 122 667 (93 7)	13 (5, 20) 12 (5, 21)	29 (28, 30) 30 (30, 30)
All-cause intensive care unit admission, mechanical ventilation, or death within 60 days from positive SARS-CoV-2 test		000 (0.0)	.,. 20 (0.0)	2,		.2 (3, 21)	
	Nirmatrelvir-ritonavir received	17 (0.2)	0 (0.0)	1,040 (14.3)	6,217 (85.5)	20 (16, 30)	59 (58, 30)
	Nirmatrelvir-ritonavir not received	257 (0.2)	4,725 (3.6)	14,394 (11.0)	111,501 (85.2)	19 (5, 35)	60 (60, 60)

Percentages among the arm of cases who did not receive nirmatrelvir-ritonavir are computed from the total number who were not dispensed treatment on their testing date; those who went on to receive treatment at a later point in time are indicated in the "Change in treatment" column, and their outcomes following treatment (censoring or endpoint occurrence) are counted within recipient sample thereafter.

### Table S6: Characteristics of patients experiencing or not experiencing hospital admission or death within 30 days of testing.

Anome Company         Anome Co	Characteristic		Frequency among cases by clinical outcome, <i>n</i> (%)							
Data disputation         Period construction         Period construction         Data disputation         Period construction         Data disputation           Age         M+51         N1-2,232         M+535         M+535         M+535         M+535         M-535         <			Nirmotrol	Ana Vir ritopovir	lytic sample	anavir not dianonood	Nirmotrol	All eliç	gible patients	novir not dianonood
Unitoria         Patient baseroad pasaroad			disp	ensed	Nirmaireivir-nic	onavir not dispensed	disp	ensed	Nirmaireivir-mo	onavir not dispensed
Observed			<u>Outcome</u>	Patient	<u>Outcome</u>	Patient censored	<u>Outcome</u>	Patient	<u>Outcome</u>	Patient censored
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			<u>observed</u>	<u>censored</u>	<u>observed</u>		<u>observed</u>	<u>censored</u>	<u>observed</u>	
Age         11 (0.2)         8 (1.2)         11 (0.2)         8 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         11 (0.2)         2 (1.2)         <			<i>N</i> =51	N=7,223	N=695	N=125,457	N=142	N=12,432	N=1,504	N=152,902
12-19 years         0 (0.0)         11 (0.2)         8 (1.2)         1146 (0.4)         0 (0.0)         27 (0.2)         19 (1.3)         12270 (87)           20-29 years         0 (0.0)         170 (2.2)         8 (1.2)         1130 (6 (0.4)         10 (0.0)         27 (0.2)         19 (1.3)         1240 (10.7)           40-49 years         6 (1.16)         1097 (15.2)         96 (1.3)         2207 (2.07)         14 (9.9)         1580 (12.7)         117 (7.6)         2238 (1.4)           60-68 years         7 (1.3)         1667 (2.3.1)         82 (1.16)         1305 (1.4.4)         18 (1.2)         2251 (1.4)         117 (7.8)         2249 (1.4,1)           80-89 years         12 (2.3.5)         549 (1.2.0)         134 (1.4.4)         9009 (7.3)         52 (1.4)         1432 (1.1.5)         269 (1.7.9)         6051 (4.0.0)           Sex         male         25 (4.9.0)         3055 (4.2.3)         255 (36.7)         56102 (4.7.7)         70 (4.9.3)         5301 (4.2.6)         636 (4.2.3)         66555 (4.6.0)           Time from symptoms         onest to testing         4 (7.8)         546 (7.5.4)         335 (4.8.2)         142 (1.3.0)         112 (1.1.5)         263 (1.1.5)         157 (1.5.0)         120 (1.4.1)         203 (1.5.2)         203 (1.5.1)         2628 (1.7.2)         120	Age									
$ \begin{array}{c} & & & & & & & & & & & & & & & & & & &$		12-19 years	0 (0.0)	11 (0.2)	8 (1.2)	11046 (8.8)	0 (0.0)	21 (0.2)	19 (1.3)	13270 (8.7)
$ \begin{array}{c} 30-39 \ years \\ 40-49 \ years \\ 40-49 \ years \\ 50-69 \ years \\ 70-79 \ years \ years \ years \\ 70-79 \ years $		20-29 years	0 (0.0)	170 (2.4)	31 (4.5)	13016 (10.4)	1 (0.7)	293 (2.4)	64 (4.3)	15405 (10.1)
$ \begin{array}{c} 40-49 \ years \\ 50-69 \ years \\ 70-79 \ years $		30-39 years	2 (3.9)	503 (7.0)	129 (18.6)	20632 (16.4)	7 (4.9)	777 (6.2)	190 (12.6)	23692 (15.5)
50-59 years         1 (20)         1555 (21.5)         51 (7.3)         1680 (18.9)         8 (5.6)         2291 (18.4)         117 (7.6)         27498 (18.0)           30-69 years         1 (22.3)         150 (11.8)         1983 (14.4)         180 (27.1)         35 (24.6)         2747 (22.1)         27 (11.8)         1983 (14.4)         180 (27.1)         141 (21.6)         139 (19.1)         141 (21.6)         139 (19.1)         141 (21.6)         139 (19.1)         141 (21.6)         139 (19.1)         141 (21.6)         139 (19.1)         141 (21.6)         139 (19.1)         141 (21.6)         139 (19.1)         141 (21.6)         139 (19.1)         141 (21.6)         139 (19.1)         141 (21.6)         139 (19.1)         141 (21.6)         139 (19.1)         141 (21.6)         142 (15.1)         141 (21.6)         141 (21.6)         129 (17.6)         141 (21.6)         129 (17.6)         141 (21.6)         129 (17.6)         141 (21.6)         121 (11.6)         117 (1.7)         77 (16.2)         203 (13.5)         257 (36.6)           Outpatient care readivad         -         -         126 (17.6)         248 (35.7)         192 (17.6)         11 (1.7)         77 (17.6)         20 (13.5)         257 (36.16.8)           Outpatient care readivad         -         126 (12.1)         203 (12.1)         203 (13.5) </td <td></td> <td>40-49 years</td> <td>6 (11.8)</td> <td>1097 (15.2)</td> <td>95 (13.7)</td> <td>26027 (20.7)</td> <td>14 (9.9)</td> <td>1580 (12.7)</td> <td>157 (10.4)</td> <td>29393 (19.2)</td>		40-49 years	6 (11.8)	1097 (15.2)	95 (13.7)	26027 (20.7)	14 (9.9)	1580 (12.7)	157 (10.4)	29393 (19.2)
$ \begin{array}{c} 60-69 \ \text{years} & 7(13.7) & 1667 (23.1) & 22(11.8) & 10035 (14.4) & 18 (12.7) & 2753 (22.1) & 186 (12.4) & 22499 (14.7) \\ 80-69 \ \text{years} & 12 (23.5) & 590 (62.0) & 105 (14.6) & 5022 (2.6) & 31 (21.6) & 1432 (21.5) & 1415 (21.6) & 1256 (6.7) \\ 80-69 \ \text{years} & 12 (23.5) & 590 (62.0) & 105 (14.0) & 682 (65.5) & 22 (17.5) & 471 (0.3) & 232 (15.4) & 1727 (15.1) \\ \text{Time from symptoms} & 112 (15.1) & 137 (11.2) & 139 (15.1) & 22 (11.8) & 685 (5.5) & 22 (11.5) & 683 (42.3) & 68555 (44.8) \\ \text{Time from symptoms} & 0.5 \ \text{days} & 26 (51.0) & 5446 (75.4) & 335 (48.2) & 84322 (67.2) & 97 (68.3) & 9941 (80.0) & 682 (45.3) & 100855 (65.0) \\ 6-14 \ days & 21 (41.2) & 1299 (17.6) & 248 (55.7) & 19822 (15.8) & 34 (23.9) & 1721 (13.8) & 619 (41.2) & 26284 (17.2) \\ \text{Outpatient care received} & 4 (7.8) & 508 (7.0) & 112 (16.1) & 21313 (17.0) & 11 (7.7) & 770 (6.2) & 203 (13.5) & 25763 (16.8) \\ \text{Outpatient care received} & 4 (7.8) & 508 (7.0) & 112 (16.1) & 21313 (17.0) & 11 (7.7) & 770 (6.2) & 203 (13.5) & 25763 (16.8) \\ \text{Outpatient care received} & 4 (7.8) & 508 (7.0) & 112 (16.1) & 21313 (17.0) & 11 (7.7) & 770 (6.2) & 203 (13.5) & 25763 (16.8) \\ \text{Outpatient care received} & 1 (22.5) & 2716 (37.6) & 141 (20.3) & 21914 (17.5) & 35 (24.6) & 4930 (39.7) & 331 (22.0) & 7347 (4.5) \\ 1-2 \ 1$		50-59 years	1 (2.0)	1555 (21.5)	51 (7.3)	23691 (18.9)	8 (5.6)	2291 (18.4)	117 (7.8)	27598 (18.0)
$ \begin{array}{c} 10^{-79} \text{ years} & 12 (23.5) & 1491 (20.6) & 114 (16.4) & 9099 (7.3) & 35 (24.6) & 227 (42.31) & 220 (18.0) & 13206 (8.7) \\ 250 \text{ years} & 11 (21.6) & 139 (1.9) & 62 (11.8) & 622 (1.2) & 136 (1.3) & 132 (1.1) & 290 (17.3) & 636 (1.3) \\ 250 \text{ years} & 11 (21.6) & 139 (1.9) & 62 (1.1) & 668 (0.5) & 24 (1.9, 7) & 411 (3.3) & 232 (15.4) & 1727 (1.1) \\ \hline \text{Sax} & \text{Male} & 25 (49.0) & 3055 (42.3) & 255 (36.7) & 56102 (44.7) & 70 (49.3) & 5011 (42.6) & 636 (42.3) & 668555 (44.8) \\ \hline \text{Order to tosting} & 0.5 days & 26 (51.0) & 544 (75.4) & 335 (48.2) & 84322 (67.2) & 97 (68.3) & 9941 (80.0) & 682 (45.3) & 100685 (66.0) \\ \hline \text{Outpatient care received} & 1 & 1266 (17.6) & 248 (35.7) & 19622 (15.8) & 34 (23.9) & 1721 (13.8) & 619 (41.2) & 26284 (17.2) \\ \hline \text{Outpatient care received} & 1 & 10 & 11 (7.7) & 770 (6.2) & 203 (13.5) & 25763 (16.8) \\ \hline \text{Charlson comorbidity} & no acute symptoms indicated at (18.8) & 203 (2.8) & 32 (4.6) & 1711 (1.4) & 20 (14.1) & 901 (7.2) & 223 (14.8) & 7574 (5.0) \\ \hline \text{Charlson comorbidity} & 0.0 & 12 (23.5) & 2716 (37.6) & 141 (20.3) & 21914 (17.5) & 35(24.6) & 4930 (39.7) & 331 (22.0) & 31716 (20.7) \\ \hline 1.2 & 12 (23.5) & 2716 (37.6) & 141 (20.3) & 21914 (17.5) & 35(24.6) & 4930 (39.7) & 331 (22.0) & 7371 (52.7) \\ \hline \text{Outpatient care} & 0 (17.6) & 273 (15.7) & 296 (42.6) & 99220 (79.1) & 29 (20.4) & 5308 (42.7) & 442 (29.4) & 110660 (72.4) \\ \hline 1.2 & 12 (23.5) & 2716 (37.6) & 141 (20.3) & 3204 (12.5) & 456 (3.0) (39.7) & 331 (22.0) & 7371 (5.0) \\ \hline \text{Outpatient visits} & 0 (0.0) & 28 (0.4) & 2 (0.3) & 4410 (3.5) & 0 (0.0) & 46 (0.4) & 4 (0.3) & 4566 (3.0) \\ \hline \text{Prior year healthcare} & 10 (22.9) & 129 (14.1) & 105 (0.8) & 10 (10.1) & 232 (14.0) & 1137 (23.0) & 333 (2.0) \\ \hline \text{Prior year healthcare} & 10 (23.9) & 177 (10.7) & 112 (1.5) & 156 (1.6) & 1097 (8.8) & 51 (3.4) & 3718 (24.3) \\ \hline \text{Prior year healthcare} & 10 (23.9) & 160 (12.5) & 46 (6.6) & 1997 (8.8) & 51 (3.4) & 3718 (24.3) & 4666 (3.0) \\ \hline \text{Prior year healthcare} & 10 (10.0) & 28 (0.4) & 20 (24.0) & 1371 (10.5) & 11$		60-69 years	7 (13.7)	1667 (23.1)	82 (11.8)	18035 (14.4)	18 (12.7)	2753 (22.1)	186 (12.4)	22499 (14.7)
B0-89 years         12 (23.5)         590 (8.2)         103 (14.8)         3222 (2.6)         31 (21.8)         (13.2)         (21.7)         (13.3)         223 (15.4)         (60.5)           Sex         Male         25 (49.0)         3055 (42.3)         255 (36.7)         56102 (47.7)         70 (49.3)         5301 (42.6)         636 (42.3)         68555 (44.4)           Time from symptoms onset to testing         0-5 days (5-14 days No acute symptoms indicated No acute symptoms indicated No acute symptoms indicated (4.14.2)         546 (175.4)         335 (48.2)         84322 (67.2)         97 (68.3)         9941 (80.0)         682 (45.3)         100855 (66.0)           Charlison comorbidity index         Any acute symptoms indicated (4.14.2)         508 (7.0)         112 (16.1)         21313 (17.0)         11 (7.7)         770 (62.2)         203 (13.5)         25763 (16.8)           Charlison comorbidity index         0         9 (17.6)         3731 (51.7)         296 (42.6)         99220 (79.1)         29 (20.4)         5308 (42.7)         442 (29.4)         110 (1050 (72.4)           3-2         12 (23.5)         16 (62.5)         126 (14.1)         3308 (26.6)         46 (32.4)         1657 (13.4)         331 (22.0)         7474 (5.0)           Index         0         0.00         29 (20.4)         1308 (26.5)         46 (30.		70-79 years	12 (23.5)	1491 (20.6)	114 (16.4)	9099 (7.3)	35 (24.6)	2874 (23.1)	270 (18.0)	13266 (8.7)
Sex         Male         25 (49.0)         305 (42.3)         255 (36.7)         56102 (44.7)         70 (49.3)         301 (42.6)         636 (42.3)         68555 (44.8)           Time from symptoms onest to testing         0-5 days 6-14 days 6-14 days         26 (51.0)         5446 (75.4)         335 (48.2)         84322 (67.2)         97 (68.3)         9941 (80.0)         682 (45.3)         100855 (66.0)           Outpatient care received at point of testing         4 (7.8)         508 (7.0)         112 (16.1)         21313 (17.0)         11 (7.7)         770 (62.2)         203 (13.5)         25763 (16.8)           Outpatient care received at point of testing         4 (7.8)         508 (7.0)         112 (16.1)         21313 (17.0)         11 (7.7)         770 (62.2)         203 (13.5)         25763 (16.8)           Charlson comorbidity index         0         9 (17.6)         3731 (51.7)         296 (42.6)         99220 (79.1)         29 (20.4)         5308 (42.7)         442 (29.4)         110650 (72.4)           1-2         12 (23.5)         2716 (37.6)         141 (20.3)         21914 (17.5)         35 (24.6)         4930 (39.7)         351 (22.0)         31112 (2.0)         31112 (2.0)         31112 (2.0)         31112 (2.0)         31112 (2.0)         31112 (2.0)         31112 (2.0)         31112 (2.0)         31112 (2.0)		80-89 years	12 (23.5)	590 (8.2)	103 (14.8)	3222 (2.6)	31 (21.8)	1432 (11.5)	269 (17.9)	6051 (4.0)
Sex         Male         25 (49.0)         3055 (42.2)         255 (36.7)         5101 (24.7)         70 (49.3)         5301 (42.6)         636 (42.3)         68555 (44.8)           Time form symptoms ones to testing         0-5 days         21 (41.2)         1286 (17.6)         248 (55.7)         19822 (15.8)         34 (23.3)         1727 (13.8)         619 (41.2)         26264 (15.0)           Outpatient care received of day before testing         4 (7.8)         508 (7.0)         112 (16.1)         21313 (17.0)         11 (7.7)         770 (6.2)         203 (13.5)         25763 (16.8)           Charlson comorbidity index         6 (11.8)         203 (2.8)         32 (4.6)         1711 (1.4)         20 (14.1)         901 (7.2)         223 (14.8)         7574 (5.0)           1.2         12 (23.5)         2716 (37.6)         141 (20.3)         21914 (17.5)         55 (24.6)         4930 (49.7)         442 (28.4)         110660 (72.4)           3.5         12 (23.5)         2716 (37.6)         141 (20.3)         121914 (17.5)         55 (24.6)         4930 (49.7)         442 (28.4)         11076 (7.4)           3.5         16 (8.5.)         126 (14.1)         3306 (2.6)         45 (32.4)         1667 (13.4)         331 (22.0)         7497 (4.9)           2.6         12 (23.5)         16 (6		≥90 years	11 (21.6)	139 (1.9)	82 (11.8)	688 (0.5)	28 (19.7)	411 (3.3)	232 (15.4)	1727 (1.1)
Male         25 (49.0)         3055 (42.3)         255 (36.7)         56102 (44.7)         70 (49.3)         5301 (42.6)         636 (42.3)         68555 (44.8)           onset to testing         0-5 days         26 (51.0)         5446 (75.4)         335 (48.2)         84322 (67.2)         97 (68.3)         944 (80.0)         682 (45.3)         100855 (66.0)           Outpatient care received         at point of testing         4 (7.8)         508 (7.0)         112 (16.1)         21313 (17.0)         11 (7.7)         770 (6.2)         203 (13.5)         2576 (36.8)           Outpatient care received         Any outpatient care         6 (11.8)         203 (2.8)         32 (4.6)         1711 (1.4)         201 (1.4)         901 (7.2)         223 (14.8)         7574 (5.0)           Charlson comorbidity	Sex									
Time from symptoms onset to testing         0-5 days 6-14 days No acute symptoms indicated at point of testing         26 (51.0) 21 (41.2)         5446 (75.4) 218 (47.6)         335 (48.2) 248 (45.7)         84322 (67.2) 848 (45.7)         976 (63.3) 34 (28.9)         991 (40.0) 1721 (13.8)         682 (45.3)         100855 (67.2) 26284 (17.2)           Outpatient care received         4 (7.8)         508 (7.0)         112 (16.1)         21313 (17.0)         11 (7.7)         770 (6.2)         203 (13.5)         25763 (16.8)           Outpatient care received         4 (7.8)         508 (7.0)         112 (16.1)         21313 (17.0)         11 (7.7)         770 (6.2)         203 (13.5)         25763 (16.8)           Charlson comorbidity index         Any outpatient care         6 (11.8)         203 (2.8)         32 (4.6)         1711 (1.4)         20 (14.1)         901 (7.2)         223 (14.8)         7574 (5.0)           12         22.13         2176 (3.7)         29 (64.2.6)         99220 (79.1)         29 (20.4)         5308 (42.7)         442 (29.4)         110650 (72.4)           34         55         21 (3.5)         216 (3.7)         124 (20.3)         21914 (17.5)         35 (24.6)         9303 (39.7)         331 (22.0)         1371 (62.7)           34         12 (23.5)         216 (1.2)         123 (17.0)         110 (17.0)         13		Male	25 (49.0)	3055 (42.3)	255 (36.7)	56102 (44.7)	70 (49.3)	5301 (42.6)	636 (42.3)	68555 (44.8)
b-6 days         26 (61.0)         54.4 (ays         21 (24.2)         1269 (17.6)         248 (35.7)         19822 (15.8)         34 (23.9)         1721 (13.8)         619 (41.2)         26284 (17.2)           Outpatient care received s1 day before testing         4 (7.8)         508 (7.0)         112 (16.1)         21313 (17.0)         11 (7.7)         770 (6.2)         203 (13.5)         25763 (16.8)           Charlson comorbidity index         Any outpatient care         6 (11.8)         203 (2.8)         32 (4.6)         1711 (1.4)         20 (14.1)         901 (7.2)         223 (14.8)         7574 (5.0)           Charlson comorbidity index         0         9 (17.6)         3731 (51.7)         296 (42.6)         999220 (79.1)         29 (20.4)         5308 (42.7)         442 (29.4)         110650 (72.4)           1-2         12 (23.5)         2716 (37.6)         141 (20.3)         21914 (17.5)         35 (24.6)         4930 (38.7)         331 (22.0)         31716 (20.7)           9 (17.6)         35.3         616 (25.2)         126 (18.1)         3308 (26.1)         46 (0.4)         4 (0.3)         4744 (9)           35         160 (2.2)         132 (19.0)         131 (12.0)         11718 (24.3)         11718 (24.3)         11718 (24.3)           1 day before tasing         0 <td< td=""><td>Time from symptoms onset to testing</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	Time from symptoms onset to testing									
6-14 days bo acute symptoms indicated at point of testing         21 (41.2)         1269 (17.6)         248 (35.7)         19822 (15.8)         34 (23.9)         1721 (13.8)         619 (41.2)         26284 (17.2)           Cutpatient care received s1 day before testing         4 (7.8)         508 (7.0)         112 (16.1)         21313 (17.0)         11 (7.7)         770 (6.2)         203 (13.5)         25763 (16.8)           Charlson comorbidity index         Any outpatient care         6 (11.8)         203 (2.8)         32 (4.6)         1711 (1.4)         20 (14.1)         901 (7.2)         223 (14.8)         7574 (5.0)           Charlson comorbidity index         0         9 (17.6)         3731 (51.7)         296 (42.6)         99220 (79.1)         29 (20.4)         5308 (42.7)         442 (29.4)         110650 (72.4)           1-2         12 (23.5)         216 (16.5)         126 (18.1)         3308 (2.6)         46 (32.4)         1667 (13.4)         331 (22.0)         7497 (4.9)           26         12 (23.5)         160 (2.2)         132 (19.0)         110 (5.0)         32 (2.5)         527 (4.2)         400 (26.6)         3039 (2.0)           Prior-year healthcare interactions         0         0         0.00         28 (0.4)         2 (0.3)         4410 (3.5)         0 (0.0)         46 (0.4)         4 (0.3)<		0-5 days	26 (51.0)	5446 (75.4)	335 (48.2)	84322 (67.2)	97 (68.3)	9941 (80.0)	682 (45.3)	100855 (66.0)
No acute symptoms indicated a point of testing         4 (7.8)         508 (7.0)         112 (16.1)         21313 (17.0)         11 (7.7)         770 (6.2)         203 (13.5)         25763 (16.8)           Outpatient care received 31 day before testing         Any outpatient care         6 (11.8)         203 (2.8)         32 (4.6)         1711 (1.4)         20 (14.1)         901 (7.2)         223 (14.8)         7574 (5.0)           Charlson comorbidity index         0         9 (17.6)         3731 (51.7)         296 (42.6)         99220 (79.1)         29 (20.4)         5308 (42.7)         442 (29.4)         110650 (72.4)           3.5         18 (35.3)         616 (8.5)         126 (18.1)         3308 (2.6)         46 (32.4)         1667 (13.4)         331 (22.0)         7497 (4.9)           26         12 (23.5)         160 (2.2)         132 (19.0)         1015 (0.8)         32 (2.5)         51 (3.4)         331 (22.0)         7497 (4.9)           26         14 outpatient visits         0 (0.0)         28 (0.4)         2 (0.3)         4410 (3.5)         0 (0.0)         46 (0.4)         4 (0.3)         4566 (3.0)           14 outpatient visits         3 (5.9)         1697 (23.5)         46 (6.6)         35790 (28.5)         111 (7.7)         2356 (19.0)         119 (7.9)         400282 (23.7)		6-14 days	21 (41.2)	1269 (17.6)	248 (35.7)	19822 (15.8)	34 (23.9)	1721 (13.8)	619 (41.2)	26284 (17.2)
at point of festing         4 (7.8)         508 (7.0)         112 (16.1)         21313 (17.0)         11 (7.7)         770 (6.2)         203 (13.5)         25763 (16.8)           Outpatient care received \$1 day before testing         Any outpatient care         6 (11.8)         203 (2.8)         32 (4.6)         1711 (1.4)         20 (14.1)         901 (7.2)         223 (14.8)         7574 (5.0)           Charlson comorbidity index         0         9 (17.6)         3731 (51.7)         296 (42.6)         99220 (79.1)         29 (20.4)         5308 (42.7)         442 (29.4)         110650 (72.4)           3.5         12 (23.5)         2716 (37.6)         141 (20.3)         21914 (17.5)         35 (42.6)         4930 (39.7)         331 (22.0)         31716 (20.7)           26         12 (23.5)         160 (2.2)         132 (18.0)         10015 (0.8)         32 (22.5)         527 (4.2)         400 (26.6)         3039 (2.0)           Prior-year healthcare interactions         0         0         28 (0.4)         2 (0.3)         44410 (3.5)         0 (0.0)         46 (0.4)         4 (0.3)         4566 (3.0)           14 douptatient visits         3 (5.9)         1697 (23.5)         416 (10.3)         34043 (27.1)         8 (56.6)         1097 (8.8)         51 (3.4)         37183 (24.2) <t< td=""><td></td><td>No acute symptoms indicated</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>		No acute symptoms indicated								
Outpatient care received s1 day before testing       Any outpatient care       6 (11.8)       203 (2.8)       32 (4.6)       1711 (1.4)       20 (14.1)       901 (7.2)       223 (14.8)       7574 (5.0)         Charlson comorbidity index       0       9 (17.6)       3731 (51.7)       296 (42.6)       99220 (79.1)       29 (20.4)       5308 (42.7)       442 (29.4)       110650 (72.4)         1-2       12 (23.5)       2716 (37.6)       141 (20.3)       21914 (17.5)       35 (24.6)       4930 (39.7)       331 (22.0)       31716 (20.7)         3-5       18 (35.3)       616 (8.5)       126 (18.1)       3308 (2.6)       46 (32.4)       1667 (13.4)       331 (22.0)       7497 (4.9)         3-5       18 (35.3)       616 (8.5)       122 (18.1)       3308 (2.6)       46 (0.4)       4 (0.3)       4400 (26.6)       3039 (2.0)         Prior-year healthcare interactions       0       0.0.0)       28 (0.4)       2 (0.3)       4410 (3.5)       0 (0.0)       46 (0.4)       4 (0.3)       4566 (3.0)         1-4       outpatient visits       3 (5.9)       1697 (23.5)       46 (6.6)       35790 (28.5)       11 (7.7)       2366 (19.0)       119 (7.9)       40028 (28.2)         1-4       outpatient visits       3 (5.9)       1040 (14.4)       84 (2.1)		at point of testing	4 (7.8)	508 (7.0)	112 (16.1)	21313 (17.0)	11 (7.7)	770 (6.2)	203 (13.5)	25763 (16.8)
s1 day before testing       Any outpatient care       6 (11.8)       203 (2.8)       32 (4.6)       1711 (1.4)       20 (1.4.1)       901 (7.2)       223 (14.8)       7574 (5.0)         Charlson comorbidity index       0       9 (17.6)       3731 (51.7)       296 (42.6)       99220 (79.1)       29 (20.4)       5308 (42.7)       442 (29.4)       110650 (72.4)         1-2       12 (23.5)       2716 (37.6)       144 (20.3)       21914 (17.5)       35 (24.6)       4803 (39.7)       331 (22.0)       7347 (4.9)         Prior-year healthcare interactions       0       12 (23.5)       160 (2.2)       132 (19.0)       1015 (0.8)       32 (2.5)       527 (4.2)       400 (26.6)       3039 (2.0)         Prior-year healthcare interactions       0       0.00       28 (0.4)       2 (0.3)       4410 (3.5)       0 (0.0)       46 (0.4)       4 (0.3)       4566 (3.0)         1-4 outpatient visits       3 (5.9)       1697 (23.5)       46 (6.6)       35790 (28.5)       11 (7.7)       236 (19.0)       131 (8.7)       23807 (15.6)         10-14 outpatient visits       3 (5.9)       1697 (23.5)       46 (6.1)       35790 (28.5)       11 (7.7)       235 (18.0)       131 (8.7)       23807 (15.6)         10-14 outpatient visits       3 (5.9)       1697 (23.5)       46 (8.1	Outpatient care received									
Any outpatient care         6 (11.8)         203 (2.8)         32 (4.6)         1711 (1.4)         20 (14.1)         901 (7.2)         223 (14.8)         7574 (5.0)           Index         0         9 (17.6)         3731 (51.7)         296 (42.6)         99220 (79.1)         29 (20.4)         5308 (42.7)         442 (29.4)         110650 (72.4)           1-2         3-5         18 (35.3)         616 (8.2)         132 (19.0)         1015 (0.8)         32 (22.5)         527 (4.2)         400 (26.6)         4930 (39.7)         331 (22.0)         7497 (4.9)           26         12 (23.5)         160 (2.2)         132 (19.0)         1015 (0.8)         32 (22.5)         527 (4.2)         400 (26.6)         4568 (3.0)           1-4 outpatient visits         0 (0.0)         28 (0.4)         2 (0.3)         4410 (3.5)         0 (0.0)         46 (0.4)         4 (0.3)         4566 (3.0)           5-9 outpatient visits         3 (5.9)         1597 (23.5)         46 (6.6)         35790 (28.5)         11 (7.7)         236 (19.0)         131 (8.7)         23807 (15.6)           15-19 outpatient visits         6 (11.8)         1409 (19.5)         56 (8.1)         1997 (15.9)         16 (11.3)         116 (11.3)         2237 (18.0)         131 (8.7)         23807 (15.6)           15-19 ou	≤1 day before testing									
Charlsson comorbidity index 0 9 9 (17.6) 3731 (51.7) 296 (42.6) 99220 (79.1) 29 (20.4) 5308 (42.7) 442 (29.4) 110650 (72.4) 1-2 12 (23.5) 2716 (37.6) 141 (20.3) 21914 (17.5) 35 (24.6) 4930 (39.7) 331 (22.0) 31716 (20.7) 26 7497 (4.9) 26 12 (23.5) 160 (2.2) 132 (19.0) 1015 (0.8) 32 (22.5) 527 (4.2) 400 (26.6) 3039 (2.0) 7497 (4.9) 26 0 outpatient visits 2 (3.9) 774 (10.7) 14 (2.0) 34043 (27.1) 8 (5.6) 1097 (8.8) 51 (3.4) 37183 (24.3) 778 (10.7) 14 (2.0) 34043 (27.1) 8 (5.6) 1097 (8.8) 51 (3.4) 37183 (24.3) 778 (12.3) 5-9 outpatient visits 2 (3.9) 774 (10.7) 14 (2.0) 34043 (27.1) 8 (5.6) 1097 (8.8) 51 (3.4) 37183 (24.3) 778 (24.3) 5-9 outpatient visits 3 (5.9) 1697 (23.5) 46 (6.6) 35790 (28.5) 11 (7.7) 2356 (19.0) 119 (7.9) 40028 (28.2) 10-14 outpatient visits 3 (5.9) 1040 (14.4) 84 (12.1) 11005 (8.8) 10 (7.0) 1834 (14.8) 156 (10.4) 14828 (9.7) 20-29 outpatient visits 9 (17.6) 477 (6.6) 116 (16.7) 4329 (3.5) 24 (16.9) 1162 (13.2 237 (18.0) 131 (6.7) 482 (6.1) 110 (1.5) 340 outpatient visits 9 (17.6) 477 (6.6) 116 (16.7) 4329 (3.5) 24 (16.9) 116 (15.9) 166 (1.7) 416 (2.7) 882 (5.8) 10 (7.0) 1834 (14.8) 156 (10.4) 146 (27.7) 882 (5.8) 10 (7.0) 1834 (14.8) 156 (10.4) 146 (27.7) 882 (5.8) 10 (7.0) 1834 (14.8) 156 (10.4) 146 (27.7) 882 (5.8) 10 (7.0) 1834 (14.8) 156 (10.4) 146 (28.9 17 (29.3) 26 (17.7) 765 (15.0) 24 (10.9) 136 (14.9) 136 (14.9) 136 (14.9) 136 (14.9) 136 (14.9) 136 (14.9) 136 (14.9) 136 (14.9) 136 (14.9) 136 (14.9) 136 (14.9) 136 (14.9) 136 (14.9) 136 (14.9) 136 (14.9) 136 (14.9) 136 (14.1) 1397 (15.9) 137 (14.9) 136 (14.9) 136 (14.1) 134 (20.9) 137 (14.9) 136 (14.9) 136 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 134 (14.9) 136 (14.1) 13		Any outpatient care	6 (11.8)	203 (2.8)	32 (4.6)	1711 (1.4)	20 (14.1)	901 (7.2)	223 (14.8)	7574 (5.0)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Charlson comorbidity index									
$\begin{array}{c} 1-2 \\ 3-5 \\$		0	9 (17.6)	3731 (51.7)	296 (42.6)	99220 (79.1)	29 (20.4)	5308 (42.7)	442 (29.4)	110650 (72.4)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		1-2	12 (23.5)	2716 (37.6)	141 (20.3)	21914 (17.5)	35 (24.6)	4930 (39.7)	331 (22.0)	31716 (20.7)
≥6         12 (23.5)         160 (2.2)         132 (19.0)         1015 (0.8)         32 (22.5)         527 (4.2)         400 (26.6)         3039 (2.0)           Prior-year healthcare interactions         0 outpatient visits         0 (0.0)         28 (0.4)         2 (0.3)         4410 (3.5)         0 (0.0)         46 (0.4)         4 (0.3)         4566 (3.0)           1-4 outpatient visits         2 (3.9)         774 (10.7)         14 (2.0)         34043 (27.1)         8 (5.6)         1097 (8.8)         51 (3.4)         37183 (24.3)           5-9 outpatient visits         3 (5.9)         1697 (23.5)         46 (6.6)         35790 (28.5)         11 (7.7)         2356 (19.0)         119 (7.9)         40028 (26.2)           10-14 outpatient visits         3 (5.9)         1040 (14.4)         84 (12.1)         11005 (8.8)         10 (7.0)         1834 (14.8)         156 (10.4)         1482 (9.7)           20-29 outpatient visits         9 (17.6)         477 (6.6)         116 (16.7)         4329 (3.5)         24 (16.9)         1162 (9.3)         266 (17.7)         7651 (5.0)           30-39 outpatient visits         9 (17.6)         274 (24.9)         4618 (3.7)         49 (34.5)         1460 (11.7)         78 (28.6)         4618 (3.7)         49 (34.5)         1460 (11.7)         78 (28.6)         83 (48.0) <td></td> <td>3-5</td> <td>18 (35.3)</td> <td>616 (8.5)</td> <td>126 (18.1)</td> <td>3308 (2.6)</td> <td>46 (32.4)</td> <td>1667 (13.4)</td> <td>331 (22.0)</td> <td>7497 (4.9)</td>		3-5	18 (35.3)	616 (8.5)	126 (18.1)	3308 (2.6)	46 (32.4)	1667 (13.4)	331 (22.0)	7497 (4.9)
Prior-year healthcare interactions       0 outpatient visits       0 (0.0)       28 (0.4)       2 (0.3)       4410 (3.5)       0 (0.0)       46 (0.4)       4 (0.3)       4566 (3.0)         1.4 outpatient visits       2 (3.9)       774 (10.7)       14 (2.0)       34043 (27.1)       8 (5.6)       1097 (8.8)       51 (3.4)       37183 (24.3)         5-9 outpatient visits       3 (5.9)       1697 (23.5)       46 (6.6)       35790 (28.5)       11 (7.7)       2356 (19.0)       119 (7.9)       40028 (26.2)         10-14 outpatient visits       3 (5.9)       1040 (14.4)       84 (12.1)       11005 (8.8)       10 (7.0)       1834 (14.8)       156 (10.4)       14828 (9.7)         20-29 outpatient visits       3 (5.9)       1040 (14.4)       84 (12.1)       11005 (8.8)       10 (7.0)       1834 (14.8)       156 (10.4)       14828 (9.7)         20-29 outpatient visits       11 (21.6)       1153 (16.0)       204 (29.4)       11291 (9.0)       24 (16.9)       2240 (18.0)       361 (24.0)       16011 (10.5)         30-39 outpatient visits       17 (33.3)       645 (8.9)       173 (24.9)       4618 (3.7)       49 (34.5)       1460 (11.7)       416 (27.7)       8828 (5.8)         Any ED presentation       36 (70.6)       2243 (31.1)       410 (59.0)       19637 (15.7)       <		≥6	12 (23.5)	160 (2.2)	132 (19.0)	1015 (0.8)	32 (22.5)	527 (4.2)	400 (26.6)	3039 (2.0)
0 outpatient visits         0 (0.0)         28 (0.4)         2 (0.3)         4410 (3.5)         0 (0.0)         46 (0.4)         4 (0.3)         4566 (3.0)           1-4 outpatient visits         2 (3.9)         774 (10.7)         14 (2.0)         34043 (27.1)         8 (5.6)         1097 (8.8)         51 (3.4)         37183 (24.3)           5-9 outpatient visits         3 (5.9)         1697 (23.5)         46 (6.6)         35790 (28.5)         11 (7.7)         2356 (19.0)         113 (8.7)         23807 (15.6)           10-14 outpatient visits         3 (5.9)         1040 (14.4)         84 (12.1)         11005 (8.8)         10 (7.0)         1834 (14.8)         156 (10.4)         14828 (9.7)           20-29 outpatient visits         3 (5.9)         1040 (14.4)         84 (12.1)         11005 (8.8)         10 (7.0)         1834 (14.8)         156 (10.4)         14828 (9.7)           20-29 outpatient visits         9 (17.6)         477 (6.6)         116 (16.7)         4329 (3.5)         24 (16.9)         2160 (11.7)         416 (27.7)         8828 (5.8)           30-39 outpatient visits         9 (7.6)         243 (31.1)         410 (59.0)         19637 (15.7)         101 (71.1)         4737 (38.1)         8920 (21.0)           Any ED presentation         36 (70.6)         244 (0.9)         577 (4.3)<	Prior-year healthcare interactions			. ,	. ,		. ,		. ,	
$ \begin{array}{c} 1-4 \text{ outpatient visits} & 2 (3.9) & 774 (10.7) & 14 (2.0) & 34043 (27.1) & 8 (5.6) & 1097 (8.8) & 51 (3.4) & 37183 (24.3) \\ 5-9 \text{ outpatient visits} & 3 (5.9) & 1697 (23.5) & 46 (6.6) & 35790 (28.5) & 11 (7.7) & 2356 (19.0) & 119 (7.9) & 40028 (26.2) \\ 10-14 \text{ outpatient visits} & 6 (11.8) & 1409 (19.5) & 56 (8.1) & 19971 (15.9) & 16 (11.3) & 2237 (18.0) & 131 (8.7) & 23807 (15.6) \\ 15-19 \text{ outpatient visits} & 3 (5.9) & 1040 (14.4) & 84 (12.1) & 11005 (8.8) & 10 (7.0) & 1834 (14.8) & 156 (10.4) & 14828 (9.7) \\ 20-29 \text{ outpatient visits} & 11 (21.6) & 1153 (16.0) & 204 (29.4) & 11291 (9.0) & 24 (16.9) & 2240 (18.0) & 361 (24.0) & 16011 (10.5) \\ 30-39 \text{ outpatient visits} & 9 (17.6) & 477 (6.6) & 116 (16.7) & 4329 (3.5) & 24 (16.9) & 1162 (9.3) & 266 (17.7) & 7651 (5.0) \\ 240 \text{ outpatient visits} & 17 (33.3) & 645 (8.9) & 173 (24.9) & 4618 (3.7) & 49 (34.5) & 1460 (11.7) & 416 (27.7) & 8828 (5.8) \\ \text{Any ED presentation} & 36 (70.6) & 2243 (31.1) & 410 (59.0) & 19637 (15.7) & 101 (71.1) & 4737 (38.1) & 989 (65.8) & 32092 (21.0) \\ \text{Any inpatient admission} & 25 (49.0) & 387 (5.4) & 284 (40.9) & 5379 (4.3) & 51 (35.9) & 877 (7.1) & 794 (52.8) & 9326 (6.1) \\ \end{array}$		0 outpatient visits	0 (0.0)	28 (0.4)	2 (0.3)	4410 (3.5)	0 (0.0)	46 (0.4)	4 (0.3)	4566 (3.0)
5-9 outpatient visits       3 (5.9)       1697 (23.5)       46 (6.6)       35790 (28.5)       11 (7.7)       2356 (19.0)       119 (7.9)       40028 (26.2)         10-14 outpatient visits       6 (11.8)       1409 (19.5)       56 (8.1)       19971 (15.9)       16 (11.3)       2237 (18.0)       131 (8.7)       23807 (15.6)         12-19 outpatient visits       3 (5.9)       1040 (14.4)       84 (12.1)       11005 (8.8)       10 (7.0)       1834 (14.8)       156 (10.4)       14828 (9.7)         20-29 outpatient visits       11 (21.6)       1153 (16.0)       204 (29.4)       11291 (9.0)       24 (16.9)       1162 (9.3)       266 (17.7)       7651 (5.0)         240 outpatient visits       17 (33.3)       645 (8.9)       173 (24.9)       4618 (3.7)       49 (34.5)       1460 (11.7)       416 (27.7)       8828 (5.8)         Any ED presentation       36 (70.6)       2243 (31.1)       410 (59.0)       19637 (15.7)       101 (71.1)       473 (38.1)       989 (65.8)       32092 (21.0)         Any inpatient admission       25 (49.0)       387 (5.4)       284 (40.9)       5379 (4.3)       51 (35.9)       877 (7.1)       794 (52.8)       9326 (6.1)         Prior COVID-19       vaccination       0 (0.0)       176 (2.4)       26 (3.7)       5514 (4.4)       3 (2.1)		1-4 outpatient visits	2 (3.9)	774 (10.7)	14 (2.0)	34043 (27.1)	8 (5.6)	1097 (8.8)	51 (3.4)	37183 (24.3)
$\frac{10-14 \text{ outpatient visits}}{15-19 \text{ outpatient visits}} = 6 (11.8) + 1409 (19.5) + 56 (8.1) + 19971 (15.9) + 16 (11.3) + 2237 (18.0) + 131 (8.7) + 23807 (15.6) + 15-19 \text{ outpatient visits}} = 3 (5.9) + 1040 (14.4) + 84 (12.1) + 11005 (8.8) + 10 (7.0) + 1834 (14.8) + 156 (10.4) + 14828 (9.7) + 20-29 \text{ outpatient visits}} = 11 (21.6) + 1153 (16.0) + 204 (29.4) + 11291 (9.0) + 24 (16.9) + 2240 (18.0) + 361 (24.0) + 160 (11.5) + 20-29 \text{ outpatient visits}} = 9 (17.6) + 477 (6.6) + 116 (16.7) + 4329 (3.5) + 24 (16.9) + 1162 (9.3) + 266 (17.7) + 7651 (5.0) + 240 \text{ outpatient visits}} = 17 (33.3) + 645 (8.9) + 173 (24.9) + 4618 (3.7) + 49 (34.5) + 1460 (11.7) + 416 (27.7) + 8828 (5.8) + 470 \text{ outpatient visits}} = 17 (33.3) + 645 (8.9) + 173 (24.9) + 4618 (3.7) + 49 (34.5) + 1460 (11.7) + 416 (27.7) + 8828 (5.8) + 470 \text{ outpatient visits}} = 17 (33.3) + 645 (8.9) + 173 (24.9) + 4618 (3.7) + 49 (34.5) + 1460 (11.7) + 416 (27.7) + 8828 (5.8) + 470 \text{ outpatient visits}} = 17 (33.3) + 645 (8.9) + 173 (24.9) + 4618 (3.7) + 49 (34.5) + 1460 (11.7) + 416 (27.7) + 8828 (5.8) + 470 \text{ outpatient visits}} = 25 (49.0) + 387 (5.4) + 284 (40.9) + 5379 (4.3) + 51 (35.9) + 877 (7.1) + 794 (52.8) + 9326 (6.1) + 7917 (20.1) + 100 ($		5-9 outpatient visits	3 (5.9)	1697 (23.5)	46 (6.6)	35790 (28.5)	11 (7. <del>7</del> )	2356 (19.Ó)	119 (7.9)	40028 (26.2)
$ \begin{array}{c} 15-19 \ \text{outpatient visits} & 3 \ (5.9) & 1040 \ (14.4) & 84 \ (12.1) & 11005 \ (8.8) & 10 \ (7.0) & 1834 \ (14.8) & 156 \ (10.4) & 14828 \ (9.7) \\ 20-29 \ \text{outpatient visits} & 11 \ (21.6) & 1153 \ (16.0) & 204 \ (29.4) & 11291 \ (9.0) & 24 \ (16.9) & 2240 \ (18.0) & 361 \ (24.0) & 16011 \ (10.5) \\ 30-39 \ \text{outpatient visits} & 9 \ (17.6) & 477 \ (6.6) & 116 \ (16.7) & 4329 \ (3.5) & 24 \ (16.9) & 1162 \ (9.3) & 266 \ (17.7) & 7651 \ (5.0) \\ \geq 40 \ \text{outpatient visits} & 17 \ (33.3) & 645 \ (8.9) & 173 \ (24.9) & 4618 \ (3.7) & 49 \ (34.5) & 1460 \ (11.7) & 416 \ (27.7) & 8828 \ (5.8) \\ Any \ ED \ presentation & 36 \ (70.6) & 2243 \ (31.1) & 410 \ (59.0) & 19637 \ (15.7) & 101 \ (71.1) & 4737 \ (38.1) & 989 \ (65.8) & 32092 \ (21.0) \\ Any \ inpatient admission & 25 \ (49.0) & 387 \ (5.4) & 284 \ (40.9) & 5379 \ (4.3) & 51 \ (35.9) & 877 \ (7.1) & 794 \ (52.8) & 9326 \ (6.1) \\ \end{array}$		10-14 outpatient visits	6 (11.8)	1409 (19.5)	56 (8.1)	19971 (15.9)́	16 (Ì1.ਤ́)	2237 (18.0)	131 (8.7)	23807 (15.6)
$\begin{array}{c} 20-29 \ \text{outpatient visits} & 11 (21.6) & 1153 (16.0) & 204 (29.4) & 11291 (9.0) & 24 (16.9) & 2240 (18.0) & 361 (24.0) & 16011 (10.5) \\ 30-39 \ \text{outpatient visits} & 9 (17.6) & 477 (6.6) & 116 (16.7) & 4329 (3.5) & 24 (16.9) & 1162 (9.3) & 266 (17.7) & 7651 (5.0) \\ \geq 40 \ \text{outpatient visits} & 17 (33.3) & 645 (8.9) & 173 (24.9) & 4618 (3.7) & 49 (34.5) & 1460 (11.7) & 416 (27.7) & 8828 (5.8) \\ \text{Any ED presentation} & 36 (70.6) & 2243 (31.1) & 410 (59.0) & 19637 (15.7) & 101 (71.1) & 4737 (38.1) & 989 (65.8) & 32092 (21.0) \\ \text{Any inpatient admission} & 25 (49.0) & 387 (5.4) & 284 (40.9) & 5379 (4.3) & 51 (35.9) & 877 (7.1) & 794 (52.8) & 9326 (6.1) \\ \end{array}$		15-19 outpatient visits	3 (5.9)	1040 (14.4)	84 (12.1)	11005 (8.8)	10 (7.0)	1834 (14.8)	156 (10.4)	14828 (9.7)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		20-29 outpatient visits	11 (21.6)	1153 (16.0)	204 (29.4)	11291 (9.0)	24 (16.9́)	2240 (18.0)	361 (24.0)	16011 (Ì0.5́)
$ \begin{array}{c} \geq 40 \ \text{outpatient visits} & 17 (33.3) & 645 (8.9) & 173 (24.9) & 4618 (3.7) & 49 (34.5) & 1460 (11.7) & 416 (27.7) & 8828 (5.8) \\ \text{Any ED presentation} & 36 (70.6) & 2243 (31.1) & 410 (59.0) & 19637 (15.7) & 101 (71.1) & 4737 (38.1) & 989 (65.8) & 32092 (21.0) \\ \text{Any inpatient admission} & 25 (49.0) & 387 (5.4) & 284 (40.9) & 5379 (4.3) & 51 (35.9) & 877 (7.1) & 794 (52.8) & 9326 (6.1) \\ \end{array} $		30-39 outpatient visits	9 (17.6)	477 (6.6)	116 (16.7)	4329 (3.5)	24 (16.9)	1162 (9.3)	266 (17.7)	7651 (5.0)
Any ED presentation       36 (70.6)       2243 (31.1)       410 (59.0)       19637 (15.7)       101 (71.1)       4737 (38.1)       989 (65.8)       32092 (21.0)         Any inpatient admission       25 (49.0)       387 (5.4)       284 (40.9)       5379 (4.3)       51 (35.9)       877 (7.1)       794 (52.8)       9326 (6.1)         Prior SARS-CoV-2 infection       Any documented infection       0 (0.0)       176 (2.4)       26 (3.7)       5514 (4.4)       3 (2.1)       344 (2.8)       55 (3.7)       7021 (4.6)         Prior COVID-19 vaccination       0 doses received       4 (7.8)       390 (5.4)       79 (11.4)       16680 (13.3)       16 (11.3)       916 (7.4)       270 (18.0)       22068 (14.4)         1 dose received       1 (2.0)       48 (0.7)       9 (1.3)       2007 (1.6)       3 (2.1)       228 (1.8)       61 (4.1)       3917 (2.6)         2 doses received       5 (9.8)       960 (13.3)       135 (19.4)       31369 (25.0)       23 (16.2)       1860 (15.0)       332 (22.1)       38174 (25.0)         3 doses received       30 (58.8)       4403 (61.0)       365 (52.5)       66373 (52.9)       66 (46.5)       6527 (52.5)       623 (41.4)       75236 (49.2)		≥40 outpatient visits	17 (33.3)	645 (8.9)	173 (24.9)	4618 (3.7)	49 (34.5)	1460 (11.7)	416 (27.7)	8828 (5.8)
Any inpatient admission       25 (49.0)       387 (5.4)       284 (40.9)       5379 (4.3)       51 (35.9)       877 (7.1)       794 (52.8)       9326 (6.1)         Prior SARS-CoV-2 infection       Any documented infection       0 (0.0)       176 (2.4)       26 (3.7)       5514 (4.4)       3 (2.1)       344 (2.8)       55 (3.7)       7021 (4.6)         Prior COVID-19 vaccination       0 doses received       4 (7.8)       390 (5.4)       79 (11.4)       16680 (13.3)       16 (11.3)       916 (7.4)       270 (18.0)       22068 (14.4)         1 dose received       1 (2.0)       48 (0.7)       9 (1.3)       2007 (1.6)       3 (2.1)       228 (1.8)       61 (4.1)       3917 (2.6)         2 doses received       5 (9.8)       960 (13.3)       135 (19.4)       31369 (25.0)       23 (16.2)       1860 (15.0)       332 (22.1)       38174 (25.0)         3 doses received       30 (58.8)       4403 (61.0)       365 (52.5)       66373 (52.9)       66 (46.5)       6527 (52.5)       623 (41.4)       75236 (49.2)		Any ED presentation	36 (70.6)	2243 (31.1)	410 (59.0)	19637 (15.7)	101 (71.1)	4737 (38.1)	989 (65.8)	32092 (21.0)
Prior SARS-CoV-2 infection       Any documented infection       0 (0.0)       176 (2.4)       26 (3.7)       5514 (4.4)       3 (2.1)       344 (2.8)       55 (3.7)       7021 (4.6)         Prior COVID-19 vaccination       0 doses received       4 (7.8)       390 (5.4)       79 (11.4)       16680 (13.3)       16 (11.3)       916 (7.4)       270 (18.0)       22068 (14.4)         1 dose received       1 (2.0)       48 (0.7)       9 (1.3)       2007 (1.6)       3 (2.1)       228 (1.8)       61 (4.1)       3917 (2.6)         2 doses received       5 (9.8)       960 (13.3)       135 (19.4)       31369 (25.0)       23 (16.2)       1860 (15.0)       332 (22.1)       38174 (25.0)         3 doses received       30 (58.8)       4403 (61.0)       365 (52.5)       66373 (52.9)       66 (46.5)       6527 (52.5)       623 (41.4)       75236 (49.2)		Any inpatient admission	25 (49.0)	387 (5.4)	284 (40.9)	5379 (4.3)	51 (35.9)	877 (7.1)	794 (52.8)	9326 (6.1)
infection       Any documented infection       0 (0.0)       176 (2.4)       26 (3.7)       5514 (4.4)       3 (2.1)       344 (2.8)       55 (3.7)       7021 (4.6)         Prior COVID-19 vaccination       0 doses received       4 (7.8)       390 (5.4)       79 (11.4)       16680 (13.3)       16 (11.3)       916 (7.4)       270 (18.0)       22068 (14.4)         1 dose received       1 (2.0)       48 (0.7)       9 (1.3)       2007 (1.6)       3 (2.1)       228 (1.8)       61 (4.1)       3917 (2.6)         2 doses received       5 (9.8)       960 (13.3)       135 (19.4)       31369 (25.0)       23 (16.2)       1860 (15.0)       332 (22.1)       38174 (25.0)         3 doses received       30 (58.8)       4403 (61.0)       365 (52.5)       66373 (52.9)       66 (46.5)       6527 (52.5)       623 (41.4)       75236 (49.2)	Prior SARS-CoV-2		()				- ()			
Any documented infection         0 (0.0)         176 (2.4)         26 (3.7)         5514 (4.4)         3 (2.1)         344 (2.8)         55 (3.7)         7021 (4.6)           Prior COVID-19 vaccination         0 doses received         4 (7.8)         390 (5.4)         79 (11.4)         16680 (13.3)         16 (11.3)         916 (7.4)         270 (18.0)         22068 (14.4)           1 dose received         1 (2.0)         48 (0.7)         9 (1.3)         2007 (1.6)         3 (2.1)         228 (1.8)         61 (4.1)         3917 (2.6)           2 doses received         5 (9.8)         960 (13.3)         135 (19.4)         31369 (25.0)         23 (16.2)         1860 (15.0)         332 (22.1)         38174 (25.0)           3 doses received         30 (58.8)         4403 (61.0)         365 (52.5)         66373 (52.9)         66 (46.5)         6527 (52.5)         623 (41.4)         75236 (49.2)	infection									
Prior COVID-19         vaccination         0 doses received       4 (7.8)       390 (5.4)       79 (11.4)       16680 (13.3)       16 (11.3)       916 (7.4)       270 (18.0)       22068 (14.4)         1 dose received       1 (2.0)       48 (0.7)       9 (1.3)       2007 (1.6)       3 (2.1)       228 (1.8)       61 (4.1)       3917 (2.6)         2 doses received       5 (9.8)       960 (13.3)       135 (19.4)       31369 (25.0)       23 (16.2)       1860 (15.0)       332 (22.1)       38174 (25.0)         3 doses received       30 (58.8)       4403 (61.0)       365 (52.5)       66373 (52.9)       66 (46.5)       6527 (52.5)       623 (41.4)       75236 (49.2)		Any documented infection	0(0.0)	176 (2.4)	26 (3.7)	5514 (4.4)	3 (2.1)	344 (2.8)	55 (3.7)	7021 (4.6)
vaccination         0 doses received         4 (7.8)         390 (5.4)         79 (11.4)         16680 (13.3)         16 (11.3)         916 (7.4)         270 (18.0)         22068 (14.4)           1 dose received         1 (2.0)         48 (0.7)         9 (1.3)         2007 (1.6)         3 (2.1)         228 (1.8)         61 (4.1)         3917 (2.6)           2 doses received         5 (9.8)         960 (13.3)         135 (19.4)         31369 (25.0)         23 (16.2)         1860 (15.0)         332 (22.1)         38174 (25.0)           3 doses received         30 (58.8)         4403 (61.0)         365 (52.5)         66373 (52.9)         66 (46.5)         6527 (52.5)         623 (41.4)         75236 (49.2)	Prior COVID-19	,	- ()		( )	/	- ()		( )	)
0 doses received         4 (7.8)         390 (5.4)         79 (11.4)         16680 (13.3)         16 (11.3)         916 (7.4)         270 (18.0)         22068 (14.4)           1 dose received         1 (2.0)         48 (0.7)         9 (1.3)         2007 (1.6)         3 (2.1)         228 (1.8)         61 (4.1)         3917 (2.6)           2 doses received         5 (9.8)         960 (13.3)         135 (19.4)         31369 (25.0)         23 (16.2)         1860 (15.0)         332 (22.1)         38174 (25.0)           3 doses received         30 (58.8)         4403 (61.0)         365 (52.5)         66373 (52.9)         66 (46.5)         6527 (52.5)         623 (41.4)         75236 (49.2)	vaccination									
1 dose received       1 (2.0)       48 (0.7)       9 (1.3)       2007 (1.6)       3 (2.1)       228 (1.8)       61 (4.1)       3917 (2.6)         2 doses received       5 (9.8)       960 (13.3)       135 (19.4)       31369 (25.0)       23 (16.2)       1860 (15.0)       332 (22.1)       38174 (25.0)         3 doses received       30 (58.8)       4403 (61.0)       365 (52.5)       66373 (52.9)       66 (46.5)       6527 (52.5)       623 (41.4)       75236 (49.2)		0 doses received	4 (7.8)	390 (5,4)	79 (11.4)	16680 (13.3)	16 (11.3)	916 (7.4)	270 (18.0)	22068 (14.4)
2 doses received 5 (9.8) 960 (13.3) 135 (19.4) 31369 (25.0) 23 (16.2) 1860 (15.0) 332 (22.1) 38174 (25.0) 3 doses received 30 (58.8) 4403 (61.0) 365 (52.5) 66373 (52.9) 66 (46.5) 6527 (52.5) 623 (41.4) 75236 (49.2)		1 dose received	1 (2.0)	48 (0.7)	9 (1.3)	2007 (1.6)	3 (2.1)	228 (1.8)	61 (4.1)	3917 (2.6)
3 doses received 30 (58.8) 4403 (61.0) 365 (52.5) 66373 (52.9) 66 (46.5) 6527 (52.5) 623 (41.4) 75236 (49.2)		2 doses received	5 (9.8)	960 (13.3)	135 (19.4)	31369 (25.0)	23 (16.2)	1860 (15.0)	332 (22.1)	38174 (25.0)
		3 doses received	30 (58.8)	4403 (61.0)	365 (52.5)	66373 (52.9)	66 (46.5)	6527 (52.5)	623 (41.4)	75236 (49.2)

_	4 doses received	11 (21.6)	1422 (19.7)	107 (15.4)	9028 (7.2)	34 (23.9)	2901 (23.3)	218 (14.5)	13507 (8.8)
Race									
	White, non-Hispanic	24 (47.1)	1897 (26.3)	228 (32.8)	26656 (21.2)	61 (43.0)	3597 (28.9)	533 (35.4)	34598 (22.6)
	Black, non-Hispanic	2 (3.9)	686 (9.5)	77 (11.1)	9904 (7.9)	11 (7.7)	1232 (9.9)	177 (11.8)	12867 (8.4)
	Hispanic	20 (39.2)	3041 (42.1)	276 (39.7)	59973 (47.8)	51 (35.9)	5084 (40.9)	600 (39.9)	72009 (47.1)
	Asian	5 (9.8)	1220 (16.9)	96 (13.8)	18793 (15.0)	19 (13.4)	1951 (15.7)	161 (10.7)	21975 (14.4)
	Pacific Islander	0 (0.0)	74 (1.0)	2 (0.3)	1245 (1.0)	0 (0.0)	118 (0.9)	6 (0.4)	1444 (0.9)
	Other/unknown/mixed race	0 (0.0)	305 (4.2)	16 (2.3)	8886 (7.1)	0 (0.0)	450 (3.6)	27 (1.8)	10009 (6.5)
Body mass index					,				( ,
	Underweight (<18.5)	2 (3.9)	36 (0.5)	13 (1.9)	5650 (4.5)	3 (2.1)	119 (1.0)	86 (5.7)	7362 (4.8)
	Normal weight (18.5-24.9)	11 (21.6)	1229 (17.0)	178 (25.6)	26372 (21.0)	48 (33.8)	2403 (19.3)	421 (28.0)	33099 (21.6)
	Overweight (25.0-29.9)	22 (43.1)	2168 (30.0)	223 (32.1)	32908 (26.2)	42 (29.6)	3693 (29.7)	430 (28.6)	40241 (26.3)
	Obese (30-39.9)	16 (31.4)	2687 (37.2)	241 (34.7)	33177 (26.4)	43 (30.3)	4321 (34.8)	439 (29.2)	40653 (26.6)
	Morbidly obese ( $\geq 40.0$ )	0(0,0)	550 (7.6)	37 (5.3)	6027 (4.8)	6(4.2)	1234 (9.9)	122 (8.1)	9330 (6.1)
Cigarette smoking		0 (0.0)	000 (110)	01 (0.0)	0021 (110)	° ()		(0)	
	Never smoked	29 (56.9)	4964 (68.7)	448 (64.5)	83038 (66.2)	88 (62.0)	8390 (67.5)	918 (61.0)	101895 (66.6)
	Current smoker	3 (5.9)	251 (3.5)	28 (4.0)	4077 (3.2)	8 (5.6)	444 (3.6)	93 (6.2)	5349 (3.5)
	Former smoker	18 (35.3)	1456 (20.2)	192 (27.6)	16299 (13.0)	43 (30.3)	2833 (22.8)	445 (29.6)	21978 (14.4)
Neighborhood deprivation			( )	( )	( )	· · · ·	( )		( )
index									
	First quintile (least deprived)	8 (15.7)	1227 (17.0)	110 (15.8)	17726 (14.1)	20 (14.1)	2127 (17.1)	211 (14.0)	21655 (14.2)
	Second quintile	10 (19.6)	1657 (22.9)	162 (23.3)	27157 (21.6)	28 (19.7)	2855 (23.0)	361 (24.0)	33197 (21.7)
	Third guintile	12 (23.5)	1813 (25.1)	166 (23.9)	31686 (25.3)	39 (27.5)	3115 (25.1)	351 (23.3)	38455 (25.2)
	Fourth quintile	16 (31.4)	1577 (21.8)	146 (21.0)	29422 (23.5)	36 (25.4)	2683 (21.6)	343 (22.8)	35745 (23.4)
	Fifth quintile (most deprived)	5 (9.8)	943 (13.1)	111 (16.0)	19372 (15.4)	19 (13.4)	1643 (13.2)	236 (15.7)	23736 (15.5)
Receipt of other		0 (0.0)	0.0 (1011)	()				200 (1011)	20100 (1010)
respiratory vaccines									
. ,	2021-22 seasonal influenza								
	vaccine	37 (72.5)	5207 (72.1)	478 (68.8)	67474 (53.8)	102 (71.8)	8972 (72.2)	1016 (67.6)	83711 (54.7)
	Pneumococcal conjugate	. ()	•=•• (•=••)						
	vaccine	35 (68 6)	2036 (28.2)	316 (45.5)	22941 (18.3)	99 (69 7)	4417 (35.5)	798 (53.1)	33270 (21.8)
	Pneumococcal polysaccharide	30 (00.0)	2000 (20.2)	010 (10.0)		00 (00.7)			30210 (21.0)
	vaccine	40 (78 4)	3872 (53 6)	372 (53 5)	20/81 (23 5)	116 (81 7)	7513 (60.4)	969 (64 4)	12621 (27.9)
	Vacune	+0(70.4)	JUIZ (JJ.0)	JIZ (JJ.J)	23401 (23.3)	110(01.7)	7515(00.4)	303 (04.4)	+2024 (27.9)

Data on exposure prevalence among treatment recipients and non-recipients within the analytic sample include all eligible cases who were assigned matches. Percentages indicated in the table are computed among individuals with non-missing observations; missing data are present in participants' smoking status, body mass index, and neighborhood deprivation index, as summarized in **Table 1**.

## Table S7: Characteristics of patients experiencing or not experiencing intensive care unit admission, mechanical ventilation, or death within 60 days of testing.

Characteristic	Frequency among cases by clinical outcome, <i>n</i> (%)								
			Analytic	c sample		-	All eligib	le patients	
		Nirmatrel	vir-ritonavir	Nirmatrelvi	ir-ritonavir not	Nirmatre	lvir-ritonavir	Nirmatrelvi	r-ritonavir not
		Outcome	Patient	Outcome	Patient	Outcome	Patient	Outcome	Patient
		observed	censored	observed	censored	observed	censored	observed	censored
		<i>N</i> =17	N=7,257	N=257	N=125,895	N=45	N=12,529	N=698	N=153,708
Age									
	12-19 years	0 (0.0)	11 (0.2)	2 (0.8)	11052 (8.8)	0 (0.0)	21 (0.2)	8 (1.1)	13281 (8.6)
	20-29 years	0 (0.0)	170 (2.3)	4 (1.6)	13043 (10.4)	0 (0.0)	294 (2.3)	9 (1.3)	15460 (10.1)
	30-39 years	0 (0.0)	505 (7.0)	9 (3.5)	20752 (16.5)	1 (2.2)	783 (6.2)	14 (2.0)	23868 (15.5)
	40-49 years	0 (0.0)	1103 (15.2)	13 (5.1)	26109 (20.7)	2 (4.4)	1592 (12.7)	30 (4.3)	29520 (19.2)
	50-59 years	1 (5.9)	1555 (21.4)	10 (3.9)	23732 (18.9)	4 (8.9)	2295 (18.3)	47 (6.7)	27668 (18.0)
	60-69 years	2 (11.8)	1672 (23.0)	40 (15.6)	18077 (14.4)	3 (6.7)	2768 (22.1)	91 (13.0)	22594 (14.7)
	70-79 years	2 (11.8)	1501 (20.7)	54 (21.0)	9159 (7.3)	10 (22.2)	2899 (23.1)	144 (20.6)	13392 (8.7)
	80-89 vears	7 (41.2)	595 (8.2) <sup>´</sup>	67 (26.1)	3258 (2.6)	14 (31.1)	1449 (11.6)́	186 (26.6)	6134 ( <u>4</u> .0)
	≥90 vears	5 (29.4)	145 (2.0)́	58 (22.6)	712 (Ò.6)	11 (24.4)	428 (3.4)	169 (24.2)	1790 (1.2)
Sex	· · · · · · · · · · · · · · · · · · ·					( )			
	Male	9 (52.9)	3071 (42.3)	139 (54.1)	56218 (44.7)	30 (66.7)	5341 (42.6)	377 (54.0)	68814 (44.8)
Time from symptoms onset to testing		- ()		,					
0	0-5 davs	9 (52.9)	5463 (75.3)	114 (44.4)	84543 (67.2)	27 (60.0)	10011 (79.9)	302 (43.3)	101235 (65.9)
	6-14 days	8 (47.1)	1282 (17.7)	115 (44.7)	19955 (15.9)	15 (33.3)	1740 (13.9)	334 (47.9)	26569 (17.3)
	No acute symptoms indicated at					- ( )			
	point of testing	0 (0 0)	512 (7 1)	28 (10.9)	21397 (17.0)	3 (6 7)	778 (6 2)	62 (8 9)	25904 (16.9)
Outpatient care received <1	point of testing	0 (0.0)	012 (7.1)	20 (10.0)	21007 (11.0)	0 (0.7)	110 (0.2)	02 (0.0)	20004 (10.0)
day before testing									
day before testing	Any outpatient care	1 (5 9)	208 (2.9)	8 (3 1)	1735 (1.4)	5 (11 1)	916 (7.3)	98 (14 0)	7699 (5.0)
Charlson comorbidity index	Any outputon ouro	1 (0.0)	200 (2.0)	0 (0.1)	1100 (1.4)	0(11.1)	010(1.0)	00 (14.0)	1000 (0.0)
	0	2 (11 8)	3738 (51 5)	46 (17.9)	00/70 (70 0)	9 (20 0)	5328 (12 5)	82 (11 7)	111010 (72.2)
	0 1_2	2 (11.0)	2724 (37.5)	61 (23 7)	2100/ (17.5)	3 (20.0) 8 (17.8)	1057 (30 G)	1/1(20.2)	31006 (20.8)
	3-5	3 (17.6)	631 (8 7)	68 (26 5)	3366 (2.7)	10 (22 2)	1703 (13.6)	200 (28 7)	7628 (5.0)
	5-5 >6	9(17.0)	164 (2.2)	82 (21.0)	1065 (0.8)	10 (22.2)	541 (4 3)	200 (20.7)	2164 (2.1)
Prior year boaltheare	20	0 (47.1)	104 (2.3)	02 (31.9)	1005 (0.0)	10 (40.0)	541 (4.5)	213 (39.4)	3104 (2.1)
interactions									
Interactions	0 outpatient visits	0(0,0)	28 (0 4)	3 (1 2)	1100 (3.5)	0(0,0)	46 (0 4)	4 (0.6)	4566 (3.0)
	$1_{-1}$ outpatient visits	0(0.0)	776 (10.7)	5 (1.2)	34052 (27.0)	2(4.4)	1103 (8.8)	40 (57)	37104 (24.2)
	5-9 outpatient visits	3 (17 6)	1607 (23 4)	26 (10 1)	35810 (28.4)	2 (4.4) 8 (17.8)	2350 (18.8)	40(3.7)	40057 (26.1)
	10 14 outpatient visits	3 (17.6)	1412 (10.5)	20 (10.1)	20006 (15.0)	6 (12.2)	2000 (10.0)	90 (12.5) 80 (11.5)	23858 (15 5)
	15 10 outpatient visits	1 (5.0)	1412(13.3) 1042(14.4)	26 (14.0)	11053 (8.8)	4 (8 0)	1940 (14.7)	74 (10.6)	23030 (13.3)
	20, 20 outpatient visits	1 (0.9)	1042 (14.4)	56 (14.0)	11000 (0.0)	4 (0.9) 7 (15 6)	1040 (14.7)	125 (17.0)	14910 (9.7)
	20-29 outpatient visits	4 (23.3)	1100 (10.0)	30 (21.0) 40 (15.6)	11439 (9.1)	7 (15.0) E (11.1)	2237 (10.0)	123(17.9)	70247 (10.0)
	S40 substitutient visits	T (5.9)	400 (0.7)	40 (15.6)	4405 (3.5)	5(11.1)	1101 (9.4)	96 (14.0)	7019 (5.1)
	240 outpatient visits	5 (29.4)	657 (9.1)	70 (27.2)	4721 (3.7)	13 (28.9)	1496 (11.9)	187 (20.8)	9057 (5.9)
	Any ED presentation	13 (76.5)	2266 (31.2)	183 (71.2)	19864 (15.8)	33 (73.3)	4805 (38.4)	501 (71.8)	32580 (21.2)
	Any inpatient admission	11 (64.7)	401 (5.5)	195 (75.9)	5468 (4.3)	25 (55.6)	903 (7.2)	563 (80.7)	9557 (6.2)
Prior SARS-CoV-2 infection									
	Any documented infection	1 (5.9)	175 (2.4)	5 (1.9)	5535 (4.4)	1 (2.2)	346 (2.8)	15 (2.1)	7061 (4.6)
Prior COVID-19 vaccination									
	0 doses received	2 (11.8)	392 (5.4)	19 (7.4)	16740 (13.3)	4 (8.9)	928 (7.4)	131 (18.8)	22207 (14.4)
	1 dose received	1 (5.9)	48 (0.7)	6 (2.3)	2010 (1.6)	1 (2.2)	230 (1.8)	25 (3.6)	3953 (2.6)
	2 doses received	2 (11.8)	963 (13.3)	44 (17.1)	31460 (25.0)	11 (24.4)	1872 (14.9)	139 (19.9)	38367 (25.0)
	3 doses received	9 (52.9)	4424 (61.0)	134 (52.1)	66604 (52.9)	21 (46.7)	6572 (52.5)	279 (40.0)	75580 (49.2)
	4 doses received	3 (17.6)	1430 (19.7)	54 (21.0)	9081 (7.2)	8 (17.8)	2927 (23.4)	124 (17.8)	13601 (8.8)

Race/ethnicity

	White, non-Hispanic	11 (64.7)	1910 (26.3)	114 (44.4)	26770 (21.3)	24 (53.3)	3634 (29.0)	269 (38.5)	34862 (22.7)
	Black, non-Hispanic	0 (0.0)	688 (9.5)	15 (5.8)	9966 (7.9)	4 (8.9)	1239 (9.9)	76 (10.9)	12968 (8.4)
	Hispanic	5 (29.4)	3056 (42.1)	91 (35.4)	60158 (47.8)	12 (26.7)	5123 (40.9)	254 (36.4)	72355 (47.1)
	Asian	1 (5.9)	1224 (16.9)	33 (12.8)	18856 (15.0)	4 (8.9)	1966 (15.7)	87 (12.5)	22049 (14.3)
	Pacific Islander	0 (0.0)	74 (1.0)	1 (0.4)	1246 (1.0)	1 (2.2)	117 (0.9)	4 (0.6)	1446 (0.9)
	Other/unknown/mixed race	0 (0.0)	305 (4.2)	3 (1.2)	8899 (7.1)	0 (0.0)	450 (3.6)	8 (1.1)	10028 (6.5)
Body mass index									
	Underweight (<18.5)	2 (11.8)	36 (0.5)	5 (1.9)	5658 (4.5)	3 (6.7)	119 (0.9)	64 (9.2)	7384 (4.8)
	Normal weight (18.5-24.9)	7 (41.2)	1233 (17.0)	102 (39.7)	26448 (21.0)	20 (44.4)	2431 (19.4)	264 (37.8)	33256 (21.6)
	Overweight (25.0-29.9)	6 (35.3)	2184 (30.1)	89 (34.6)	33042 (26.2)	14 (31.1)	3721 (29.7)	193 (27.7)	40478 (26.3)
	Obese (30-39.9)	2 (11.8)	2701 (37.2)	55 (21.4)	33363 (26.5)	7 (15.6)	4357 (34.8)	139 (19.9)	40953 (26.6)
	Morbidly obese (≥40.0)	0 (0.0)	550 (7.6)	3 (1.2)	6061 (4.8)	1 (2.2)	1239 (9.9)	34 (4.9)	9418 (6.1)
Cigarette smoking		( )	( )	· · ·	( )	( )	( )	( )	( )
6 6	Current smoker	9 (52.9)	4984 (68.7)	139 (54.1)	83347 (66.2)	23 (51.1)	8455 (67.5)	389 (55.7)	102424 (66.6)
	Former smoker	2 (11.8)	252 (3.5)	11 (4.3)	4094 (3.3)	2 (4.4)	450 (3.6)	41 (5.9)	5401 (3.5)
	Never smoked	6 (35.3)	1468 (20.2)	98 ( <u>38.1</u> )	16393 (13.0)	18 (40.0)	2858 (22.8)	242 (34.7)	22181 (14.4)
Neighborhood deprivation		( )	( )	· · · ·	· · · · ·	( )	( )	( )	(
index									
	First quintile (least deprived)	4 (23.5)	1231 (17.0)	53 (20.6)	17783 (14.1)	9 (20.0)	2138 (17.1)	111 (15.9)	21755 (14.2)
	Second guintile	5 (29.4)	1662 (22.9)	64 (24.9)	27255 (21.6)	15 (33.3)	2868 (22.9)	163 (23.4)	33395 (21.7)
	Third quintile	3 (17.6)	1822 (25.1)	58 (22.6)	31794 (25.3)	7 (15.6)	3147 (25.1)	161 (23.1)	38645 (25.1)
	Fourth guintile	4 (23.5)	1589 (21.9)	51 (19.8)	29517 (23.4)	10 (22.Ź)	2709 (21.6)	163 (23.4)	35925 (23.4)
	Fifth quintile (most deprived)	1 (5.9)	947 (13.0) <sup>´</sup>	31 (12.1)	19452 (15.5)	4 (8.9)	1658 (13.2)	98 (Ì4.0)	23874 (15.5)
Receipt of other respiratory		( )		( )		· · ·	× ,	ζ, γ	
vaccines	2021 22 accordingly on to								
		40 (70 0)	F000 (70 4)	400 (75 4)		20 (74 4)	0040 (70.0)	400 (74 0)	04000 (54.0)
	vaccine	12 (70.6)	5232 (72.1)	193 (75.1)	67759 (53.8)	32 (71.1)	9042 (72.2)	498 (71.3)	84229 (54.8)
	Pneumococcal conjugate	11 (00 1)	0057 (00.0)	477 (00.0)		05 (77 0)	4404 (05 0)	404 (70.0)	00577 (04.0)
	vaccine	14 (82.4)	2057 (28.3)	177 (68.9)	23080 (18.3)	35 (77.8)	4481 (35.8)	491 (70.3)	33577 (21.8)
	Pneumococcal polysaccharide						===== (=== =)		
	vaccine	16 (94.1)	3896 (53.7)	198 (77.0)	29655 (23.6)	40 (88.9)	7589 (60.6)	574 (82.2)	43019 (28.0)

Data on exposure prevalence among treatment recipients and non-recipients within the analytic sample include all eligible cases who were assigned matches. Percentages indicated in the table are computed among individuals with non-missing observations; missing data are present in participants' smoking status, body mass index, and neighborhood deprivation index, as summarized in **Table 1**.

Endpoint	Timing of testing and dispense in relation to symptoms onset	Discord	ant pairs	Effectiveness	s (95% CI), %	
		Outcome observed for recipient, non- recipient censored	Outcome observed for non-recipient, recipient censored	Estimate, % (95% confidence interval)	<i>p</i> -value (two- sided)	
All-cause hospital admission or death within 30 days from positive SARS-CoV-2 test						
	0-5 days after symptoms onset	5	9	89.6 (50.2, 97.8)	$4.5 \times 10^{-3}$	
	At any time, regardless of symptoms	6	15	77.7 (31.3, 92.7)	$8.3 \times 10^{-3}$	
All-cause intensive care unit admission, mechanical ventilation, or death within 60 days from positive SARS-CoV-2 test						
	0-5 days after symptoms onset	0	3			
	At any time regardless of symptoms	0	5			

Treatment effectiveness is measured as  $(1 - \text{adjusted hazard ratio}) \times 100\%$ , comparing outcomes among individuals who received treatment to those who did not. Time at risk is measured from the date of the index positive test, updating individuals' exposure status at the point of treatment. Estimates are fitted via Cox proportional hazards models across each of 5 pseudo-datasets generated by multiple imputation of missing values. Regression strata include age age (±10 years); sex; time from symptoms onset or absence of symptoms; receipt of outpatient care in association with testing; Charlson comorbidity index (0, 1-2, 3-5, and ≥6); prior-year healthcare interactions (including 0-4, 5-14, 15-24, 25-34, and ≥35 outpatient visits, and any emergency department presentation or inpatient admission); prior COVID-19 vaccination, defined by number of doses received ≥14 days prior testing; and body mass index (underweight [<18.5], normal weight [18.5-24.9], overweight [25.0-29.9], obese [30.0-39.9], or morbidly obese [≥40.0]). Further variables listed in **Table 1** are controlled for via covariate adjustment. We use the symbol "- –" to indicate cells for which estimates could not be obtained due to positivity violations.

Table S9: Effectiveness of nirmatrelvir-ritonavir in preventing progression to severe disease endpoints within subgroups treated at differing stages in the clinical course.

Endpoint	Timing of dispense in relation to symptoms onset	Discord	ant pairs	Effectiveness		
		Outcome observed for recipient, non- recipient censored	Outcome observed for non-recipient, recipient censored	Estimate, % (95% confidence interval)	<i>p</i> -value (two-sided)	
All-cause hospital admission or death within 30 days from positive SARS-CoV-2 test						
	0-3 days after symptoms onset	7	10	81.1 (34.1, 94.6)	$9.0 \times 10^{-3}$	
	≥6 days after symptoms onset, or while asymptomatic	18	12	43.8 (-33.3, 81.7)	0.16	
	At any time after symptoms onset	24	23	59.5 (12.8, 81.2)	0.021	
	While asymptomatic only	2	0	/		
All-cause intensive care unit admission, mechanical ventilation, or death within 60 days from positive SARS-CoV-2 test						
	0-3 days after symptoms onset	1	4			
	≥6 days after symptoms onset, or while asymptomatic	8	4	63.6 (–124.6, 94.1)	0.23	
	At any time after symptoms onset	10	11	86.2 (34.6, 97.1)	0.013	
	While asymptomatic only	0	0			

Treatment effectiveness is measured as  $(1 - adjusted hazard ratio) \times 100\%$ , comparing outcomes among individuals who received treatment to those who did not. Time at risk is measured from the date of the index positive test, updating individuals' exposure status at the point of treatment. Estimates are fitted via Cox proportional hazards models across each of 5 pseudo-datasets generated by multiple imputation of missing values. Regression strata include age age (±10 years); sex; time from symptoms onset or absence of symptoms; receipt of outpatient care in association with testing; Charlson comorbidity index (0, 1-2, 3-5, and ≥6); prior-year healthcare interactions (including 0-4, 5-14, 15-24, 25-34, and ≥35 outpatient visits, and any emergency department presentation or inpatient admission); prior COVID-19 vaccination, defined by number of doses received ≥14 days prior testing; and body mass index (underweight [<18.5], normal weight [18.5-24.9], overweight [25.0-29.9], obese [30.0-39.9], or morbidly obese [≥40.0]). Further variables listed in **Table 1** are controlled for via covariate adjustment. We use the symbol "- –" to indicate cells for which estimates could not be obtained due to positivity violations.

Characteristic							
			Analytic sam	ole	in cymptenie en	All eligible ca	ses
		<u>0-5 days</u>	<u>6-14 days</u>	No acute symptoms	<u>0-5 days</u>	<u>6-14 days</u>	No acute symptoms
				recorded			recorded
		<i>N</i> =90,129	<i>N</i> =21,360	N=21,937	N=111,575	N=28,658	N=26,747
Age							
	12-19 years	7112 (7.9)	1108 (5.2)	2845 (13.0)	8576 (7.7)	1429 (5.0)	3305 (12.4)
	20-29 years	9079 (10.1)	1762 (8.2)	2376 (10.8)	10783 (9.7)	2224 (7.8)	2756 (10.3)
	30-39 years	15419 (17.1)	3227 (15.1)	2620 (11.9)	17710 (15.9)	3926 (13.7)	3030 (11.3)
	40-49 years	19493 (21.6)	3997 (18.7)	3735 (17.0)	22170 (19.9)	4778 (16.7)	4196 (15.7)
	50-59 years	17596 (19.5)	3899 (18.3)	3803 (17.3)	20765 (18.6)	4890 (17.1)	4359 (16.3)
	60-69 years	12957 (14.4)	3524 (16.5)	3310 (15.1)	16564 (14.8)	4764 (16.6)	4128 (15.4)
	70-79 years	5954 (6.6)	2449 (11.5)	2313 (10.5)	9384 (8.4)	3845 (13.4)	3216 (12.0)
	80-89 years	2050 (2.3)	1072 (5.0)	805 (3.7)	4302 (3.9)	2061 (7.2)	1420 (5.3)
	≥90 years	469 (0.5)	321 (1.5)	130 (0.6)	1321 (1.2)	740 (2.6)	337 (1.3)
Sex							
	Male	40208 (44.6)	8277 (38.8)	10952 (49.9)	49896 (44.7)	11342 (39.6)	13324 (49.8)
Outpatient care received ≤1 day before testing							
5	Any outpatient care	1256 (1.4)	533 (2.5)	163 (0.7)	5685 (5.1)	2211 (7.7)	822 (3.1)
Charlson comorbidity index			( )			· · · ·	
	0	71518 (79.4)	14595 (68.3)	17143 (78.1)	80338 (72.0)	16985 (59.3)	19106 (71.4)
	1-2	15865 (17.6)	4984 (23.3)	3934 (17.9)	23784 (21.3)	7558 (26.4)	5670 (21.2)
	3-5	2153 (2.4)	1225 (5.7)	690 (3.1)	5395 (4.8)	2661 (9.3)	1485 (5.6)
	≥6	593 (Ò.7)	556 (2.6) <sup>´</sup>	170 (0.8)	2058 (1.8)	1454 (S.1)	486 (1.8) <sup>´</sup>
Prior-year healthcare interactions			. ,		. ,	. ,	
	0 outpatient visits	3151 (3.5)	377 (1.8)	912 (4.2)	3275 (2.9)	392 (1.4)	949 (3.5)
	1-4 outpatient visits	25022 (27.8)	3541 (16.6)	6270 (28.6)	27477 (24.6)	4037 (14.1)	6825 (25.5)
	5-9 outpatient visits	26115 (29.0)	5200 (24.3)	6221 (28.4)	29545 (26.5)	6022 (21.0)	6947 (26.0)
	10-14 outpatient visits	14438 (16.0)	3613 (16.9)	3391 (15.5)	17648 (15.8)	4511 (15.7)	4032 (15.1)
	15-19 outpatient visits	7864 (8.7)	2431 (11.4)	1837 (8.4)	10924 (9.8)	3380 (11.8)	2524 (9.4)
	20-29 outpatient visits	7776 (8.6)	2964 (13.9)	1919 (8.7)	11492 (10.3)	4384 (15.3)	2760 (10.3)
	30-39 outpatient visits	2841 (3.2)	1369 (6.4)	721 (3.3)	5329 (4.8)	2426 (8.5)	1348 (5.0)
	≥40 outpatient visits	2922 (3.2)	1865 (8.7)	666 (3.0)	5885 (5.3)	3506 (12.2)	1362 (5.1)
	Any ED presentation	14490 (16.1)	5238 (24.5)	2598 (11.8)	24412 (21.9)	9178 (32.0)	4329 (16.2)
	Any inpatient admission	3547 (3.9)	1609 (7.5)	919 (4.2)	6286 (5.6)	3205 (11.2)	1557 (5.8)
Prior SARS-CoV-2 infection							
	Any documented infection	3933 (4.4)	756 (3.5)	1027 (4.7)	5066 (4.5)	1052 (3.7)	1305 (4.9)
Prior COVID-19 vaccination							
	0 doses received	11386 (12.6)	2204 (10.3)	3563 (16.2)	15241 (13.7)	3490 (12.2)	4539 (17.0)
	1 dose received	1415 (1.6)	274 (1.3)	376 (1.7)	2840 (2.5)	657 (2.3)	712 (2.7)
	2 doses received	22400 (24.9)	4616 (21.6)	5453 (24.9)	27601 (24.7)	6247 (21.8)	6541 (24.5)
	3 doses received	48825 (54.2)	11822 (55.3)	10524 (48.0)	56038 (50.2)	14383 (50.2)	12031 (45.0)
	4 doses received	6103 (6.8)	2444 (11.4)	2021 (9.2)	9855 (8.8)	3881 (13.5)	2924 (10.9)
Race							
	White, non-Hispanic	19054 (21.1)	5108 (23.9)	4643 (21.2)	25163 (22.6)	7518 (26.2)	6108 (22.8)
	Black, non-Hispanic	6637 (7.4)	1814 (8.5)	2218 (10.1)	8813 (7.9)	2627 (9.2)	2847 (10.6)
	Hispanic	43472 (48.2)	9967 (46.7)	9871 (45.0)	53005 (47.5)	12969 (45.3)	11770 (44.0)
	Asian	13604 (15.1)	2999 (14.0)	3511 (16.0)	16207 (14.5)	3786 (13.2)	4113 (15.4)
	Pacific Islander	917 (1.0)	202 (0.9)	202 (0.9)	1069 (1.0)	253 (0.9)	246 (0.9)
	Other/unknown/mixed race	6445 (7.2)	1270 (5.9)	1492 (6.8)	7318 (6.6)	1505 (5.3)	1663 (6.2)
Body mass index							
	Underweight (<18.5)	3646 (4.0)	660 (3.1)	1395 (6.4)	4776 (4.3)	1060 (3.7)	1734 (6.5)
	Normal weight (18.5-24.9)	18278 (20.3)	4655 (21.8)	4857 (22.1)	23379 (21.0)	6462 (22.5)	6130 (22.9)
	Overweight (25.0-29.9)	23510 (26.1)	5986 (28.0)	5825 (26.6)	29298 (26.3)	8008 (27.9)	7100 (26.5)

#### of acuto symptom **c** . -11-E al. C 44 ..... . . . h

	Obese (30-39.9)	24456 (27.1)	6511 (30.5)	5154 (23.5)	30473 (27.3)	8546 (29.8)	6437 (24.1)
	Morbidly obese (≥40.0)	4612 (5.1)	1212 (5.7)	790 (3.6)	7304 (6.5)	2131 (7.4)	1257 (4.7)
Cigarette smoking							
	Current smoker	59597 (66.1)	14705 (68.8)	14177 (64.6)	74392 (66.7)	19481 (68.0)	17418 (65.1)
	Former smoker	2810 (3.1)	779 (3.6)	770 (3.5)	3748 (3.4)	1165 (4.1)	981 (3.7)
	Never smoked	11642 (12.9)	3518 (16.5)	2805 (12.8)	16076 (14.4)	5366 (18.7)	3857 (14.4)
Neighborhood deprivation index		× ,	( )			· · · · ·	· · · ·
<b>o</b>	First quintile (least deprived)	12670 (14.1)	3155 (14.8)	3246 (14.8)	15738 (14.1)	4268 (14.9)	4007 (15.0)
	Second guintile	19526 (21.7)	4762 (22.3)	4698 (21.4)	24326 (21.8)	6379 (22.3)	5736 (21.4)
	Third quintile	22855 (25.4)	5415 (25.4)	5407 (24.6)	28194 (25.3)	7204 (25.1)	6562 (24.5)
	Fourth quintile	21226 (23.6)	4842 (22.7)	5093 (23.2)	26113 (23.4)	6512 (22.7)	6182 (23.1)
	Fifth guintile (most deprived)	13784 (15.3)	3166 (14.8)	3481 (15.9)	17122 (15.3)	4270 (14.9)	4242 (15.9)
Receipt of other respiratory vaccines		( )	· · · · ·	( )	· · · · ·	( )	( )
	2021-22 seasonal influenza vaccine	48751 (54.1)	12880 (60.3)	11565 (52.7)	61798 (55.4)	17524 (61.1)	14479 (54.1)
	Pneumococcal conjugate vaccine	14954 (16.6)	4778 (22.4)	5596 (25.5)	22957 (20.6)	7921 (27.6) <sup>´</sup>	7706 (28.8)
	Pneumococcal polysaccharide	( )	( )	· · · ·	· · · · ·	( )	· · · ·
	vaccine	21026 (23.3)	7102 (33.2)	5637 (25.7)	31785 (28.5)	11341 (39.6)	8096 (30.3)

Data on exposure prevalence among treatment recipients and non-recipients within the analytic sample include all eligible cases who were assigned matches. Percentages indicated in the table are computed among individuals with non-missing observations; missing data are present in participants' smoking status, body mass index, and neighborhood deprivation index, as summarized in Table 1.

Table S11: Characteristics of individuals dispensed nirmatrelvir-ritonavir 0–5 days or 6–14 days after symptoms onset, or in the absence of ac	ute
symptoms.	

Characteristic			Frequency an	nong cases by time fron	n symptoms ons	et to dispense,	n (%)
		<u>0-5 days</u>	<u>6-14 days</u>	No acute symptoms	<u>0-5 days</u>	6-14 days	No acute symptoms
		·		recorded		-	recorded
		<i>N</i> =5,145	<i>N</i> =1,616	<i>N</i> =512	<i>N</i> =9,195	N=2,596	<i>N</i> =781
Age	10.10	0 (0 0)	0 (0 4)		40 (0.0)	0 (0 1)	0 (0 0)
	12-19 years	9 (0.2)	2 (0.1)	0 (0.0)	19 (0.2)	2 (0.1)	0 (0.0)
	20-29 years	125 (2.4)	32 (2.0)	13 (2.5)	223 (2.4)	52 (2.0)	19 (2.4)
	30-39 years	371 (7.2)	117 (7.2)	17 (3.3)	583 (6.3)	174 (6.6)	27 (3.5)
	40-49 years	791 (15.4)	239 (14.8)	73 (14.3)	1173 (12.8)	334 (12.7)	87 (11.1)
	50-59 years	1156 (22.5)	313 (19.4)	87 (17.0)	1713 (18.6)	464 (18.0)	121 (15.5)
	60-69 years	1215 (23.6)	357 (22.1)	101 (19.7)	2069 (22.5)	547 (21.1)	154 (19.7)
	70-79 years	1025 (19.9)	337 (20.9)	141 (27.5)	2104 (22.9)	592 (22.7)	213 (27.3)
	80-89 years	375 (7.3)	164 (10.1)	63 (12.3)	1010 (11.0)	323 (12.6)	130 (16.6)
	≥90 years	78 (1.5)	55 (3.4)	17 (3.3)	301 (3.3)	108 (4.2)	30 (3.8)
Sex	· · · · · ·						
	Male	2242 (43.6)	568 (35.1)	270 (52.7)	4011 (43.6)	979 (37.6)	381 (48.8)
Outpatient care received ≤1 dav		()	()	()	()		
before testing							
Soloro tooting	Any outpatient care	69 (1 3)	128 (7 9)	12 (2 3)	619 (6 7)	273 (10.5)	29 (37)
Charlson comorbidity index	any outpation date	00 (1.0)	120 (1.0)	12 (2.0)	010(0.7)	210 (10.0)	20 (0.7)
	0	2820 (54.8)	675 (41.8)	245 (47 0)	4067 (44-2)	030 (36 7)	330 (12 3)
	1.2	1808 (36.0)	626 (38 7)	243 (47.3)	3616 (30.3)	1034 (30.7)	314 (40.2)
	2.5	266 (7.1)	020(30.7)	203 (39.0)	1177 (10 0)	1034 (39.0)	314(40.2)
	5-5	300 (7.1)	213 (13.2)	55 (10.7)	1177 (12.0)	421 (15.9)	113 (14.7)
	20	61 (1.2)	102 (6.3)	9(1.8)	335 (3.6)	202 (7.6)	22 (2.8)
rior-year nealthcare interactions			0 (0 1)	4 (0, 0)	00 (0 4)	4 (0.0)	
		22 (0.4)	2(0.1)	4 (0.8)	38 (0.4)	4 (0.2)	4 (0.5)
	1-4 outpatient visits	623 (12.1)	83 (5.1)	70 (13.7)	897 (9.8)	126 (5.2)	82 (10.5)
	5-9 outpatient visits	1351 (26.3)	234 (14.5)	115 (22.5)	1877 (20.4)	345 (13.9)	145 (18.6)
	10-14 outpatient visits	1075 (20.9)	234 (14.5)	106 (20.7)	1738 (18.9)	366 (14.3)	149 (19.1)
	15-19 outpatient visits	754 (14.7)	211 (13.1)	78 (15.2)	1384 (15.1)	349 (13.8)	111 (14.2)
	20-29 outpatient visits	768 (14.9)	315 (19.5)	81 (15.8)	1587 (17.3)	524 (20.1)	153 (19.6)
	30-39 outpatient visits	268 (5.2)	186 (11.5)	32 (6.2)	792 (8.6)	326 (12.2)	68 (8.7)
	≥40 outpatient visits	284 (5.5)	351 (21.7)	26 (5.1)	882 (9.6)	556 (20.3)	69 (8.8)
	Any ED presentation	1501 (29.2)	671 (41.5)	106 (20.7)	3505 (38.1)	1127 (42.5)	204 (26.1)
	Any inpatient admission	212 (4.1)	176 (10.9)	24 (4.7)	587 (6.4)	291 (Ì0.6)	50 (6.4)
Prior SARS-CoV-2 infection	5	( )		( )			
	Any documented infection	112 (2.2)	52 (3.2)	12 (2.3)	245 (2.7)	80 (2.9)	22 (2.8)
Prior COVID-19 vaccination		= (=.=)	02 (012)	.= (=)	2.0 (2)	00 (2.0)	()
	0 doses received	258 (5.0)	116 (7 2)	20 (3 9)	665 (7.2)	212 (8 4)	55 (7.0)
	1 dose received	27 (0.5)	20(12)	20(0.0)	181 (2.0)	43(17)	7 (0 9)
	2 deses received	705 (13 7)	20 (12.0)	51 (10.0)	1400 (15.3)	385(1.7)	PR (11 2)
	2 doses received	2197 (61.0)	209 (12.9)	202 (50.2)	1409 (13.3)	12/1 (51.7)	410 (52 6)
	4 doooo roooiyod	069 (19.9)	943 (30.4) 229 (20.2)	303 (39.2) 126 (26.6)	4033 (32.0)	615 (02 5)	419 (00.0)
	4 doses received	900 (10.0)	320 (20.3)	130 (20.0)	2107 (22.9)	015 (23.5)	212 (27.1)
kace	M/hite were lienenie	4004 (05.0)	400 (00 7)	407 (04.0)	0070 (00 4)	770 (00 5)	
	white, non-Hispanic	1331 (25.9)	403 (28.7)	127 (24.8)	2070 (29.1)	119 (29.5)	203(20.0)
	Black, non-Hispanic	465 (9.0)	166 (10.3)	56 (10.9)	860 (9.4)	291 (11.3)	91 (11.7)
	Hispanic	2177 (42.3)	695 (43.0)	189 (36.9)	3/8/ (41.2)	1054 (40.9)	293 (37.5)
	Asian	896 (17.4)	223 (13.8)	106 (20.7)	1455 (15.8)	367 (14.3)	148 (19.0)
	Pacific Islander	52 (1.0)	14 (0.9)	8 (1.6)	86 (0.9)	22 (0.9)	10 (1.3)
	Other/unknown/mixed race	224 (4.4)	55 (3.4)	26 (5.1)	331 (3.6)	83 (3.0)	36 (4.6)
Body mass index							
	Underweight (<18.5)	12 (0.2)	20 (1.2)	6 (1.2)	82 (0.9)	32 (1.0)	8 (1.0)
	Normal weight (18 5-24 9)	842 (16 4)	286 (17.7)	112 (21.9)	1749 (19.0)	526 (20.3)	176 (22.5)

	Overweight (25.0-29.9)	1541 (30.0)	492 (30.4)	157 (30.7)	2726 (29.6)	769 (29.4)	240 (30.7)
	Obese (30-39.9)	1940 (37.7)	603 (37.3)	159 (31.1)́	3222 (35.0)	898 (35.1)	242 (31.0)
	Morbidly obese (≥40.0)	380 (7.4)	149 (9.2)	21 (4.1)	901 (9.8)	288 (11.0)	51 (6.5)
Cigarette smoking		( )	· · · ·			( )	
c c	Current smoker	3533 (68.7)	1131 (70.0)	328 (64.1)	6212 (67.6)	1764 (67.8)	501 (64.1)
	Former smoker	150 (2.9)	74 (4.6)	30 (5.9)	303 (3.3)	112 (4.2)	37 (4.7)
	Never smoked	1024 (19.9)	347 (21.5)	103 (20.1)	2068 (22.5)	628 (24.2)	179 (22.9)
Neighborhood deprivation index		· · · ·	· · · ·	· · · ·		· · · ·	
	First quintile (least deprived)	908 (17.6)	241 (14.9)	86 (16.8)	1620 (17.6)	395 (15.4)	132 (16.9)
	Second quintile	1144 (22.2)	408 (25.2)	115 (22.5)	2074 (22.6)	635 (23.7)	174 (22.3)
	Third quintile	1285 (25.0)	408 (25.2)	131 (25.6)	2300 (25.0)	657 (25.6)	196 (25.1)
	Fourth quintile	1129 (21.9)	346 (21.4)	118 (23.0)	1984 (21.6)	551 (21.5)	184 (23.6)
	Fifth quintile (most deprived)	675 (13.1)	213 (13.2)	60 (11.7)	1210 (13.2)	358 (13.8)	93 (11.9)
Receipt of other respiratory vaccines			· · · ·		· · · ·	· · · ·	· · · ·
	2021-22 seasonal influenza vaccine	3655 (71.0)	1187 (73.5)	401 (78.3)	6563 (71.4)	1902 (73.5)	608 (77.8)
	Pneumococcal conjugate vaccine	1334 (25.9)	558 (34.5)	179 (35.0)	3175 (34.5)	1016 (39.0)	325 (41.6)
	Pneumococcal polysaccharide vaccine	2656 (51.6)	945 (58.5)	310 (60.5)	5491 (59.7)	1639 (63.3)	497 (63.6)
Clinical outcomes		. ,	. ,	. ,		. ,	. ,
	Any hospital admission within 30 days	21 (0.4)	21 (1.3)	4 (0.8)	79 (0.9)	43 (1.6)	10 (1.3)
	Any intensive care unit admission within						
	60 days	3 (0.1)	6 (0.4)	0 (0.0)	14 (0.2)	8 (0.3)	2 (0.3)
	Mechanical ventilation within 60 days	0 (0.0)	1 (0.1)	0 (0.0)	3 (0.0)	1 (0.0)	1 (0.1)
	Death within 60 days	4 (0.1)	6 (0.4)	0 (0.0)	11 (0.Í)	14 (0.4)	2 (0.3)

Data on exposure prevalence among treatment recipients and non-recipients within the analytic sample include all eligible cases who were assigned matches. Percentages indicated in the table are computed among individuals with non-missing observations; missing data are present in participants' smoking status, body mass index, and neighborhood deprivation index, as summarized in **Table 1**.

Characteristic			Frequency among cases, n (%)				
		Analyti	Analytic sample All eligible cases				
		Dispensed on test	Dispensed after test	Dispensed on test	Dispensed after test		
		date	<u>date</u>	<u>date</u>	date		
		<i>N</i> =2,549	N=4,725	N=3,967	<i>N</i> =8,607		
Age							
	12-19 years	7 (0.3)	4 (0.1)	12 (0.3)	9 (0.1)		
	20-29 years	69 (2.7)	101 (2.1)	121 (3.1)	173 (2.0)		
	30-39 years	193 (7.6)	312 (6.6)	272 (6.9)	512 (5.9)		
	40-49 years	361 (14.2)	742 (15.7)	508 (12.8)	1086 (12.6)		
	50-59 years	495 (19.4)	1061 (22.5)	691 (17.4)	1608 (18.7)		
	60-69 vears	619 (24.3)	1055 (22.3)	903 (22.8)	1868 (21.7)		
	70-79 years	501 (19.7)	1002 (21.2)	824 (20.8)	2085 (24.2)		
	80-89 years	236 (9.3)	366 (7 7)	474 (11.9)	989 (11.5)		
	>90 vears	68 (2 7)	82 (1 7)	162 (4 1)	277 (3.2)		
Sev		00 (EII)	02 (117)	102 (4.1)	211 (0.2)		
0ex	Male	1103 (43 3)	1977 (41.8)	1725 (43 5)	3646 (42.4)		
Time from symptoms onset to testing	Male	1100 (40.0)	13/1 (41.0)	1720 (40.0)	3040 (42.4)		
Time nom symptoms onset to testing		2100 (96.2)	2272 (60.2)	2272 (95.0)	6666 (77 4)		
	0-5 days	2199 (00.3)	3273 (09.3)	3372 (03.0) 527 (12.5)	10000 (77.4)		
	6-14 days	316 (12.4)	974 (20.6)	537 (13.5)	1218 (14.2)		
	No acute symptoms indicated at point of	04 (4.0)	470 (40.4)		700 (0, 1)		
	testing	34 (1.3)	478 (10.1)	58 (1.5)	723 (8.4)		
Outpatient care received ≤1 day before							
testing							
	Any outpatient care	72 (2.8)	137 (2.9)	354 (8.9)	567 (6.6)		
Charlson comorbidity index							
	0	1255 (49.2)	2485 (52.6)	1697 (42.8)	3640 (42.3)		
	1-2	976 (38.3)	1752 (37.1)	1534 (38.7)	3431 (39.9)		
	3-5	262 (10.3)	372 (7.9)	551 (13.9)	1162 (13.5)		
	≥6	56 (2.2)	116 (2.5)	185 (4.7)	374 (4.3)		
Prior-year healthcare interactions				. ,			
•	0 outpatient visits	18 (0.7)	10 (0.2)	29 (0.7)	17 (0.2)		
	1-4 outpatient visits	265 (10.4)	511 (10.8)	395 (10.0)	710 (8.2)		
	5-9 outpatient visits	602 (23.6)	1098 (23.2)	816 (20.6)	1551 (18.0)		
	10-14 outpatient visits	460 (18.0)	955 (20.2)	684 (17.2)	1569 (18.2)		
	15-19 outpatient visits	388 (15.2)	655 (13.9)	575 (14.5)	1269 (14.7)		
	20-29 outpatient visits	410(161)	754 (16.0)	667 (16.8)	1597 (18.6)		
	30-39 outpatient visits	191 (7 5)	295 (6 2)	365 (9.2)	821 (9 5)		
	$\geq 10$ outpatient visits	215 (8 4)	<i>117</i> (9.5)	436 (11.0)	1073 (12.5)		
	Any ED presentation	1221 (48.2)	1048 (22.2)	2247 (56.6)	2501 (20.1)		
	Any inpotiont admission	151 (40.3)	261 (5.5)	2247 (30.0)	2391 (30.1)		
Driver CADC CoV/ 2 infection	Any inpatient authission	131 (3.9)	201 (3.3)	323 (0.2)	003 (7.0)		
Phor SARS-Cov-2 Intection	Any decumented infection	61 (2.4)	115 (2.4)	106 (2 7)	241 (2.8)		
	Any documented infection	61 (2.4)	115 (2.4)	106 (2.7)	241 (2.0)		
Prior COVID-19 vaccination		100 (7.4)					
	0 doses received	180 (7.1)	214 (4.5)	375 (9.5)	557 (6.5)		
	1 dose received	19 (0.7)	30 (0.6)	98 (2.5)	133 (1.5)		
	2 doses received	378 (14.8)	587 (12.4)	647 (16.3)	1236 (14.4)		
	3 doses received	1478 (58.0)	2955 (62.5)	2006 (50.6)	4587 (53.3)		
	4 doses received	494 (19.4)	939 (19.9)	841 (21.2)	2094 (24.3)		
Race							
	White, non-Hispanic	694 (27.2)	1227 (26.0)	1178 (29.7)	2480 (28.8)		
	Black, non-Hispanic	259 (10.2)	429 (9.1)	416 (10.5)	827 (9.6)		
	Hispanic	1066 (41.8)	1995 (42.2)	1622 (40.9)	3513 (40.8)		
	Asian	406 (15.9)	819 (17.3)	576 (14.5)	1394 (16.2)		
	Pacific Islander	20 (0.8)	54 (1.1)	34 (0.9)	84 (1.0)		
		· ·	· ·	• •	• •		

#### Table S12: Characteristics of individuals dispensed nirmatrelvir-ritonavir on or after the day of their index test.

	Other/unknown/mixed race	104 (4.1)	201 (4.3)	141 (3.6)	309 (3.6)
Body mass index					
	Underweight (<18.5)	7 (0.3)	31 (0.7)	38 (1.0)	84 (1.0)
	Normal weight (18.5-24.9)	454 (17.8)	786 (16.6)	810 (20.4)	1641 (19.1)
	Overweight (25.0-29.9)	827 (32.4)	1363 (28.8)	1238 (31.2)	2497 (29.0)
	Obese (30-39.9)	926 (36.3)	1777 (37.6)	1313 (33.1)	3051 (35.4)
	Morbidly obese (≥40.0)	185 (7.3)	365 (7.7)	398 (10.0)	842 (9.8)
Cigarette smoking					
	Current smoker	1737 (68.1)	3256 (68.9)	2658 (67.0)	5820 (67.6)
	Former smoker	95 (3.7)	159 (3.4)	157 (4.0)	295 (3.4)
	Never smoked	549 (21.5)	925 (19.6)	908 (22.9)	1968 (22.9)
Neighborhood deprivation index					
	First quintile (least deprived)	445 (17.5)	790 (16.7)	684 (17.2)	1463 (17.0)
	Second quintile	558 (21.9)	1109 (23.5)	866 (21.8)	2017 (23.4)
	Third quintile	624 (24.5)	1201 (25.4)	974 (24.6)	2180 (25.3)
	Fourth quintile	550 (21.6)	1043 (22.1)	846 (21.3)	1873 (21.8)
	Fifth quintile (most deprived)	369 (14.5)	579 (12.3)	593 (14.9)	1069 (12.4)
Receipt of other respiratory vaccines					
	2021-22 seasonal influenza vaccine	1763 (69.2)	3481 (73.7)	2706 (68.2)	6368 (74.0)
	Pneumococcal conjugate vaccine	741 (29.1)	1330 (28.1)	1367 (34.5)	3149 (36.6)
	Pneumococcal polysaccharide vaccine	1386 (54.4)	2526 (53.5)	2343 (59.1)	5286 (61.4)

Data on exposure prevalence among treatment recipients and non-recipients within the analytic sample include all eligible cases who were assigned matches. Percentages indicated in the table are computed among individuals with non-missing observations; missing data are present in participants' smoking status, body mass index, and neighborhood deprivation index, as summarized in **Table 1**.



Figure S1: Causal directed acyclic graph. We provide a schematic representation of the causal process used to identify a minimally sufficient set of variables for adjustment. We define the exposure of interest ( $E_t$ ) as receipt of nirmatrelyirritonavir at time t, and the outcome of interest as severe disease resulting in hospital admission (or other indication of disease progression) at a later point in time, t+1, as  $D_{t+1}$ . The analytic objective is to measure the effect of  $E_t$  on  $D_{t+1}$ , plotted as a red arrow. Clinical status at time  $t(C_t)$ , risk factors severe illness (X), and healthcare-seeking behavior (H) jointly influence whether individuals will be exposed to treatment at time t. We further hypothesize that the outcome  $D_{t+1}$  is influenced by clinical status at time t, patient risk factors, and healthcare-seeking behavior (for instance, if individuals seek pre-hospital care which could prevent or forestall the need for admission at time t+1, or if individuals seek and receive hospital care at a given threshold of disease severity). The minimal adjustment set needed to identify the effect of  $E_t$  on  $D_{t+1}$  thus includes X,  $C_t$ , and H. We measure X via patients' age, sex, Charlson comorbidity index, history of vaccination and SARS-CoV-2 infection, race, body mass index, cigarette smoking, and neighborhood socioeconomic status. We measure  $C_t$  via the presence of symptoms and time from symptoms onset, and by whether individuals received or did not receive clinical care in any outpatient setting in association with testing. We measure H via individuals' prior-year history of healthcare utilization across outpatient, inpatient, and emergency department settings and their receipt of other respiratory vaccines (noting as well that variables such as COVID-19 vaccination, receipt of healthcare in association with testing, and documentation of prior infection may also provide relevant information on H, even if their inclusion in the analysis is based on other attributes they are primarily expected to measure).